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Abstract 
 
Previous studies have shown that cytotoxic CD8+ T cells are important mediators of 
immunity against the bovine intracellular protozoan parasite T. parva. The present 
study set out to determine the role of granule enzymes in mediating killing of 
parasitized cells, first by characterising the granzymes expressed by bovine 
lymphocytes and, second, by  investigating their involvement in killing of target 
cells.  
 
Experiments using the perforin inhibitor concanamycin A confirmed that CD8+ T 
cell killing of T. parva-infected cells is dependent on granule exocytosis, a process 
that involves release of granzymes into the target cell, resulting in activation of 
apoptotic pathways. Analysis of the bovine genome sequence identified orthologues 
of granzymes A, B, H, K and M, as well as another gne O, most closely related to 
granzyme A. The genes were found within 3 loci in the genome. Using specific PCR 
assays, all of these granzymes were shown to be expressed in Theileria-specific 
CD8+ T cells. Further studies were undertaken to study the role of granzyme B in 
killing. DNA constructs encoding functional and non-fu ctional forms of bovine 
granzyme B were produced and the proteins expressed in COS cells were used to 
establish an enzymatic assay to detect and quantify expression of functional 
granzyme B protein. Using this assay, the levels of killing of different T. parva-
specific CD8+ T cell clones were found to be significantly correlating with levels of 
granzyme B protein expression. Moreover, the granzyme B inhibitor III, Z-IETD-
FMK was shown to inhibit killing by CD8+ T cell clones.  
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Chapter 1  Introduction 
 
1.1 Theileria parva and East coast fever  
Theileria parasites are members of the class Sporozoa, subphyl m Apicomplexa, 
which includes several other pathogens of great importance such as Plasmodium, 
Babesia, Toxoplasma and Eimeria. The most important pathogenic species are 
Theileria annulata and Theileria parva, which cause severe clinical diseases in cattle 
known as Tropical Theileriosis and East Coast Fever (ECF), respectively. T. parva is 
transmitted by the brown ear tick Rhipicephalus appendiculatis and is distributed in a 
large area of eastern, southern and central Africa.  
 
ECF is an acute, and lymphoproliferative disease characterised by sustained fever 
and lymph node swelling. Infection of susceptible European breeds of cattle with T. 
parva results in death of the majority of animals within 4 weeks. Breed differences in 
susceptibility to the disease have been observed, although the mechanisms 
responsible are unknown. In particular, indigenous Bo  indicus cattle living in ECF-
endemic areas develop less severe disease and suffer lower levels of mortality than 
introduced European Breeds (Bos taurus) or breeds of Bos indicus cattle that have 
been selected for improved productivity. Therefore, ECF is considered as a serious 
constraint to improvement of the local livestock in affected areas. Moreover, the 
financial losses resulting from the disease and cost of measures taken to control it 
have been estimated at approximately US$168 million per year (Mukhebi et al., 
 2 
1992). Thus, ECF has a huge impact on the livestock industries and economies of 
countries in the affected region.  
 
1.1.1 Life cycle of T. parva  
 
Figure 1.1 Theileria parva lifecycle 
Reproduced from the Annual Report of the International Laboratory of 
Research on Animal Disease (ILRAD) 1990 
 
 
The life cycle of T. parva is illustrated in figure 1.1. The infective stage of T. parva 
for ticks is the piroplasm form of the parasites present in erythrocytes of infected 
cattle. Ticks are infected during the larval or nymphal developmental stages when 
 3 
they feed on infected cattle and on completion of feeding they drop onto the pasture 
and moult to the next developmental stage, nymphs and adults respectively, which 
can then transmit the infection when they feed on a fresh bovine host. Following 
ingestion by the tick, the parasites start to undergo a sexual cycle initially involving 
differentiation of the released piroplasms into micro- and macro-gametes (haploid), 
which fuse together to form diploid zygotes (Schein t al., 1977). The zygote forms 
then invade the epithelial cells of the gut wall and differentiate into motile kinetes, 
which migrate from the gut to the salivary glands where they infect glandular 
epithelial cells (Mehlhorn and Shein, 1984). Within a  infected gland cell, each 
kinete undergoes a process of sporogony, which can give rise to 30,000 to 50,000 
sporozoites (Fawcett et al., 1982), the infective stage for cattle (Shaw, 2003). The 
process of sporogony involves a meiotic division, during which genetic 
recombination can occur in zygotes arising from infection with mixed parasite 
genotypes. Therefore sporozoites and all subsequent developmental stages in cattle 
contain a haploid genome.   
 
Infection is transmitted to cattle during tick feeding by release of sporozoites into the 
saliva following 2-4 days of tick feeding. The lifecycle of the parasite in cattle 
involves successive developmental stages in lymphocytes and erythrocytes. First, 
sporozoites rapidly enter lymphocytes by receptor-mediated endocytosis (Fawcett et 
al., 1984). In vitro studies have shown that B and T lymphocytes, including CD4+ T 
cells, CD8+ T cells and TCR γδ+ population, are susceptible to infection with T. 
parva at similar frequency (Baldwin et al., 1988). However, the majority of 
parasitized cells in cattle undergoing primary infection are CD4+ and CD8+ T 
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lymphocytes (Emery et al., 1988). Once inside lymphocytes, the sporozoite rapidly 
disrupts the surrounding host cell membrane in order to escape from the endosome 
and subsequently lies free in the cytoplasm within 15-30 min. Within 3-4 days, the 
sporozoite differentiates into a multinucleate schizont (Stagg et al., 1981), which 
induces activation and proliferation of the host cell. Division of parasites occurs 
synchronously with that of the host cell. This is achieved by close association of the 
parasite with the host mitotic spindle, with parasite nuclei being distributed randomly 
to both daughter cells during the process of division (Hulliger et al., 1964; Irvin et al., 
1982). Although the mechanism of host cell transformation is not fully understood, T. 
parva-has been shown to induce constitutive activation of NF-κB (Heussler et al., 
1999), which initiates host cell activation and up-regulation of a number of anti-
apoptosis proteins that maintain the viability of the infected cells. Proliferation of the 
infected cells results in rapid clonal expansion of the cells initially infected with 
sporozoites. A proportion of them eventually undergo merogony involving 
differentiation of the schizonts to merozoites, which are released upon destruction of 
the host cells and infect erythrocytes giving rise to piroplasms. The piroplasms, 
which undergo little or no multiplication, are the infective stage for the tick vector.  
 
1.1.2 Clinical disease  
The pathogenesis of ECF in cattle is mainly attribua le to the schizont-infected 
stage. Cattle experimentally infected with tick-deriv d sporozoites develop clinical 
signs, namely pyrexia and enlargement of the lymph nodes, 5-10 days (depending on 
dose) after infection, coincident with initially detectable schizonts in the lymph 
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nodes draining the site of infection (Emery, 1981b; Morrison et al., 1981; Shatry et 
al., 1981). Later, the schizont-infected cells disseminate throughout the lymphoid 
system (Emery, 1981b; Morrison et al., 1981; Shatry e  al., 1981) and non-lymphoid 
tissues such as gut and lungs, causing generalized lymphadenopathy and, in the 
terminal stages, respiratory distress (Irvin and Mwamachi, 1983). In the later stages 
of disease, there is extensive lymphocytolysis and severe leucopaenia (DeMartini and 
Moulton, 1973; Emery, 1981b; Emery et al., 1981; Morris n et al., 1981; Shatry et 
al., 1981). Susceptible breeds of animals suffer high levels of mortality and death 
generally occurs within 4 weeks of infection. Animals that recover become 
asymptomatic carriers of infection. They carry small numbers of parasites (both 
schizonts and piroplasms), which are usually not detect d microscopically, for 
months or years (Geysen et al., 1999; Skilton et al., 2002). This carrier state allows 
transmission of the parasite by tick feeding. In endemic areas, transmission from 
carrier animals has been estimated by mathematical modelling to account for 90% of 
new infections in cattle (Medley et al., 1993).  
 
1.1.3 Control of T. parva  
In the past, control of ECF has been largely based on spraying or dipping of cattle 
with acaricides to prevent tick infestation. Although this has been an effective 
method of controlling the disease, it has a number of shortcomings. Continuous 
application is required for effective prevention of disease. This is expensive and 
requires careful management. Contamination of the environment by the chemicals is 
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also a serious issue and their prolonged use has resulted in emergence of acaricide-
resistant ticks.  
 
Chemotherapy using two theilericidal compounds (parvaquone and buparvaquone) 
has been employed to control the disease. However, the treatment needs to be applied 
in the early stages of clinical disease to be effectiv  and this is not always possible. 
Also, the high cost of these two drugs is not affordable for many small holder 
farmers.  
 
Vaccination has been used in some areas as a control measure. An infection and 
treatment protocol involving infection with a defined dose of sporozoites and 
simultaneous treatment with a single dose of long-acting oxytetracycline, was 
developed for immunisation of cattle against T. parva (Radley et al., 1975a). This 
protocol generated protective immunity to challenge with the same (homologous) T.
parva isolate for at least 3.5 years (Burridge et al., 1972). However, some animals 
immunised with a single parasite isolate remained susceptible to challenge with 
heterologous parasite isolates (Radley et al., 1975a). Nevertheless, immunisation 
with a cocktail of 3 different parasite isolates (Muguga, Kiambu 5 and Serengeti) 
resulted in immunity to a range of heterologous isolates (Radley et al., 1975b). 
Subsequently, immunisation with another single isolate, T. parva (Marikebuni), was 
also shown to generate immunity to challenge with a range of heterologous isolates 
(Morzaria et al., 1987). This isolate was subsequently found to be genetically and 
antigenically heterogeneous (Morzaria et al., 1987; Goddeeris et al., 1990; Toye et al., 
1991). Immunisation of cattle by the infection and treatment method using the 
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mixture of 3 isolates referred to above (termed the Muguga cocktail) has been used 
for field vaccination of cattle on a local scale in some regions of Africa to control 
ECF (Uilenberg et al., 1976; Morzaria et al., 1987; Marcotty et al., 2002). Although 
it has proved to be effective, it has a number of limitations that have prevented its 
utilization on a large scale. The method for producing sporozoites from infected ticks 
requires local infrastructure and expertise and is ifficult to quality control, The 
sporozoites require storage in liquid nitrogen and the lack of a cold chain to transport 
vaccine to remote areas is a serious constraint., Introduction of the strains of parasite 
used in the vaccine into the local tick populations as a consequence of vaccine-
induced carrier infection is also considered as a dis dvantage (Maritim et al., 1989; 
Kariuki et al., 1995; Geysen et al., 1999). Because of these constraints, research is 
being directed to developing alternative method of vaccination.  
 
 
1.2 Effector mechanism of immunity to T. parva 
 
1.2.1 The role of CD8+ T cells in protective immuni ty 
Studies of the immune responses in cattle immunised against T. parva by infection 
and treatment have provided insight into the immune responses involved. Following 
challenge of immune animals there is transient emergence of schizont parasitosis 
(Morrison et al., 1987), indicating that infection is not prevented at the early stage of  
parasite development, but at the schizont-infected stage. Other studies of 
experimental immunization showed that animals could also be immunized against 
 8 
homologous challenge by administering large numbers of chizont-infected cells 
(Emery et al., 1982). These findings indicated that protective immunity against T. 
parva is largely attributable to immune responses to the schizont stage rather than 
sporozoites. As the schizont remains within host lymphocytes during parasite 
multiplication, it is inaccessible to antibody. Several experiments examining the role 
of antibody from immune animals in immunity have failed to demonstrate a 
protective effect. Thus, transfer of serum and gamm-globulins from immunized to 
susceptible cattle (Muhammed et al., 1975) did not confer protection and attempts to 
demonstrate antibodies reactive with the surface of schizont-infected cells gave 
negative results (Wagner et al., 1974; Creemers, 1982).  
 
In contrast, transfer of thoracic duct leukocytes from immune to naïve twin calves 
was shown to confer immunity, indicating an important role for cell-mediated 
immune response in immunity (Emery, 1981a). Other in vitro and ex vivo studies of 
cellular immune responses in immune animals identifi d strong cytotoxic activity 
against parasitized lymphocytes mediated by CD8+ T cells (Pearson et al., 1979; 
Eugui and Emery, 1981; Morrison et al., 1987). A further adoptive transfer study 
demonstrated that transfer of CD8+ T cells from immune to non-immune twin calves 
conferred strong protective immunity (McKeever et al., 1994), confirming an 
important role for CD8+ T cells in immunity against T. parva. Immunisation by 
infection and treatment also stimulates strong parasite-specific CD4+ T cell 
responses as well as CD8+ T cell responses (Baldwin et al., 1987), and Taracha et al., 
(1997) reported evidence that optimal activation of parasite-specific CD8+ T cells in 
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vitro required help from CD4+ T cells from immune animals. This supports the idea 
that CD4+ T cell responses may also contribute to immunity (Taracha et al., 1997). 
 
1.2.2 Parasite stain specificity and major histocom patability class 
I (MHC1) restriction  
Studies of cross-protection following immunisation and challenge with single 
parasite isolates have illustrated the parasite-stain pecificity of protective immunity 
(Radley et al., 1975c). Further studies have demonstrated that cytotoxic CD8+ T cell 
responses induced by immunising with a single isolate also show parasite strain 
specificity (Goddeeris et al., 1986b; Morrison et al., 1987; Taracha et al., 1995a; 
Taracha et al., 1995b). Thus, CD8+ T cell lines derived from animals immunized 
with the Muguga T. parva isolate often recognize some, but not other parasite 
isolates in vitro (Goddeeris et al., 1986a; Goddeeris t al., 1986b). A cross-protection 
experiment with 22 animals immunized with either T. parva (Muguga) or a cloned 
population of the T. parva (Marikebuni) isolate (3219) and subsequently challenged 
with the reciprocal parasite demonstrated a close crrelation between parasite strain 
specificity of CD8+ T cell responses and susceptibility of animals to heterologous 
parasite challenge. Nine of the 22 animals had cross- eactive CD8+ T cell responses 
following immunisation and showed solid immunity following challenge with the 
heterologous parasite, whereas the remaining 13 animals generated strain-specific 
CD8+ T cell responses and remained susceptible to hterologous challenge (Taracha 
et al., 1995a).  
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Additional experiments by Taracha et al. using the same animals provided evidence 
that disparity in parasite strain specificity of CD8+ T cell responses of the animals is 
influenced by major histocompatability class I (MHCI) phenotype (Taracha et al., 
1995b). These and other studies (Morrison et al., 1987; Taracha et al., 1995b) 
showed that MHC restriction of the response in MHC-heterozygous animals is often 
biased towards one of the MHCI haplotypes and that among groups of immunised 
animals responses are predominantly restricted by certain haplotypes in preference to 
others.  
 
1.2.3 Identification of antigens and epitopes  
Studies carried out by Graham and colleagues (Graham et al., 2006; Graham et al., 
2007; Graham et al., 2008) have identified a number of antigens recognized by T.
parva-specific CD8+ T cells derived from immune animals of different MHC 
genotypes. Candidate antigens were identified by screening either a T. parva schizont 
cDNA expression library or expressed isolated cDNAs encoding proteins with a 
predicted signal peptide, selected by bioinformatic nalyses of the T. parva (Muguga) 
genome. T. parva-specific CD8+ T cell lines were used to screen Cos cells co-
transfected with parasite cDNA and cDNAs encoding the respective bovine class I 
MHC heavy chains. Antigen recognition by the specific CD8+ T cells was detected 
by measuring release of IFN-γ. Based on these immuno-screens, 6 T. parva antigens 
(Tp1, Tp2, Tp4, Tp5, Tp7 and Tp8) were identified and further epitope mapping 
studies identified 9 epitopes within these antigens. Tp1 and 2 are predicted as 
hypothetical proteins, whereas Tp4, 5, 7 and 8 show mology to the ε-subunit of T 
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complex protein 1, elongation translation factor 1A, heat-shock proteins 90 and 
cysteine protease, respectively. Analyses of the MHC restriction of T cell responses 
to the antigens showed that each antigen tended to be presented by different MHC 
genotypes and that the responses restricted by certain MHC types appear to be 
predominantly focused on a single dominant epitope.  
 
1.2.4 Immunodominance  
MHCI-restricted CD8+ T cell responses are important in mediating immunological 
control of many intracellular pathogens, including viruses, bacteria and parasites 
(Wong and Pamer, 2003). A well-established feature of the CD8+ T cell response to 
many virus infections in mice and humans is that, despite the ability of the host to 
respond to numerous antigenic epitopes, the response is often focused only on a few 
epitopes. This is known as immunodominance (Yewdell, 2006). Several studies have 
provided evidence that immunodominance is also a featur  of CD8+ T cell responses 
to Theileria parva infection (Taracha et al., 1995b; MacHugh et al., 2009). Taracha 
et al. studied responses of genetically identical twin calves carrying a MHCI 
haplotype expressing the A10 and KN104 class I proteins, one immunized with T. 
parva (Muguga) and the other with T. parva (Marikebuni 3219). The Muguga 
immunised animal generated a KN104-restricted, strain-specific CD8+ T cell 
response and was susceptible to subsequent challenge with Marikebuni 3219, 
whereas the Marikebuni 3219-immunised animal had a KN104-restricted, cross-
reactive CD8+ T cell response and was protected against challenge with Muguga. 
Moreover, after suffering a severe clinical reaction upon challenge with Marikebuni, 
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the Muguga-immunized twin recovered and subsequently had a KN104-restricted, 
cross-reactive CD8+ T cell response. This indicated that the initial failure of this 
animal to respond to the conserved epitope(s) shared by the two T. parva isolates was 
due to the immunodominance of a variable epitope in the T. parva (Muguga) isolate 
(Taracha et al., 1995b). Recent studies of CD8+ T cell responses of immune animals 
to defined T. parva antigens have confirmed the immunodominant nature of the 
response. CD8+ T cell responses in MHCI-homozygous animals (A18 or A10) 
recognised only one of 5 T. parva antigens tested, Tp1 in A18+ animals and Tp2 in 
A10+ animals. Furthermore, in each case over 60% of CD8+ T cells were specific 
for a single dominant epitope, Tp1214-224 and Tp249-59, respectively (MacHugh et al., 
2009). 
 
1.2.5 Subunit vaccine - Immunization with T. parva antigens 
Given the disadvantages of live vaccines for control of ECF, investigation of 
alternative methods of vaccination, focusing particularly on subunit vaccines, has 
been undertaken over the last 3 decades.  
 
In the early 1980s, monoclonal antibodies specific for a sporozoite surface antigen, 
p67 were found to neutralize the infectivity of sporozoites for lymphocytes in vitro 
(Musoke et al., 1982; Dobbelaere et al., 1984; Musoke et al., 1984). Attempts were 
therefore made to use recombinant p67 protein incorporated in adjuvants for 
vaccination. However, although animals vaccinated with a p67 subunit vaccine 
generated high titres of neutralising antibodies, a field trial of the vaccine revealed 
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that the overall incidence of severe ECF was only reduced by approximately 50% in 
vaccinated animals (total number of 83 animals from 3 different sites in Kenya) 
(Musoke et al., 2005). These results indicated that vaccination with p67 is unable to 
provide sufficient protection for field use.  
 
As experimental studies provided evidence that MHCI-restricted CD8+ T cell 
responses against cells infected with T. parva are important in mediating 
immunological control of the infection, investigation of subunit vaccines has recently 
focused on CD8+ T cell target antigens. Following identification of T. parva antigens 
recognized by specific CD8+ T cells, 5 of the antigens were used to immunise 
animals employing a prime-boost protocol, involving priming with antigen expressed 
in a DNA plasmid or a recombinant canarypox virus and boosting after 4 weeks with 
antigen expressed in modified vaccinia virus Ankara str in (Graham et al., 2006). 
Plasmid DNAs and recombinant viruses expressing individual antigens were used. 
Although 19 of 24 immunised animals generated detectable antigen-specific CD8+ T 
cell IFN- γ responses to one or more antigens, only a few of the animals showed 
evidence of protection against parasite challenge (Graham et al., 2006). In contrast to 
CD8+ T cells induced by infection and treatment, the CD8+ T cells generated by this 
prime boost protocol exhibited weak or no cytotoxic activity. This suggests that 




1.3 CD8+ T cell- mediated effector mechanisms against 
intracellular pathogens 
Previous studies using T cell subset depletion and gene-knock mouse models have 
indicated that CD8+ T cells are important mediators of adaptive immunity against a 
number of viruses and intracellular protozoa and bacteria. They act as effectors upon 
engagement with the target cell via T cell receptor (TCR)-mediated recognition of 
pathogen-derived peptides complexed with self class I MHC glycoproteins (pMHCI). 
In general, they can act by cytokine-mediated killing of the intracellular pathogens or 
by directly killing the infected cells via two distinct molecular pathways: the granule 
exocytosis pathway, which involves release of perforin and granzymes (Henkart and 
Sitkovsky, 1994), or Fas/Fas ligand interaction which results in classical caspase-
dependent apoptosis (Nagata and Golstein, 1995). The former frequently involves 
IFN- γ and a number of different intracellular mechanisms of IFN- γ-mediated killing 
of intracellular pathogens have been described (Boehm t al., 1997).  Studies of 
responses to the Gram-positive intracellular bacterium Listeria monocytogenes in 
mice, in which immunity has been shown to be mediat by CD8+ T cells (Mielke et 
al., 1989; Roberts et al., 1993; Kaufmann and Ladel, 1994; Ladel et al., 1994), have 
also demonstrated that immunity can develop in mice deficient in IFN- γ, perforin  or 
Fas or combinations of these deficiencies (Harty and Bevan, 1995; White and Harty, 
1998; Badovinac and Harty, 2000). TNF-α was implicated in this immunity 
(Samsom et al., 1995; White and Harty, 1998; White et al., 2000), but the precise 
mechanisms are still poorly understood.  In addition o their direct effector functions, 
CD8+ T cells can express chemokines that mediate recruitment of inflammatory cells 
towards infection sites for clearance of pathogens.  
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1.3.1 Cytokine-mediated mechanisms in Theileria  
Previous in vitro studies have shown that despite the presence of large numbers of 
IFN-γ expressing cells in T. parva-specific CD8+ T cell populations (Ballingall et al., 
2000), the schizont stage of T. parva in infected leukocytes is not susceptible to IFN-
γ or TNF-α (DeMartini and Baldwin, 1991). What is more, some parasitized cell 
lines constitutively express IFN-γ both at the level of RNA (McKeever et al., 1997) 
and functionally active protein (DeMartini and Baldwin, 1991). Other studies of the 
in vivo response to primary infection with T. parva (Houston et al., 2008) have 
detected production of a large amount of IFN-γ by uninfected T lymphoblasts during 
the early stages of infection, coinciding with rapid multiplication of parasitized cells. 
Thus, there is no evidence of cytokine-mediated killing of T. parva by the specific 
CD8+ T cell response. 
 
1.3.2 Mechanisms of cell-mediated cytotoxicity 
1.3.2.1 Death receptor pathway (Fas-Fas Ligand)  
Fas (CD95), a death receptor belonging to the tumor nec osis factor (TNF) receptor 
superfamily is constitutively expressed on the cellsurface of many cells (Watanabe-
Fukunaga et al., 1992b). In contrast, expression of Fas ligand (FasL) is mainly 
restricted to T and NK cells (Montel et al., 1995; Suda et al., 1995). In T cells, de 
novo synthesis of FasL is induced upon T cell activtion via TCR/CD3 engagement 
with a specific peptide/MHCI complex (Vignaux et al., 1995). After binding to FasL, 
signalling through the Fas receptor induces apoptosis of target cells via activation of 
caspases, which is regulated by several intracellular inhibitors at different molecular 
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levels (Chang et al., 2002; Salvesen and Duckett, 2002). Although mediation of cell 
death by this interaction is independent of Ca2+ (Rouvier et al., 1993), production of 
FasL on the cell surface upon T cell activation requires extracellular Ca2+ (Lowin et 
al., 1996). Fas-mediated cell death is believed to primarily contribute to regulating 
lymphocyte homeostasis (lymphocyte proliferation and apoptosis) via an immune 
process known as activation-induced cell death (AICD) (Watanabe-Fukunaga et al., 
1992a; Takahashi et al., 1994) and is involved in maintaining immune-privileged 
sites (eg. eye and testis cells constitutively exprss FasL, allowing them to 
immediately kill any invading activated inflammatory cells (Suda et al., 1993; 
Griffith et al., 1995). Several studies in mouse models using Fas-mutant lpr mice or 
FasL-mutant gld mice have revealed defective cytotoxic activity in CD4+ T cells 
(Henkart and Sitkovsky, 1994; Stalder et al., 1994) and, using perforin-deficient mice, 
demonstrated the absence of cytotoxic activity in CD8+ T cells (Kagi et al., 1994b), 
indicating that CD4+ T cells predominantly utilize the Fas-mediated pathway to 
induce apoptosis, whereas CD8+ T cells primarily mediat  cell death via granule 
exocytosis.  
 
A study by Kuenzi in 2003 found that T. parva-infected cells from cell lines 
maintained in vitro were less susceptible to Fas-induced cell death than the same 
cells from which the parasite had been removed by treatment with the theilericidal 
compound BW720. However, expression of both Fas and FasL was detected on the 
cell surface of infected cells and was unaffected by theilericidal drug treatment 
(Kuenzi et al., 2003). The enhanced resistance was attributed to T. parva-induced 
upregulation of several anti-apoptotic proteins including FLIP, X-chromosome-
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linked inhibitor of apoptosis protein (XIAP) and c-IAP, which act as endogenous 
inhibitors of caspases (Kuenzi et al., 2003). Because of the apparent resistance of 
Theileria-infected cells to Fas-mediated killing, Fas-induced ll death is considered 
less likely to be used as a mechanism of killing of T. parva-infected cells by CD8+ T 
cells  
 
1.3.2.2 Granule exocytosis pathway 
In human and mouse, there is evidence that the granule exocytosis pathway plays a 
predominant role in killing of target cells by antigen-specific CD8+ T cells (Kagi et 
al., 1994b; Yasukawa et al., 2000). Several studies in perforin-deficient mice have 
demonstrated that perforin-based cytotoxic activity is required for effective control 
of infections with a number of intracellular pathogens (Kagi et al., 1994a; Walsh et 
al., 1994; Nickell and Sharma, 2000). Membrane lysis and DNA damage of target 
cells are achieved by polarized release of cytotoxic effector molecules, including 
perforin (a pore-forming protein) and granzymes, which mediate cell death by 
cleaving a number of substrate proteins involved in mediating cell death. These 
effector proteins are stored in lytic granules, refe red to as secretory lysosomes, 
which are specialized organelles found predominantly i  CD8+ T cells and NK cells 
(Burkhardt et al., 1990; Peters et al., 1991). Lytic granules are dual-function 
organelles, having the function of secretory granules (ie, storage and secretion of 
proteins) as well as that of conventional lysosomes (i , degradation of proteins) 
found in other cell types. The acidic environment within lytic granules is important 
in regulating the functional activity of the effector proteins. In contrast to the 
lysosomal hydrolases in conventional lysosomes, which are functionally active under 
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acidic conditions, perforin and granzymes require neutral pH conditions to be 
functionally active. Within the granules, they remain functionally inactive by 
forming complexes with a proteoglycan, serglycin (SG) because of the acidic pH 
(Masson et al., 1990). This protects the CD8+ T cells/NK cells themselves from 
these toxic enzymes. Resting NK cells have secretory granules and constitutively 
express perforin and granzymes, whereas naïve CD8+ T cells do not have the 
secretory granules or express their enzyme contents. Upon activation of CD8+ T 
cells by TCR recognition of specific antigen and engagement of costimulatory 
molecules, they differentiate into cytotoxic CD8+ T cells after several days, 
concurrent with development of lytic granules and synthesis of perforin and 
granzymes. Degranulation and release of these effector molecules occurs rapidly 
when these differentiated CD8+ T cells again recognise antigen via TCR recognition 
alone, thus resulting in rapid apoptosis of target cells.  
 
1.4 Perforin  
Perforin is a Ca2+ dependent pore-forming protein, with homology to some of the 
complement components (Muller-Eberhard, 1986). It facilitates delivery of 
granzymes into the cytosol of target cells, and thus plays an essential role in 
lymphocyte-mediated cytotoxicity (Redelman and Hudig, 1980; Hudig et al., 1991). 
Several studies in perforin-deficient mice have provided direct evidence of its 
absolute requirement for killing target cells by CD8+ T cells (Kagi et al., 1994b; 
Kojima et al., 1994; Lowin et al., 1994). Purified perforin alone has been shown to 
induce direct lysis of target cells under some conditions; however, induction of DNA 
damage of the same cells only occurred in the presenc  of granzymes (Hayes et al., 
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1989; Shi et al., 1992a; Shi et al., 1992b), indicating synergetic activity of perforin 
and granzymes in inducing apoptotic cell death.  
 
Perforin expression has been found in most NK, NKT andγδ+ cells as well as CD8+ 
T cells and a subpopulation of CD4+ T cells (Williams and Engelhard, 1997; Kelso 
et al., 2002; Johnson et al., 2003; Bade et al., 2005). The nascent protein is 
synthesized as a 70 kDa inactive precursor, modified by addition of glycans in the 
Golgi apparatus and cleaved at the C-terminus in the lytic granule, thus yielding a 60 
kDa active form (Uellner et al., 1997). The presence of a low concentration of Ca2+ 
in the lytic granule as well as the formation of complexes with serglycins in the 
acidic environment, results in the mature form of perforin remaining functionally 
inactive within the granules (Masson et al., 1990). Upon degranulation, perforin 
binds Ca2+ which induces conformational changes in the C2-domain that confer an 
ability to bind lipids (Uellner et al., 1997). This allows perforin to enter into the lipid 
bi-layer and by polymerisation form a 16nm membrane pore. Pores formed at the site 
of the T cell synapse were originally thought to all w granzymes to pass through the 
cell membrane (Young et al., 1986; Podack and Hengart er, 1989). However, the 
precise site at which granzymes enter the target cell is still under debate. Evidence 
has been presented that granzymes and perforin together are taken up by the target 
cells by endocytosis and that delivery of granzymes into the cytosol via perforin 
pores occurs within the endosomes (Froelich et al., 1996b; Metkar et al., 2002). 
Moreover, it has been proposed that mannose-6-phosphate receptor (MPR) proteins 
on the cell surface may bind granzymes and perforin and deliver them into 
endosomes (Motyka et al., 2000; Metkar et al., 2002). 
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1.5 Granzymes  
Granzymes are a subfamily of serine proteases that make up a major proportion of 
the mass of lytic granules in cytotoxic CD8+ T lymphocytes and NK cells. They play 
an important role in killing of susceptible target cells, acting on various cellular 
pathways that regulate programmed cell death (Jenne a d Tschopp, 1988). So far, 
five granzymes - A, B, K, H and M – have been identified in humans and ten 
granzymes - A, B, K, E, M, C, D, F, G and N - have b en identified in mice 
(Grossman et al., 2003). Granzyme H appears to be restricted to humans, while C, D, 
E, F, G and N are exclusively expressed in mouse.  
 
Granzymes are structurally related to chymotrypsin with typical features of a 
catalytic triad of amino acid residues (His-57, Asp-103 and Ser-195) at the active 
sites (Murphy et al., 1988) and a substrate-binding cleft, the shape of which 
determines their enzymatic specificity. In general, fo lowing specific docking into 
the substrate binding cleft of the protease, the substrate is cleaved after the cleavage 
residue (referred to as amino acid P1 position in the substrate) through the proteolytic 
activity of the catalytic triad. The binding site on the protease typically interacts with 
at least three amino acids on each side of P1 in the substrate. The nomenclature 
applied to amino acid positions flanking the cleavage residue in the substrate is Pn-
P4-P3-P2-P1-P1'-P2'-P3'-P4'-Pn', while the nomenclature for corresponding sites in 
the protease is Sn-S4-S3-S2-S1-S1'-S2'-S3'-S4'-Sn' (Schechter and Berger, 1967), 
where S1 is the key site  that interacts with the substrate P1 residue. This S1 site of 
the protease determines “primary substrate specificity”, which is strictly restricted to 
 21 
certain amino acids, whereas other binding sites of the protease that interact with 
other substrate residues determine the “extended substrate specificity”, which is less 
specific but has substantial influence on the proteoly ic efficiency. Additional shared 
features of granzymes have been defined including the presence of a consensus 
sequence at the N-terminus (Bleackley et al., 1988; Jenne and Tschopp, 1988; 
Murphy et al., 1988), a conserved activation peptide (Gly-Glu or Glu-Glu) (see 
section 1.5.1) and 3 or 4 intra-molecular disulfide bridges (Smyth et al., 1996; 
Trapani, 2001; Piuko et al., 2007).  
 
Genes encoding each member of the granzyme family are classified into three 
distinct subgroups based on their enzymatic activity (trypsin-like, chymotrypsin-like 
and metase) and this corresponds to segregation int d fferent gene loci on three 
chromosomes (Table1.1) (Trapani, 2001). Granzymes A and K are found together on 
human 5q11-q12 and mouse 13D chromosomal regions, respectively. Granzymes B 
and H are located on human 14q11-q12 chromosomal region and mouse granzymes 
B, C, E, M, D, F, G and N on 14D chromosomal region. In addition to these 
granzymes, the chymotrypsin-like locus contains genes encoding other serine 
proteases such as cathepsin G and mast cell proteases in both species. Granzyme M 
is located on human 19p13.3 and mouse 10q21.2 chromos al regions, respectively; 
a cluster of neutrophil elastase genes including azurocidin 1(ZAU1), proteinase 
3(PRTN3), neutrophil expressed (ELANE) and complement factor D (CFD) are 
present 200-500kb downstream of granzyme M (Pilat et al., 1994). Interspecies 
comparisons of granzyme sequences reveal a clearly lower level of similarity 
between the 3 subgroups within a species (30-40%) than between group members 
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across species (55-70%) (Piuko et al., 2007). Several studies have demonstrated that 
the substrate specificity of granzymes corresponds to their phylogenetic relatedness 
and their genome loci. For example, granzyme A and K are tryptases that prefer to 
cleave their target proteins after basic residues (arginine or lysine); Granzyme B has 
an unusual Aspase activity, specifically requiring an Asp residue; Granzyme H 
exhibits the chymase specificity and cleaves after aromatic residues (phenylalanine, 
tryptophan or tyrosine); Granzyme M has metase activity and prefers to cleave after 
long narrow hydrophobic residues (methionine or leucine). In contrast, the substrate 
specificities of mouse granzymes C, E, D, F, G and N were not defined (Smyth et al., 
1996; Smyth et al., 2001) and are still unknown so far. 
 
Table 1.1 Mouse and human granzymes grouped according to their 
chromosomal localization 





1.5.1 Synthesis and processing of granzymes  
As granzymes are extremely toxic, causing cell death through various cellular 
pathways, expression of these molecules is regulated to avoid enzymatic activity 
during their post-translational transport and storage. Their function is strongly related 
to the structural conformation of the proteins. Nascent granzymes are synthesized as 
inactive zymogens and have to undergo two modificaton steps to become 
enzymatically activated. Firstly, the signal sequence is removed when it passes 
through the endoplasmic reticulum (ER), leaving an activation peptide attached at the 
amino terminus of what is destined to be the mature protein (Masson and Tschopp, 
1987). This pro-protein is then delivered via the Golgi apparatus into the lytic 
granules. Transport occurs predominantly by the mannose-6-phosphate receptor 
(MPR) pathway, although approximately 30% of granzyme A and B have been 
shown to be delivered into the lytic granules in an MPR-independent way (Griffiths 
and Isaaz, 1993). Second, once inside the granules, a specific peptidase, dipeptidyl 
peptidase I/cathepsin C, cleaves the 2 N-terminal residues of the activation peptide, 
producing the active form of the enzyme (Pham and Ley, 1999) (Brown et al., 1993). 
This form remains enzymatically non-functional within the low pH environment of 
the granules and only becomes active following release upon engagement of target 
cells (McGuire et al., 1993). This process of granzyme production is broadly similar 
for the different granzymes, except for granzyme M which is converted to the active 
form by N-terminal cleavage of a hexapeptide instead of a dipeptide to generate the 
mature protein sequence (Smyth et al., 1995; Kelly et al., 1996). 
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1.5.2 Expression of granule enzymes 
Granzymes are expressed primarily in lymphoid lineage cells such as CD4+ and 
CD8+ T cells and their thymic precursors, and γδ+ T cells, NK cells and NKT cells 
(Table 1.2) (Anthony et al., 2010; Bovenschen and Kummer., 2010). Their 
differential expression and discordant regulation in lymphocytes has been reported in 
several studies. Unstimulated thymocytes only express detectable transcripts of 
granzyme A. However following in vitro stimulation with PMA, ionomycin and IL-2, 
cultured CD4-CD8- thymocytes, both TCR γ/δ+ and TCRα/β+, were shown to 
contain transcripts for most granzyme genes (Garcia-Sanz et al., 1990). Lymphocyte 
subsets involved in innate immunity, namely NK cells  γδ+ T cells, and NKT cells, 
were found to have constitutive expression and granule storage of granzymes 
(Garcia-Sanz et al., 1990), whereas CD4+ and CD8+ T cells required antigen 
stimulation or other types of stimuli to induce granzyme expression (Garcia-Sanz et 
al., 1990; Grossman et al., 2003). Initial studies of granzyme gene expression in 
different populations of cytotoxic lymphocytes reported that CD8+ T cells obtained 
from allogeneic mixed lymphocyte reactions expressed predominantly granzyme A 
and B, whereas levels of expression of other granzymes comparable to that of 
granzyme A and B were found in NK and lymphokine-activ ted killer cells (LAK) 
cells (Pham et al., 1996). Recent studies in mice indicated that, while perforin and 
most or all of granzymes can be expressed simultaneously by virus-specific CD8+ T 
cell clones and populations activated in vitro, the genes encoding perforin and the 
granzymes may be differentially regulated in activated CD8+ T cells at the single cell 
level (Kelso et al., 2002). This was confirmed by another single cell study of virus-
specific CD8+ T cells, which showed distinct patterns of expression of perforin and 
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the granzyme transcripts in single cells from the same T cell culture (Johnson et al., 
2003). 
 
Additional studies have shown that the levels of expr ssion of perforin and the 
various granzymes by CD8+ T cells may be influenced by several cytokines. 
Regulation of expression of granzymes and perforin in CD8+ T cells has been 
reported for IL-2, IL-4, IL-12, IL-15 and IL-21. IL-2 and IL-15 were shown capable 
of stimulating proliferation of CD8+ T cells and up-regulating expression of 
granzyme A and B and perforin genes (Ye et al., 1996). Provision of IL-12 as a third 
signal (ie, in addition to TCR engagement and IL-2 co-stimulation), was found to 
promote development of full cytolytic function of CD8+  T cells and enhanced levels 
of granzyme B protein expression (Curtsinger et al., 2005). IL-21 in combination 
with IL-15 was found to promote expression of granzyme B (Zeng et al., 2005). In 
contrast, IL-4 has been reported to induce a subpopulation of non-cytolytic T cells 
with low surface CD8+ and low levels of granzymes and perforin expression 










Table 1.2 Summary of information on cell types/tissues expressing different 
granzymes 
Granzyme Species Expression 
A H, M CD4+ T cells, CD8+ T cells, NK, NKT, γδ+ T cells and thymus 
B H, M CD4+ T cells, CD8+ T cells, NK, NKT, γδ+ T cells and thymus 
C M CD4+ T cells, CD8+ T cells and thymus 
D M CD4+ T cells, CD8+ T cells, NK and thymus 
E M CD4+ T cells, CD8+ T cells, NK and thymus 
F M CD4+ T cells, CD8+ T cells, NK and thymus 
G M CD4+ T cells, CD8+ T cells, NK and thymus 
H H CD4+ T cells, CD8+ T cells, NK  
K H, M CD4+ T cells, CD8+ T cells, NK, NKT, γδ+ T cells 
L M Unknown 
M H, M CD8+ T cells, NK, NKT, γδ+ T cells 
N M Testis 
H - human; M - mouse;. This table is a modified version of data reported by 
Anthony et al., 2010 and Bovenschen and Kummer., 201 .  
 
1.5.3 Apoptotic function of granzymes  
Granzyme A and B are the most abundant granzymes and h ve been studied in most 
detail. Current thinking regarding the molecular basis of GzmA and GzmB-induced 
cell death is based largely on experiments using a mast cell exocytosis model 
(Nakajima et al., 1995) and on i vitro studies using purified effector molecules 
delivered with sub-lytic concentrations of perforin or other pore-forming analogues. 
However, the relevance of these in vitro findings to the in vivo models of action of 
the granzymes is not always well established. Also cell death may not always be 
dependent on apoptosis. Despite the finding that CD8+ T cells deficient in granzyme 
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A and B are defective inducers of classical apoptosis, they can still mediate target 
cell death, suggesting that other granzymes may be op rating via alternative 
pathways (Simon et al., 1997; Mullbacher et al., 1999; Davis et al., 2001; 
Waterhouse et al., 2006). Little is known about the functions of other granzymes, 
hence their designation as ‘orphans’ (Grossman et al., 2003). Although granzyme K, 
H and M molecules are found at low levels in human CD8+  T cell granules, it has 
been shown that they can induce cell death (Bovenschen and Kummer., 2010). 
 
Table 1.3 Characteristics cell death induced by individual granzymes and 
phenotypes of mice with granzyme deficiencies 
Granzyme  Function in cell death 
A 
Caspase-independent, depolarization of the mitochondrial membrane, 
generation of ROS and cleavage of SET, and DNA nicks  
B 
  
Caspase-dependent and -independent cell death.  
Direct processing of effector caspases such as pro-caspase-3 and cleavage 
activation of ICAD, cleavage of Bid leading to mitochondrial damage and 
release of SMAC/DIABLO and cytochrome c, formation f an apoptosome 
resulting in DNA fragmentation   
C  
Caspase-independent cell death with mitochondrial inner membrane 
depolarization and DNA nicks  
H 
Caspase-independent cell death with mitochondrial inner membrane 
depolarization and ROS formation, resulting in DNA nicks  
K 
Bid cleavage and caspase-independent cell death, with ROS production due to 
mitochondrial inner membrane depolarization and DNA nicks  
M 
Caspase-independent, with unique morphological changes, possible cleavage 
of ICAD and PARP 
D-G,J, L 
and N  Not described  
Deficiency Mouse Phenotype 
GrzA -/- Healthy, fertile; moderate increase in susceptibility to MCMV and ectromelia. 
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Unaltered apoptotic response  
GrzB -/- 
Healthy, fertile; moderate increase in susceptibiliy to ectromelia and MCMV. 
CD8+ T cells induce delayed nuclear changes in targe  cell. 
GrzAB -/- 
Healthy, fertile; highly susceptible to both MCMV and ectromelia. CTL 
induce delayed nuclear changes in target cell 
GrzM -/- 
Healthy, Fertile; mild susceptibility to MCMV but normal response to 
ectromelia. Unaltered apoptotic response  
The table is cited from Anthony et al., 2010. MCMV = Murine cytomegalovirus;  
 
1.5.3.1 Apoptotic function of Granzyme A  
In vitro studies have shown that recombinant granzyme A delivered with purified 
perforin results in cell death by causing damage of the inner mitochondrial 
membrane and inducing nicks in single-stranded DNA (Figure 1.2) (Lieberman and 
Fan, 2003). Unlike granzyme B, granzyme A-induced cll death does not require 
caspase activation (Beresford et al., 1999; Fan et al., 2003a). Granzyme A has been 
shown to act on 3 major cellular targets: lamins, hi tones and the endoplasmic 
reticulum-associated SET complex (Beresford et al., 2001; Zhang et al., 2001a; 
Zhang et al., 2001b). Production of reactive oxygen species (ROS) occurs when 
granzyme A causes inner mitochondrial membrane damage, thus leading to 
translocation of the SET complex from the cytoplasmic surface of the ER to the 
nucleus (Beresford et al., 1999; Martinvalet et al., 2005). Although the biological 
function of the SET complex is not fully understood, it is probably involved in 
activation of transcription and transcription-relatd DNA repair upon oxidative 
stress. It contains three granzyme A substrates, the nucleosome assembly protein 
SET, the DNA binding protein HMG-2 and the base excision repair enzyme, Ape1 
(Beresford et al., 1999; Fan et al., 2003a; Fan et al., 2003b). The SET protein acts as 
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an inhibitor of an endonuclease in the SET complex (NM23-H1) and cleavage of 
SET by granzyme A allows activation of NM23-H1, thus resulting in single-strand 
DNA nicks. Lamins are responsible for maintaining nuclear structure and histones 
are the basic building blocks of chromatin structure (Zhang et al., 2001a; Zhang et 
al., 2001b). Overall, the activity of granzyme A induces apoptosis of target cells 
through degradation of  DNA and disruption of chromatin structural integrity (Pardo 
et al., 2004).  
 
Figure 1.2 Granzyme A-mediated apoptotic pathway 
The figure is cited from Lieberman, 2003 
 
Although several studies have demonstrated cytotoxic activity of granzyme A in 
vitro, the physiological significance of these findings remains controversial (Metkar 
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et al., 2008; Trapani and Bird, 2008; Pardo et al., 2009). A recent study of human 
and mouse granzyme A by Metkar et al., showed this protease does not have 
cytotoxic activity after delivery by human perforin or adenoviral particles and is not 
able to induce cell death at low concentrations (nanomolar), based on use of a short-
term cell-death assay and cell survival in a long-term proliferative assay (Metkar et 
al., 2008). Although cell death was observed with hgh concentrations of granzyme A 
(micromolar) with sublytic concentrations of perforin, this was not associated with 
apoptosis but with necrosis due to virtually instantaneous membrane lysis (Metkar et 
al., 2008). In addition, several investigators have reported that granzyme A-deficient 
mice have no defect of CD8+ T cell or NK cell-mediated cytotoxicity, suggesting 
that granzyme A does not play an essential role in cell-mediated cytotoxicity (Ebnet 
et al., 1995; Mullbacher et al., 1996; Riera et al., 2000). 
 
1.5.3.2 Apoptotic function of Granzyme B  
In contrast to granzyme A, there seems to be little dispute that granzyme B is a 
potent inducer of apoptosis and an important mediator of cytotoxicity. Direct 
evidence has been obtained from studies of granzyme B-d ficient mice, which  show 
dramatically reduced efficiency in the induction of rapid cell death of allogeneic 
target cells by CD8+ T cells, implying its critical role in rapid granule-mediated 
apoptosis (Heusel et al., 1994). Granzyme B induces apoptosis by caspase-dependent 
and –independent pathways (Figure 1.3) (Lieberman, 2003). It can directly hydrolyse 
but only partially process effector caspases such as procaspase-3 and -7, as their full 
activation requires a further process known as autoc talysis which is regulated by the 
release of other pro-apoptotic mitochondrial factors (Martin et al., 1996; Goping et 
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al., 2003; Sutton et al., 2003). The endonuclease CAD is activated after its inhibitor, 
inhibitor of caspase-activated DNase (ICAD), is cleav d by the fully activated 
effector caspases, thus resulting in cell death via DNA fragmentation. Alternatively, 
granzyme B can induce cell death by triggering mitochondrial outer membrane 
permeabilization as a consequence of cleaving a pro-a optotic protein of the Bcl-2 
family, BH3-interaction domain death agonist (Bid). The truncated Bid protein 
initiates mitochondrial-dependent apoptosis by activ ting Bax and/or Bak (pro-
apoptotic proteins of the Bcl-2 family) and promoting their oligomerization within 
the mitochondrial outer membrane, which leads to mitochondria permeabilization 
and the subsequent release of cytochrome c, SMAC/DIABLO and  Htra2/Omi (Barry 
et al., 2000; Sutton et al., 2000; Alimonti et al.,2001; Sutton et al., 2003). Release of 
SMAC/DIABLO and Htra2/Omi sequesters the inhibitor of apoptosis proteins (IAP), 
which acts as an endogenous inhibitor of the activity of caspases, and thus facilitate 
full activation of caspases via autocatalysis (Martin et al., 1996; Goping et al., 2003; 
Sutton et al., 2003). In addition, release of cytochr me c into the cytosol leads to the 
formation of the apoptosome, a multimeric complex  comprising cytochrome c, 
apoptotic protease activating factor 1 (APAF-1) and procaspase-9 (Li et al., 1997; 
Jiang and Wang, 2000). The assembly of apoptosomes results in activation of 
caspase-9, an apical caspase (ie. involved in initial stages of caspase-mediated 
apoptosis), followed by activation of the downstream caspase cascade (Slee et al., 





Figure 1.3 Human granzyme B-mediated apoptotic pathway 
 
Solid arrows refer to the major cytotoxic pathways mediated by human 
granzyme B; Dotted arrows refer to minor pathways, which reinforce actions of 
the major pathways but are not able to induce apoptosis alone; The figure is 
cited from Trapani, 2001.  
 
 
Recent studies have shown that the precise pathways by which granzyme B mediates 
apoptosis are species-dependent (Kaiserman et al., 2006; Cullen et al., 2007). Human 
granzyme B is much more effective at mediating apoptosis than mouse granzyme B 
because it can cleave and activate Bid, whereas mouse granzyme B cleaves Bid 
poorly and does not utilise it for initiating apoptsis (Cullen et al., 2007). In addition, 
the failure of human granzyme B to kill cells induced to over-express the anti-
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apoptotic protein Bcl-2, which blocks Bid-initiated cell death, indicates that it lacks 
the capacity to independently and fully activate apoptosis by direct activation of 
caspases (Goping et al., 2003; Sutton et al., 2003). Thus, mouse granzyme B directly 
activates caspases to promote apoptosis in a Bid-independent manner, whereas 
human granzyme B may kill by indirect activation of caspases via Bid.  
 
Although activation of caspases was originally thought to be required for granzyme 
B-mediated cell death, studies by a number of groups indicate that their requirement 
is not absolute. An in vitro study of mouse CD8+ T cells showed that apoptotic 
nuclear damage induced by granule exocytosis was abrog ted by a pan-caspase 
inhibitor Z-VAD-FMK, whereas lysis of the cells was unaffected (Sarin et al., 1997). 
Similar results have been obtained in studies with purified human granzyme B, 
caspase inhibition preventing granzyme-induced DNA damage but not cell lysis 
(Trapani et al., 1998). Some studies also showed that granzyme B can directly cleave 
and activate several downstream substrates of caspase  such as the inhibitor of the 
caspases-activated DNase (ICAD), poly (ADP-ribose) polymerase (PARP), DNA-
dependent protein kinase (DNA-PK) and lamin B (Froelich et al., 1996a; Andrade et 
al., 1998; Thomas et al., 2000; Sharif-Askari et al., 2001; Zhang et al., 2001a) to 
induce DNA fragmentation. These findings strongly indicated an important role of 
caspase-independent pathway(s) in granzyme B-mediated apoptosis.  
 
1.5.3.3 Apoptotic function of orphan granzymes  
Purified recombinant human granzyme H, delivered by perforin or a pore-forming 
analogue streptolysin O (SLO), has been shown to mediate cell death characterised 
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by chromosomal condensation, DNA fragmentation, mitochondrial inner membrane 
depolarization and ROS production (Fellows et al., 2007). The granzyme H-induced 
cell death in vitro is independent of Bid and caspases, implying a cell-death pathway 
distinct from that of granzyme B (Fellows et al., 2007). However, this mechanism of 
granzyme H-induced cell death has been challenged by another group, who provided 
evidence for caspase-dependent apoptosis involving B d and ICAD and release of 
cytochrome c (Hou et al., 2008). The latter cell death was induced by purified 
recombinant granzyme H after delivery by adenovirus or a cationic lipid-based 
transfection reagent Pro-Ject into target cells.  
 
Human granzyme K was initially thought to act in a similar way and provide an 
alternative to granzyme A for inducing apoptosis, snce cell death was reported to 
occur independently of caspases and similar to granzyme A was associated with 
single-strand DNA nicks and ROS production (MacDonald et al., 1999; Martinvalet 
et al., 2005; Zhao et al., 2007b). Granzyme K has also been reported to cleave the 
granzyme A substrate SET to induce cell death (Zhao et al., 2007b). However, recent 
studies have strongly suggested that it has a distinct function, as indicated by a 
dependence on mitochondrial depolarisation initiated by direct processing of Bid to 
release cytochrome c and endonuclease G (Zhao et al., 2007a). 
 
Purified recombinant human granzyme M delivered with perforin or streptolysin O 
(SLO) has been found to rapidly induce death of tumo r cells in vitro, which show 
an unusual cell death-morphology characterised by formation of large cytoplasmic 
vacuoles, dilated ER and shrunken nuclei; no DNA nicki g or fragmentation was 
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observed (Kelly et al., 2004; Bovenschen et al., 2008; Cullen et al., 2009). The cell 
death was independent of Bid and caspases and DNA fragmentation, indicating a 
potentially unique form distinct from that of granzyme A and B. However, a study of 
granzyme M-deficient mice has shown that killing of tumour cells by NK cells in 
vitro was comparable to that of wild-type mice (Pao et al., 2005). 
 
1.5.3.4 Inhibitors of granzyme activity  
Protease inhibitor 9 (serpinB9 / PI-9), a member of the clade B serpins, is an 
endogenous inhibitor of human granzyme B. PI-9 acts as a pseudo substrate, 
employing a reactive centre loop (RCL) to react with residues at the active site of 
granzyme B, thus blocking its function by forming an irreversible stable complex 
(Sun et al., 1996). PI-9 shows a very broad tissue and cellular distribution, with high 
and stable levels found in cytotoxic T cells, antigen-presenting cells, a number of 
other cell types, including endothelial and mesothelial cells, and cells at 
immunologically privileged sites (Sun et al., 1996; Bladergroen et al., 2001; Buzza et 
al., 2001; Hirst et al., 2001). PI-9 is located in both the cytoplasm and nucleus of 
cells (Bird et al., 2001) and is thought to protect cytotoxic T cells and bystander cells 
from misdirected granzyme B (Sun et al., 1996; Bladergroen et al., 2001; Buzza et 
al., 2001; Hirst et al., 2001; Bird et al., 1998).  
 
Recent studies have proposed that some tumour cells up-regulate PI-9 expression in 
order to evade the immune system. Studies of natural levels of PI-9 expression in a 
number of tumour cells (including lymphoid tumours) showed that the level of 
expression was associated with increased resistance to perforin/ granzyme B-
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mediated killing activity by CD8+ T cells and NK cells (Medema et al., 2001; 
Bladergroen et al., 2002; ten Berge et al., 2002; van Houdt et al., 2005; Bossard et al., 
2007), although this notion is challenged by Godal et al., (2006), who presented 
evidence that PI-9 expression in several lymphoma cells was irrelevant to perforin-
dependent killing  by CD8+ T cells and NK cells (Godal et al., 2006).  
  
Granzyme M has recently been reported to facilitate granzyme B-induced cell death 
by inactivating the PI-9 inhibitor. Granzyme M hydrolysed PI-9 in vitro and thus 
inactivated its inhibitory activity on granzyme B (Mahrus et al., 2004). Although the 
physiological significance of this finding remains to be examined, it suggests that 
granzyme M can promote the efficiency of granzyme B-induced killing by 
inactivating its endogenous inhibitor.  
 
Adenovirus 5 has been shown to encode an inhibitor of granzyme B, L4-100K 
assembly protein, which forms a stable complex with the active sites of granzyme B, 
thus inhibiting its proteolytic activity (Andrade et al., 2001). However, granzyme H 
is able to neutralise this inhibitor, thus facilitating killing of the adenovirus-infected 
cells granzyme B (Andrade et al., 2007). These findings demonstrated the ability of 
granzymes to operate cooperatively to induce apoptosis and to bypass viral and 






1.5.4 Other possible functions of granzymes  
In addition to their role in apoptosis, evidence has emerged recently that granzymes 
have other biological functions, including direct inactivation of intracellular 
pathogens, remodelling extracellular matrix (ECM) and induction of pro-
inflammatory cytokines.  
 
Several studies in mouse models indicated an important ole of granzymes for viral 
clearance. For example, mice deficient in granzyme A, B or M or both granzyme A 
and B have shown various degrees of increased susceptibility to murine 
cytomegalovirus (MCMV) and ectromelia infection, despite the finding that their 
CD8+ T cells generally retain cytotoxic activity comparable with that of wild-type 
mice (Table 1.3) (Anthony et al., 2010). Also as dicussed above, granzyme H 
restricts the replication of adenovirus by directly cleaving and inactivating an 
adenovirus DNA binding protein DBP essential for viral replication. Overall, these 
findings indicate that granzymes may influence control the pathogen infections by 
mechanisms other than killing of infected cells.  
 
A number of extracellular proteins have been shown to act as substrates for 
granzymes. For example, fibronectin, laminin, basement membrane collagen type IV 
and other substrates such as the thrombin receptor are processed by granzyme A 
(Simon et al., 1988; Simon et al., 1991; Vettel et al., 1993; Suidan et al., 1994). 
Granzyme B is also reported to cleave the extracellular substrates vitronectin, 
fibronectin and laminin (Buzza et al., 2005). As a consequence of cleavage of these 
three proteins involved in extracellular matrix structure and function, granzyme B 
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induces perforin-independent killing via a process, known as anoikis (cell death 
induced by detachment) and inhibits tumour cell spreading, migration, and invasion 
(Buzza et al., 2005). In addition to lymphoid cells, granzyme B expression has also 
been found in non-lymphoid cells such as mast cells (Pardo et al., 2007; Strik et al., 
2007), basophils (Tschopp et al., 2006) and epidermal keratinocytes (Berthou et al., 
1997) and macrophages (Kim et al., 2007). However, th  function of granzyme B in 
these cell types is unknown.  
 
Human and murine granzyme A in the absence of perforin have been reported to 
trigger expression of  IL-1β, TNFα and IL-6 by human monocytes and expression of 
IL-1β in primary mouse macrophages, respectively (Metkar et al., 2008). The 
mechanisms involved were not investigated in detail, but cytokine release from 













1.6 Aims of the project 
 
The above discussion indicates that the cytotoxic activity of CD8+ T cells is an 
important factor in mediating immunity against the bovine intracellular protozoan 
parasite Theileria parva. However, the mechanism by which the specific CD8+ T 
cells kill parasitized cells is not understood. In human and mouse, the predominant 
pathway used by CD8+ T cells to kill pathogen-infected cells is granule exocytosis, 
involving release of a membrane disrupting protein perforin and a number of 
granzymes (5 in human and 10 in mouse). Granzyme B is the best-characterized and 
most potent member of the granzyme family in these species and is considered to be 
the major initiator of granule-mediated apoptosis. However, there is no published 
information on the identity or biological activities of bovine granzymes.  
 
The hypothesis addressed by this protect was that killing of T. parva-infected cells 
by CD8+ T cells occurs by release of lytic granules and that granzyme B is an 
important mediator of the cytotoxic activity. The overall aim was to characterise 
granzymes in cattle and investigate their involvement in killing of Theileria-infected 
cells by CD8+ T cells, focusing particularly on the role of granzyme B.  
 
The specific objectives were as follows: 
• Determine the role of granule exocytosis in killing of Theileria-infected cells by 
CD8+ T cells.  
• Identify and characterize the functional granzyme genes in the bovine genome 
and examine their expression in T. parva-specific CD8+ T cells.  
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• Investigate the relationship of killing levels and the granule enzyme transcript 
profiles of Theileria-specific CD8+ T cells.  
• Generate recombinant cDNA constructs of bovine granzyme B to allow 
production of functionally active protein for development of a biological assay to 
measure specific granzyme B activity.  
•  Using the above assay and commercially available inhib tors, determine the role 















Chapter 2   Materials and Methods 
 
This chapter will describe methods used throughout the study, while methods 
peculiar to the work reported in individual results chapters will be described in the 
respective chapters 
 
2.1 Experimental animals  
 
Three animals used in the study (641, 011 and 592) were Holstein Friesians bred at 
the Institute for Animal Health (IAH), Compton. These animals were immunised by 
infection with T. parva and treatment The animals were bred from MHC-defined 
dams and sires and their MHC phenotypes were identified using a panel of MHC1-
specific monoclonal antibodies (Ellis et al., 1999). Animal 641 was homozygous for 
the A18 MHC1 haplotype and 011 and 592 were homozygus for the A10 MHC1 
haplotype.  
 
2.2 General cell culture techniques  
2.2.1 Lymphocyte preparation  
Peripheral blood mononuclear cells (PBMC) were isolated as described in Goddeeris 
and Morrison, 1988. Blood was collected by jugular venipuncture into an equal 
volume of Alsever’s solution (Appendix C.1). Aliquots of 30ml of blood in Alsever’s 
solution were carefully overlaid onto 20ml of Ficoll-paque (GE Healthcare, Uppsala, 
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Sweden) in 50ml falcon tubes and centrifuged at 800x g for 30 min at room 
temperature. PBMC were harvested from the interface nd mixed with an equal 
volume of Alsever’s solution before pelleting at 450 x g at 10 min at room 
temperature. The pellet was then washed 3 times in Alsever’s prior to re-suspension 
in standard culture medium (SCM- Appendix C.2) and cells counted using a 
haemocytometer. 
 
2.2.2 Concanavalin A (ConA)- activated PBMC 
Uninfected lymphoblast lines were established in 24 well plates by stimulation of 
PBMC with ConA (Sigma-Aldrich) for 3 days and immediately harvested for the 
further experiment. Each well was seeded with 2x106/ml PBMC in SCM together 
with ConA at a final concentration of 5ug/ml. Plates were incubated for 3 days in a 
humidified incubator in an atmosphere of 5% CO2 at 37°C. 
 
2.2.3 Complement-mediated cell lysis 
Cells were re-suspended in SCM at a final concentration of 1 x 107 cells/ml and 1ml 
of hybridoma culture supernatant containing monoclonal antibodies ILA-12 (anti-
CD4, IgG2a) and CC15 (WC1 –expressed on γδ+ T cells, IgG2a) added per 5 x 107 
cells, and incubated on ice for 45 min. Cells were pelleted by centrifugation at 180 x 
g for 10 min at 4°C and washed twice in SCM. Cells were subsequently re-
suspended in SCM at 5x106cells/ml and rabbit serum was added, as a source of 
complement, to give a final dilution of one in five. The mixture was incubated at 
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37°C for 40 min to allow complement-mediated lysis. The cells were pelleted and 
washed twice in SCM, re-suspended in 9 ml SCM and overlaid on 6ml Ficoll-
PaqueTM PLUS in 15ml polypropylene tubes and then centrifuged at 900 x g for 20 
min at room temperature. Live, unlysed cells were colle ted from the Ficoll/SCM 
interface, washed in an equal volume of SCM and pelleted at 450 x g for 10 min at 
room temperature. The effectiveness of the lysis was ssessed by 
immunofluorescence staining of a sample the remaining live cell population and 
analysis by flow cytometry (Section 2.2.7). 
 
2.2.4 Generation of CD8+ T cell lines in vitro  
T. parva-specific CD8+ T-cell lines were generated by the mthod described by 
Goddeeris and Morrison, 1988, with minor modifications: 
1st-stimulation 
PBMC were isolated from blood of a T. parva immune animal as described above. 
Established cell lines infected with T. parva (Muguga strain - TPM) derived from 
each of the animals from which T cell lines were generated, referred to as 641TPM, 
011TPM and 592TPM were provided by Drs Niall MacHugh and Timothy Connelley 
in the Roslin Institute. Autologous T .parva-infected cells were harvested, counted 
and resuspended at 1x105/ml SCM. They were exposed to 60Gy of gamma 
irradiation from a 137Cesium source (Roslin Institute). Aliquots of 1 ml of PBMC at 
2x106/ml and irradiated autologous stimulators at 1x105/ml were added to each well 
of 24-well plates. Plates were incubated for 7 days in a humidified incubator in an 
atmosphere of 5% CO2 at 37°C. 
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2nd-stimulation 
Cells from the first stimulation were harvested, viable cells counted and re-cultured 
in 24-well plates. Each well was seeded with 2x106 responder cells together with 
1x105 irradiated autologous stimulators in a final volume of 2ml SCM. Plates were 
incubated for 7 days in a humidified incubator in an atmosphere of 5% CO2 at 37°C. 
3rd-stimulation 
Cells from the second stimulation were harvested, counted and the CD4+ and γδ+ T-
cell populations lysed as described above (section 2.2.3). The remaining viable cells 
were resuspended at 2x105/ml in SCM and 1ml aliquots added into the wells of 24-
well plates along with 1x106 of irradiated autologous stimulators and recombinant 
human IL-2 (Chiron Corporation Emeryville, CA., USA) added to give a final 
concentration of 100U/ml. The plates were incubated for 7 days in a humidified 
incubator in an atmosphere of 5% CO2 at 37°C. 
 
2.2.5 Expansion of clones  
Selected CD8+ T cell clones, kindly provided by Dr Tim Connelley and Ms Victoria 
Carroll, respectively were expanded in the wells of 24-well plates. Each well was 
seeded with 1x105 responder cells together with 5x105 irradiated autologous 
parasitized stimulators and recombinant human IL-2 added to give a final 
concentration of 100U/ml. The plates were incubated for 14 days in a humidified 
incubator in an atmosphere of 5% CO2 at 37°C. 
 
2.2.6 Cryopreservation of cellular samples 
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Aliquots of 2x106 cells were pelleted and re-suspended in 500ul heat-inac ivated 
Foetal bovine serum (FBS) and 20% dimethylsulphoxide (DMSO, Sigma, Poole, 
Dorset, UK)/500ul FBS was slowly added to each aliquot. The 1ml aliquots were 
transferred into polypropylene cryovials (CryoTube, Nunc, Roskilde, Denmark), 
places in an isopropanol jacketed container (Cryo 1°C Freezing Container, Nalgene, 
Neerijse, Belgium) and slowly frozen at -70°C for at least 3 hour before being 
transferred to liquid nitrogen storage. For recovery of the cells, cryopreserved 
samples were rapidly thawed by incubation in a water bath at 37 °C, made up to  
10ml by addition of SCM, pelleted to remove DMSO and re-suspended in SCM. 
Cells were then kept in a humidified incubator in an atmosphere of 5% CO2 at 37°C  
 
2.2.7 Flow cytometry 
Cells were stained by indirect immunofluorescence and nalysed by flow cytometry 
using a cell analyser (FACScalibur, Beckton Dickinso , Mountain View, CA., USA). 
The monoclonal antibodies (mAbs) were primary antibod es used for FACS analysis. 
The second antibody was fluorescein isothiocyanate (FITC)-labelled, polyvalent goat 
anti-mouse immunogolobulin G, A, M antibody (Sigma-Aldrich, Poole, Dorset, UK). 
 
For phenotypic analysis, aliquots of 50ul of cells suspended at 2x107cells/ml in 
FACS medium (Appendix C.3) were distributed in wells of 96-well round-bottom 
well plates and 25ul of primary mAb added to each well. As a negative control, cells 
were incubated with FACS medium instead of primary antibody. The antibodies used 
are listed in table 2.1. Plates were incubated at 4°C for 30 min, washed three times in 
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FACS medium and re-suspended in 25ul of FITC-labelled goat polyvalent anti-
mouse immunoglobulin diluted 1:100 in FACS medium. Following incubation at 
4°C for 30 min, the cells were washed three times in FACS medium and then re-
suspended in 200ul FACS medium for analysis using a cell analyser (FACScalibur, 
Beckton Dickinson, Mountain View, CA., USA).  
 
Table 2.1 Monoclonal antibodies used for primary labelling in FACS analysis 
Antibody Isotype Specificity Cell distribution 
MM1A IgG1 CD3 T-cells 
IL-A12 IgG2a CD4 CD4+ T-cells 
IL-A51  IgG1 CD8α chain CD8+ T-cells, subset NK cells 
IL-A105  IgG2a CD8 CD8+ T-cells, subset NK cells 
CC15 IgG2a WC1 Peripheral γδ+ T-cells  
GB21A IgG2b γδ TCR All γδ+ T-cells  
IL-A30 IgG1 IgM B-cells 
AKS1 IgG1 NKp46  NK cells  
 
 
2.2.8 Cytotoxicity assay  
Cell mediated cytotoxicity was measured using 111Indium (111In) 4-hour release 
assays as described by Goddeeris and Morrison (1988). In some experiments, longer 
periods of incubation of effectors with targets were used.  
Preparation of target cells  
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Autologous TPM-infected cell lines (641TPM, 011TPM and 592TPM) were used as 
target cells to test cytotoxicity against infected cells. T. annulata (TA)-infected cell 
lines 641TA and 592TA from the same animals, provided by Dr Niall MacHugh, 
were used as to test cytotoxicity against defined MHC1 A18-restricted and A10-
restricted epitopes using cells pulsed with synthetic peptides. Peptide for the A18-
restricted epitope Tp1214-224 (VGYPKVKEEML) was kindly provided by Dr. 
E.Taracha (ILRI, Nairobi, Kenya) and peptide for the A10-restricted epitope Tp249-59 
(KSSHGMGKVGK) was produced by Pepscan Systems (Lelystad, Netherlands). T. 
parva-infected target cells were suspended at 2x107cells/ml in cytotoxicity medium 
(Appendix C.4) and 5µCi of 111In (GE Healthcare Ltd., Little Chalfont, Bucks, UK) 
was added to 50ul of this suspension (1x 106 cells) and incubated for 30 min at 37°C 
in a 15ml falcon tube. Cells were then washed six times with 10ml cytotoxicity 
medium by centrifugation at 180 x g for 5 min and re-suspended in 10ml of 
cytotoxicity medium to give a concentration of 1x 105 cells/ml. T. annulata (TA) 
infected cell lines, 641TA and 592TA were adjusted o 1x106/ml in cytotoxicity 
medium and incubated with 100ng/ml Tp1214-224 and 1000ng/ml Tp249-59 peptide 
respectively for 0.5 hour at 37°C. The peptide-pulsed target cells were then pelleted, 
labelled with 5µCi of 111In and resuspended at a concentration of 1x105 cells/ml as 
described above.  
Preparation of effector cells  
CD8+ T cells were harvested and suspended in cytotoxicity medium to a 
concentration of 1x106cells/ml.  
111In 4h-release cytotoxicity assays  
 48 
Duplicate aliquots of 100ul of two-fold dilutions of the effector cells were distributed 
into the wells of 96-well V-bottomed plates to give a range of 1x105-6.25x103 cells 
per well; 50ul of target cells were added to each well. Spontaneous release and 
maximal release were measured for each of target cell in triplicate. For spontaneous 
release, 50ul of target cells were incubated with 100ul cytotoxicity medium, whereas, 
for maximal release, 50ul of target cells were incubated with 100ul 0.2% Tween 20 
(Sigma, Poole, Dorset, UK). Plates were briefly centrifuged for 1 min at 120xg to 
sediment the effector and target cell mixtures and then incubated for 4 hour in a 
humidified incubator in an atmosphere of 5% CO2 at 37°C.  After 4-hour incubation, 
plates were centrifuged for 5 min at 180xg and 75ul of supernatants per well was 
transferred into individual gamma counter tubes. To capture radioactive material in 
solid form to avoid spillage, small drops of bromophenol blue-stained 1.5% agarose 
were added into each sample. Radioactivity release was measured with a Wallac 
Wizard 1470 Automatic Gamma Counter (PerkinElmer, Beaconsfield, Bucks., UK) 
and the percentage of cytotoxicity for each sample was calculated using the 
following formula:  
Cytotoxicity (%) = 100 x (Test 111In release- Spontaneous 111In release)  
                                Maximal 111In release- Spontaneous 111In release  
Levels of cytotoxicity of >10% were considered to be significant positive results; 
these values were well in excess of 3 standard deviations above the values obtained 




2.3 General molecular techniques  
2.3.1 Isolation of RNA  
Total RNA was extracted from cell pellets using the Tri-Reagent Kit (Sigma, Sigma-
Aldrich, UK) according to the manufacturer’s protocol. Aliquots of 5-10 x 106 cells 
re-suspended in approximately 100ul of medium were lys d with 1ml Tri-Reagent by 
repeat pipetting and the mixture was incubated at room temperature for 5 min to 
complete dissociation of nuclear-protein complexes. Following the addition of 0.2ml 
of chloroform, the mixture was vigorously vortexed for 15 seconds, incubated at 
room temperature for 2-15 min and then centrifuged at 12,000xg for 15 min at 4°C. 
The aqueous phase was transferred to a new Eppendorf tube and mixed with 0.5ml 
isopropanol. After 5-10 min incubation at room temperature, the RNA was pelleted 
by centrifugation at 12,000xg for 10min at 4°C and then washed with 1ml of 75% 
ethanol by centrifugation at 7,500xg for 5min at 4°C. The washed pellet was air-
dried and re-suspended in 25ul of nuclease-free watr. RNA was stored at -70°C 
until further use. 
 
2.3.2 RNA and DNA quantification  
Absorbance of light at 260 and 280nm wavelengths by RNA/DNA samples was 
measured using a NanoDrop ND-1000 spectrophotometer (Labtech International 
Ltd) according to the manufacturer’s protocol. RNA/DNA concentration was 
estimated based on the assumptions that RNA and DNAhave absorbance readings of 
1.0 at 260nm at concentrations of 40ug/ml and 50ug/ml, respectively. The purity of 
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RNA/DNA samples was determined by the ratio of readings obtained at 
260nm:280nm >1.8.  
 
2.3.3 RNA reverse transcription  
cDNA was synthesized from RNA using the Reverse Transcription system (Promega, 
Madison, WI, USA) according to the manufacturer’s protocol. Briefly, 1ug RNA was 
incubated at 70°C for 10 min and placed on ice until added to the reaction in the 
following order: 4ul MgCl2 (25mM), 2ul of 10x Reverse transcription Inhibitor, 2ul 
dNTP mixture (10mM), 0.5ul Recombinant RNAsin Ribonuclease Inhibitor, 15U 
avian myeloblastoma virus reverse transcriptase (AVM-RT), 0.5ug Oligo(dT)15 
Primer or Random Primers, 1ug RNA sample and nuclease-free water added to give 
a final volume of 20ul. When using Oligo(dT)15 primer, the mixture was incubated at 
42°C for 1h, heated at 95°C for 5 min and then incubated at 0°C for 5 min to 
inactivate the AMV-RT and prevent it from binding the cDNA. When using Random 
Primers, the mixture was first incubated at room tep rature for 10 min before 
incubation at 42°C for 1h, then heated at 95°C for 5 min and incubated at 0°C for 5 
min. cDNA was stored at -20°C until use.  
 
2.3.4 General RT-PCR assay  
PCR primers were designed using the Primer3 programme (website 
http://www.bioinformatics.nl/cgi-bin/primer3/primer3_www.cgi) or manually and 
synthesized by MWG biotech (Ebersberg, Germany). Standard PCR reactions were 
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completed in a G-storm thermal cycler (Genetic Research instrumentation, Essex, 
UK). Standard PCR assays were composed of 10 pmol of primers, 0.5 units 
BIOTAQ (5 units/ul Bioline, London, UK), 2ul SM-0005 buffer (ABgene, Epsom, 
Surrey, UK-Appendix C.5), 1ul cDNA (0.05ug/ul) in DDW, and nuclease-free water 
to give a final volume of 20ul. The programme used was as follows: 94°C for 3 min, 
30 cycles (94°C for 1.5 min, 55°C for 1.5 min, 72°C for 1.5 min) and a final 
extension period of 72°C for 10 min.  
 
2.3.5 Agarose gel electrophoresis  
The PCR products were analysed by electrophoresis in 1.5% agarose gels 
incorporating 10ul Gel Red (Biotium Inc, Hayward, CA, USA)/100ul 1 x TAE 
(Appendix C.6). Aliquots of 10ul of PCR product plus 3ul of a 1 in 6 dilution of 
loading buffer (Appendix C.7) were applied to each lane and run at 110 V for 50 min 
in the midi-gel system (PowerPac 200, BIO-RAD), using 1 x TAE as running buffer. 
1ug of 1kb Plus DNA Ladder (Invitrogen Ltd., Paisley, UK) was used to enable 
estimation of product sizes.  
 
2.3.6 DNA purification  
PCR product purification  
PCR products were purified using the Wizard Preps DNA purification system 
(Promega, Madison, WI, USA) according to the manufact rer’s protocol. Briefly, 30-
300ul of PCR products were added to 100ul of Direct Purification Buffer and 
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vortexed briefly. After addition of 1ml of DNA resin, the mixture was vortexed 3 
times over a 1 min period and passed through a mini-column to allow the DNA/resin 
to bind to the membrane. The mini-column was then washed with 2ml of 80% 
isopropanol and centrifuged twice at 10,000x g for 2 min to dry the resin. 30ul of 
nuclease-free water was added to the mini-column to elute the purified DNA by 
centrifugation at 10,000xg for 1 min. DNA was stored at -20°C.  
 
Gel purification 
Gel purification of the desired DNA products was performed using the Wizard Preps 
DNA purification system (Promega, Madison, WI, USA) according to the 
manufacturer’s protocol. The predicted sizes of DNA bands were estimated by 
reference to a 1kb Plus DNA Ladder. Bands were excis d with a clean scalpel from 
the low-melting-temperature agarose and the isolated garose slice (less than 300mg) 
was transferred into a 1.5ml microcentrifuge tube and incubated at 70°C until it was 
melted. Following the addition of 1ml of DNA resin, the mixture was briefly mixed, 
attached to the membrane of the mini-column, washed with 80% isopropanol and the 
purified DNA was eluted with 30ul of nuclease-free water as described above.  
 
2.3.7 Sub-cloning of PCR products  
Purified cDNA products of the predicted size were sub-cloned into pGEM-T Easy 
vector system (Promega, Madison, WI, USA) according to the manufacturer’s 
protocol. The ligation reactions were composed of 1ul pGEM-T Easy Vector, 25ng 
purified PCR product, 1ul T4 DNA Ligase (3 Weiss units/ul), 5ul of 2x Rapid 
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ligation Buffer and DDW, to give a final volume of 10ul. The products were 
transferred into JM109 High Efficiency Competent Cells (Promega, Madison, WI, 
USA) and the cells were plated onto duplicate Luria-Bertani 
(LB)/ampicillin/IPTG/X-Gal plates (Appendix C.9) according to the manufacturer’s 
protocol. The plates were incubated overnight at 37°C. White colonies containing 
inserts were selected from the plates and transferred into 30ml flasks with 6ml LB 
media (Appendix C.10) and 100ug/ml ampicillin. The cells containing clones were 
expanded by incubating overnight at 37°C with agitation at 220 rpm.  
 
2.3.8 Plasmid DNA Preparation-(Mini-preps)  
The plasmid DNA was extracted from bacteria and purified using the Wizard Plus 
SV Minipreps DNA Purification System (Promega, Madison, WI, USA) according to 
the manufacturer’s protocol. 5ml of bacterial cultures were harvested, pelleted by 
centrifugation at 10,000xg for 5 min, re-suspended in 250ul of Cell Resuspension 
Solution and lysed with 250ul of Cell Lysis Solution. After addition of 10ul of 
Alkaline Protease Solution, the bacterial lysates were incubated for 5 min at room 
temperature, mixed with 350ul Neutralisation Solutin and pelleted by centrifugation 
at 14,000xg for 10 min. The cleared lysates were transferred into a Spin Column and 
centrifuged at 14,000xg for 1 min to allow them to attach the membrane. The Spin 
Column was washed with 750ul of Column Wash Solution (ethanol added) by 
centrifugation at 14,000xg for 2 min and the washing was repeated with 250ul of 
Column Wash Solution. 50ul of nuclease-free water was added to the Spin Column 
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to elute the purified plasmid DNA by centrifugation at 14,000xg for 1 min. The 
plasmid DNA was stored at -20°C.  
 
2.3.9 Identification the insert containing plasmid clones  
To identify the presence of inserts, the plasmid DNA was digested in the reaction 
composed of 20units Eco R1 (20,000 units/ml, New England Biolabs, Hitchin, Herts., 
UK), 1ul 10x Eco R1 buffer(New England Biolabs, Hitchin, Herts., UK), 5ul mini-
preps and 3ul DDW to give a final volume of 10ul and i cubated at 37°C for 1 h. 
10ul of digested products was added with 3ul loading buffer and analysed by 1.5% 
agarose gel electrophoresis as described above (Section 2.3.5 ).  
 
2.3.10 Sequencing  
Purified plasmid products with inserts (3.2pmol/ul) were sent to DBS Genomic 
(Durham University) for sequencing. The sequence obtained for each sample was 








Chapter 3   Identification and characterisation of bovine 
granzymes 
 
3.1 Introduction  
 
Granzymes are a family of serine proteases that exhibit various primary substrate 
specificities. They are found in the lytic granules of cytotoxic T lymphocytes (CTLs) 
and NK cells and play a significant role in killing of susceptible target cells, acting 
on various cellular pathways that regulate programmed cell death (Jenne and 
Tschopp, 1988). Five granzymes - A, B, K, H and M - have been identified in 
humans. In mouse, there are ten granzymes - A, B, K, E, M, C, D, F, G and N 
(Grossman et al., 2003). Granzyme H appears to be restricted to human, while C, D, 
E, F, G and N are exclusively expressed in mouse. Th  granzyme family has been 
classified into three distinct evolutionary groups, which are clearly discriminated 
based on their primary substrate specificities and correspond to three different 
chromosomal locations (Trapani, 2001). The members of the three groups have 
trypsin-like (A and K on human 5q11-q12 and mouse 13D chromosomal regions, 
respectively), chymotrypsin-like (B and H on human 14q11-q12; B, C, E, M, D, F, G 
and N on mouse 14D) and metase (M on human 19p13.3 and mouse 10q21.2, 
respectively) enzymatic activities (Smyth et al., 1996). Genome mapping of the 
granzyme genes has revealed that other serine proteases such as the cathepsin G and 
mast cell proteases are closely linked with granzyme B and H in the chymotrypsin 
locus, while the metase locus holds a cluster of neutrophil elastase genes, including 
azurocidin 1 (ZAU1), proteinase 3 (PRTN3), neutrophil expressed (ELANE) and 
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complement factor D (CFD), 200 to 500kb downstream of granzyme M (Pilat Daniel, 
1994). Consistent with granzymes being structurally re ated to chymotrypsin, studies 
of human and mouse granzymes by several groups havedefined a number of 
common features, including a shared consensus sequence at the N-terminus 
(Bleackley et al., 1988; Jenne and Tschopp, 1988; Murphy et al., 1988), conserved 
activation peptides (propeptides), a three amino acid catalytic triad (His-57, Asp-103 
and Ser-195) (Murphy et al., 1988) and 3-4 disulfide bridges (Smyth et al., 1996; 
Trapani, 2001; Piuko et al., 2007). However, sequence comparisons show a higher 
level of conservation within granzyme subgroups (55-70%) than between groups 
(30-40%) (Piuko et al., 2007). Further detailed comparison of sequence and structure 
also reveal that each group of granzymes has unique features. Substrate specificity is 
dependent on protein structure (Perona and Craik, 1995), which is determined by 
variation in key amino acid residues that form the substrate binding pocket (Smyth et 
al., 1996).  
 
The studies described in this chapter aimed: (i). To identify and characterise bovine 
granzyme genes by mining existing genomic and expression sequence tag databases. 
(ii). To conduct inter-species comparative analysis of their nucleotide and amino acid 







3.2 Materials and methods  
 
3.2.1 Bovine granzyme genome analysis  
The nucleotide sequences of bovine granzymes were id ntified in the bovine genome 
assembly, Btau_4.0 (http://www.ensembl.org/Bos_taurus/blastview) using the 
nucleotide-nucleotide basic local alignment search tool (BLASTN) with the 
sequences listed in table 3.1. Use of the obtained genome sequences to search the 
bovine expressed sequence tags (EST) database 
(http://www.ncbi.nlm.nih.gov/sites/entrez) identified the corresponding cDNA 
sequences.  
 
Table 3.1 Accession numbers of cDNA sequences of human and mouse 
granzyme genes obtained from the National Center for Biotechnology 
Information (NCBI) RefSeq database (http://www.ncbi.nlm.nih.gov/) 
Species Granzyme 
Human Mouse 
A NM_006144 NM_010370 
B NM_004131 NM_013542 
H NM_033423  
K NM_002104 NM_008196 
C  NM_010371 
E  NM_010373 
D  NM_010372 
F  NM_010374 
G  NM_010375 
N  NM_153052 
M NM_005317 NM_008504 
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3.2.2 Sequence analysis  
Sequence analyses such as CLUSTAL W alignment and tr slations were performed 
by using the DNAsis Max V2.7 programme (MiraiBio, Alameda, CA, USA). 
Prediction of the signal sequence cleavage site was performed using an algorithm 
described by von Heijne et al. (1986). Residues involved in the catalytic triad and 
disulfide bridge formation were analysed by EBI PPsearch 
(http://www.ebi.ac.uk/Tools/ppsearch/) and Prosite (http://www.expasy.org/prosite/). 
 
3.2.3 Chromosomal location analysis  
In humans and mice, granzyme-related trypsin-like, chymotrypsin-like and metase 
loci have been found on three separate chromosomes (Smyth et al., 1996). The 
nucleotide sequences of bovine orthologues in three loci were identified using 
BLASTN searches in the bovine genome assembly, Btau_4.0 with the sequences in 
table 3.2. The chromosomal localization of trypsin-like, chymotrypsin-like and 
metase loci on bovine genome were annotated using ge e mapping with identified 









Table 3.2 Summary of accession numbers of human and mouse genes in trypsin-
like, chymotrypsin-like and metase loci 
Species Chromosomal Locus 
H.sapiens (Hs) M.musculus (Mm) 
GzmK (NM_002104) GzmK (NM_008196) Trypsin-like  
GzmA (NM_006144) GzmA (NM_010370) 
   
CMA1 (NM_001836) Cma1 / Mcpt5 (NM_010789) 
- Mcpt1 (NM_008570) 
- Mcpt9 (NM_010782) 
- Mcpt2 (NM_008571) 
- Mcpt4 (NM_010779) 
- Mcpt8 (NM_008572) 
CTSG (NM_001911) Ctsg (NM_007800) 
- GzmE (NM_010373) 
- GzmD (NM_010372) 
- GzmG (NM_010375) 
- GzmN (NM_153052) 
- GzmF (NM_010374) 
- GzmC (NM_010371) 
GzmH (NM_033423) - 
Chymotrypsin-like  
GzmB (NM_004131) GzmB (NM_013542) 
   
GzmM (NM_005317) GzmM (NM_008504) 
AZU1 (NM_001700) - 
PRTN3 (NM_002777) Prtn3 (NM_011178) 
ELANE (NM_001972) Elane (NM_015779) 
Metase  
CFD (NM_001928) Cfd (NM_013459) 
The cDNA sequences of these genes located on three loci were obtained from the 
NCBI RefSeq database (Smyth et al., 1996; Grossman et al., 2003; Gallwitz and 
Hellman, 2006). -, no; Gzm = granzyme; CMA /Mcpt = mast cell chymase /mast 
cell protease; Ctsg = cathepsin G; ZAU1 = azurocidin 1; PRTN3 = proteinase 3; 
ELANE = neutrophil elastase preproprotein; CFD = complement factor D.  
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3.2.4 Phylogenetic analysis  
Phylogenetic analysis was performed on the cDNA sequence of granzyme genes of 
human, mouse, pig and bovine as identified in table 3.2 and 3.6. The relationships 
across species were established by analysing CLUSTAL W alignment with the 
Neighbour-joining method by using MEGA4 software (Tamura et al., 2007).  
 
3.2.5 Amplification of granzyme and perforin transc ripts from 
cDNA by RT-PCR 
Total RNA was extracted from cell pellets of the unclo ed T.parva-specific CD8+ T 
cell lines day 7 after 3rd stimulation, which were isolated from animals 641 and 011. 
The cDNA was synthesized from RNA as described in section 2.3.1- 2.3.3. Primers 
were designed to amplify full-length coding regions for bovine granzymes and 
perforin based on sequences identified from bovine genomic and EST databases. 
Primers were designed using the Primer3 programme or manually and synthesized by 
MWG biotech (Ebersberg, Germany). The sequences of the primers are shown in 
table 3.3. The PCR products were amplified, sub-cloned into the pGEM-T vector and 
sent to DBS Genomic (Durham University) for sequencing as described in section 
2.3.4- 2.3.10.  
 
Table 3.3 PCR primers designed for detection of bovine granzymes and perforin 
Primers Sequences  ( 5’---3’ ) 
GzmA (For) ATTGATTGATGTGGGGACAC 
GzmA (Rev) AAAAAGTAACAGCAAATGAAATACAA  
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GzmO (For) AGTCTCCATATGTGAATAACAGGAG 
GzmO (Rev) CCCTTTCACTTGGTTACTTCG 
GzmB (For) CATCCTGGGCAGTCTTTCTA 
GzmB (Rev) CCTGCAGTGTGATTCTGGAT 
GzmH (For) CTGACCTGGGCAAATCTTCT 
GzmH (Rev) GGACAATGGTCAGTGCAGAG 
GzmK (For) TTCCTTTGCCAATACAGTCAG 
GzmK (Rev) AGCAGCTGATAGAGCCAAGA 
GzmM (For) GAGGCCCCCCAGATCCAAG 
GzmM (Rev) CCCCTTGGAACACAGAATCA 
Perforin (For) CAG GGT GGT CAA GCT AGA GG 















3.3 Results  
 
3.3.1 Identification of bovine granzyme genes 
Previous studies have identified five granzymes (A, B, K, H and M) in human and 
ten granzymes (A, B, K, C, E, D, F, G, N and M) in mouse. BLASTN searches of the 
bovine genome assembly, Btau_4.0 using nucleotide sequences of human and mouse 
granzymes identified 6 putative granzyme genes predicted to encode full-length 
functional proteins (Table 3.4 and accession numbers are listed in Table 3.5). These 
included genes orthologous to the 5 granzyme genes found in humans (A, B, K, H 
and M) and a further gene with no close orthologue, but most closely related to 
granzyme A. This novel nucleotide sequence in the bovine genome 
(ENSBTAG00000027865) was designated as Granzyme O. So far, a close 
orthologue of this gene has not been described in any other species. However, a 
BLASTN search of the pig genome revealed a full-length functional gene 
(ENSSSG00000016902) that shows 89% similarity in the coding region to the cattle 
gene (discussed in further detail below). To enable further cross-species comparison, 
we also searched the pig genome assembly, Sscrofa9 (April 2009), for other 
granzyme genes and found orthologues of granzymes A, B, K and H (Table 3.4 and 
accession numbers were listed in Table 3.5). A gene for granzyme M was not found, 
although assembly of the region on pig chromosome 2 predicted to contain granzyme 





Table 3.4 Summary of functional granzyme genes identified in different species 
Granzyme Species 
A           O B H K  C E D F G N M  
Human + - + + + - - - - - - + 
Murine  + - + - + + + + + + + + 
Cattle + + + + + - - - - - - + 
Pig + + + + + - - - - - - ND 
Genes for bovine granzymes are highlighted in red.  ND – not detected 




Sequences matching each of the bovine granzyme genes identified from the genome 
were found within the GenBank bovine EST database 
(http://www.ncbi.nlm.nih.gov/sites/entrez). Searches of this database using other 
murine granzyme gene sequences suggest that no additional bovine granzymes are 








Table 3.5 Summary of accession numbers of granzyme g nes identified in 
bovine and pig genome and EST databases 
Bovine  Pig  Granzyme 
Genome (Btau_4.0) EST Genome  
A ENSBTAG00000021958 1907915310 corr_ENSSSCG00000016903 
O ENSBTAG00000027865 CK830799 ENSSSG00000016902 
B corr_ENSBTAG00000010057 CK952629 corr_ENSSSCG00000001978 
H corr_ENSBTAG00000010828 CK776010 ENSSSCG00000001981 
K ENSBTAG00000005164 1382286268 ENSSSCG00000016901 
M ENSBTAG00000002100 1907810005  
Corr - Manually corrected sequence  
 
 
The cattle granzyme genes range in length from 3,484 to 10,785bp, with coding 
regions of cDNAs ranging from 741 to 795bp (Appendix A). The nucleotide 
sequences of the genes all exhibit the same exon-intron gene arrangement as the 
human and murine genes, each composed of 5 exons, with exon 1 encoding the 
leader peptide. Exons 2, 3 and 5 each contain one of the three amino acids that make 
up the catalytic triad (Appendix A) (Trapani, 2001).  Most of the exon-intron 
boundaries of the granzyme genes fulfil the GT-AG rule, though granzyme H has a 
GC-AG splice site between exon 3 and intron 3 (Appendix A-(d)) (Burset et al., 
2000). The granzyme M gene displays the distinguishing feature that the intron 1 
boundary falls at the codon for Gly-7 (position with respect to the mature functional 
protein) prior to the putative hexapeptide Asn(-6) - His(-1) (Appendix A- (f)), which 
is cleaved to yield the functionally active polypeptide. This distinct gene 
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arrangement is shared with human and mouse granzyme M and also genes in the 
linked neutrophil elastase gene cluster, such as azurocidin (AZU1), proteinase-3 
(PRTN3) and neutrophil elastase (ELA2) (Zimmer et al., 1992; Pilat et al., 1994; 
Kelly et al., 1996). 
 
3.3.2 Comparison of sequences between species  
Alignments of identified granzyme sequences from different species were used to 
investigate the similarity between species. Alignmets of the predicted amino acid 
sequences and levels of identity between species are illustrated in figure 3.1- 3.6. 
Alignments of nucleotide sequences are available in Appendix B. Analysis of 
sequence homology showed that each of the bovine granzymes was more closely 
related to the respective counterparts in human tha mouse than other bovine 
granzyme genes, with levels of 76-83% nucleotide similarity and 70-77% amino acid 
identity with the respective human counterparts and70-75% nucleotide similarity 










Figure 3.1 Granzyme A – comparison of bovine, human and murine amino acid 
sequences 
 (a). Alignment of amino acid sequences 
             1          11         21         31         41         51                               
             .          .          .          .          .          .                            
BovineGZMA   MRNSSTFLAA TLSIVV-FLL IPEDLCE KIIGGNQVTP HSRPYMVLL- -DGGNICAGALIA 
Human GZMA   ....YR...S S..V..SL.. ....V.. ......E... .........S L.RKT........ 
MurineGZMA   ...A.GPRGP S.ATLLFL.. ...GG.. R....DT.V. ......A..K LSSNT.......E 
 
             61         71         81         91         101        111 
             .          .          .          .          .          .  
BovineGZMA   KDWVLTA AHCSLNQKSQ IILGAHSRNK EEPEKQIMFV KKEFPYPCYD PDTHEGDLKLLKL 
Human GZMA   ....... ...N..KR.. V......ITR ...T....L. .......... .A.R......VR. 
MurineGZMA   .N..... ...NVGKR.K F......I.. .-..Q..LT. ..A....... EY.R....Q..Q. 
 
                       
             121        131        141        151        161        171 
             .          .          .          .          .          .  
BovineGZMA   NKKATLN KNVAILQLPK EGKDVEPGTA CRVAGWGQFY NNSP-VSKIL REVNVTIIDRKIC 
Human GZMA   ME..KI. .Y.T..H... K.D..K...M .Q.....RTH .SAS-W.DT. ....I......V. 
MurineGZMA   K....V. R.....H... K.D..K...R .......R.G .K.A-P.ET. ....I.V...... 
                                                                                                     
 
             181        191        201        211        221        231 
             .          .          .          .          .          .  
BovineGZMA   NDQSHYN YNPVIGLNMI CAGSLQGGKD SCHGDSGSPL ICKDTFRGIT AFGIPGRCGDPRG 
Human GZMA   ..RN... F.....M..V .....R..R. ..N....... L.EGV...V. S..LENK...... 
MurineGZMA   ..EK... FH........ ...D.R.... ..N....... L.DGIL.... S..GE-K...R.W 
 
             241        251        261     
             .          .          .          
BovineGZMA   PGVYTLL SKKHLNWIVK TMKQAV 
Human GZMA   ....I.. ........IM .I.G.. 
MurineGZMA   .....F. .D......K. I..GS. 
 
Dot-Identical; Dash-Gap; Dark- Mature protein sequence; Yellow-Activation peptide 
 
(b). Percentage amino acid sequence identities (and nucleotide similarities) between 
species           
 BtGzmA HsGzmA MmGzmA 
BtGzmA  73 (83) 67 (75) 
HsGzmA   69 (77) 




Figure 3.2 Granzyme O – comparison of bovine and pig amino acid sequences 
(a). Alignment of amino acid sequences 
1          11         21          31        41         51                              
                .          .          .          .          .          .   
 
BovineGZMO MNIPFPFSFP PAICLLLIPG VFPVSCEGII GGNEVAPHTR RYMALIKGLK LCAGALIKEN 
PigGZMO    .E.....F.. A.M...I... ......D... .....S.... ......E... V......... 
                 
61         71         81         91         101        111 
                .          .          .          .          .          .  
 
BovineGZMO WVLTAAHCDL KGNPQVILGA HSTSHKEKLD QVFSIKKAIP YPCFDPQTFE GDLQLLQLEG 
PigGZMO    .......... .......... ........Y. .T........ .......... .......... 
 
121        131        141        151        161        171 
                .          .          .          .          .          .  
 
BovineGZMO KATMTKAVGI LQLPRTEDDV KPHTKCHVAG WGSTKKDACQ MSNALREANV TVIDRKICND 
PigGZMO    .......... .K..N.GK.. E......... ....R..S.K I..T...V.I ......M... 
 
                181        191        201        211        221        231 
                .          .          .          .          .          .  
 
BovineGZMO AQHYNFNPVI DLSMICAGGR KGEDDSCEGD SGSPLICDNV FRGVTSFGKC GNPQKPGIYI 
PigGZMO    .......... ..G....V.. .......... .........I .......... .......V.. 
 
                241        251                        .          .          .         
BovineGZMO LLTKKHLNWI KKTIAGAI* 
PigGZMO    .......... ......... 
 
Dot-Identical; Dash-Gap; Dark- Mature protein sequence; Yellow-Activation peptide  
 
(b). Percentage amino acid sequence identities (and nucleotide similarities) between 
species      
 BtGzmO SsGzmO 
BtGzmO  89 (91) 








Figure 3.3 Granzyme B – comparison of bovine, human and murine amino acid 
sequences 
(a). Alignment of amino acid sequences 
             1          11         21         31         41         51                    
             .          .          .          .          .          .                    
BovineGZMB   MKPLLLLVAF LLTPRAKAGE IIGGHEAKPH SRPYMAYLQY WNQDVQSRCG GFLVRQDFVL 
Human GZMB   .Q.I...L.. ..L...D... .......... ........MI .D.KSLK... ...I.D.... 
MurineGZMB   ..I....LTL S.AS.T.... ......V... ......L.SI KD.QPEAI.. ...I.E.... 
 
             61         71         81         91         101        111 
             .          .          .          .          .          .  
BovineGZMB   TAAHCNGSSI KVTLGAHNIK QQERTQQVIR VRRAISHPDY NPKNFSNDIM LLKLERKAKQ 
Human GZMB   .....W.... N......... E..P...F.P .K.P.P..A. .......... ..Q......R 
MurineGZMB   .....E..I. N......... E..K.....P MVKC.P.... ...T...... ....KS...R 
 
             121        131        141        151        161        171 
             .          .          .          .          .          .  
BovineGZMB   TSAVKPLSLP RAKARVKPGQ TCSVAGWGRD S-TDTYADTL QEVKLIVQED QKCEAYLRNF 
Human GZMB   .R..Q..R.. SN..Q..... ........QT APLGKHSH.. ....MT.... R...SD..HY 
MurineGZMB   .R..R..N.. .RNVN....D V.Y......M APMGK.SN.. ...E.T..K. RE..S.FK.R 
 
             181        191        201        211        221        231 
             .          .          .          .          .          .  
BovineGZMB   YNRAIQLCVG DPKTKKASFQ GDSGGPLVCD NVAQGIVSYG KRDGSTPRAF TKVSSFLPWI 
Human GZMB   .DST.E.... ..EI..T..K .........N K......... RNN.MP...C ......VH.. 
MurineGZMB   ..KTN.I.A. .....R...R .........K K..A...... YK...P.... .......S.. 
 
             241         
             .          
BovineGZMB   KKTMKSL 
Human GZMB   .....RY 
MurineGZMB   ......S 
 
Dot-Identical; Dash-Gap; Dark- Mature protein sequence; Yellow-Activation peptide 
 
(b). Percentage amino acid sequence identities (and nucleotide similarities) between 
species      
 BtGzmB HsGzmB MmGzmB 
BtGzmB  72 (79) 69 (75) 
HsGzmB   68 (76) 





Figure 3.4 Granzyme H– comparison of bovine and human amino acid 
sequences 
(a). Alignment of amino acid sequences 
             1          11         21         31         41         51                    
             .          .          .          .          .          .                    
BovineGZMH   MQLLLLLMAF LLPPGLGEPF LSEEIIGGHE AKPHSRPYMA FVQFLGEKSW KRCGGVLIQK 
Human GZMH   ..PF...L.. ..T..A.T-- --........ .......... .....Q...R .....I.VR. 
 
 
             61         71         81         91         101        111 
             .          .          .          .          .          .  
BovineGZMH   DFVLTAAHCR GSSINVTLGA HNIKQQERTQ QVIQVKRAIH HPDYNPKTFS NDIMLLQLER 
Human GZMH   .........Q .......... ....E..... .F.P...P.P ..A....N.. .......... 
 
 
             121        131        141        151        161        171 
             .          .          .          .          .          .  
BovineGZMH   KAKQTSAVKP LSLPKAKAQV KPGEVCSLAG WGKVALGTPA TTLQEVELTV QEDRVCESLN 
Human GZMH   ...W.T..R. .R..SS.... ...QL..V.. ..Y.SMS.L. ......L... .K.CQ..R.F 
 
 
             181        191        201        211        221        231 
             .          .          .          .          .          .  
BovineGZMH   PRNYSRATQI CVGDPRKVKT GFKGDSGGPL VCKKVVHGIF SYGKTNGTPP GVFTQVSHFL 
Human GZMH   HG......E. .....K.TQ. .......... ...D.AQ..L ...NKK.... ..YIK..... 
 
 
             241         
             .          
BovineGZMH   PWIKRTMKHL 
Human GZMH   ........R. 
 
Dot-Identical; Dash-Gap; Dark- Mature protein sequence; Yellow-Activation peptide 
 
(b). Percentage amino acid sequence identities (and nucleotide similarities) between 
species          
 BtGzmH HsGzmH 
BtGzmH  77 (81) 






Figure 3.5 Granzyme K – comparison of bovine, human and murine amino acid 
sequences 
(a). Alignment of amino acid sequences 
             1          11         21         31         41         51                    
             .          .          .          .          .          .                    
BovineGZMK   MTKFSSFFLC FLLAGTYMTP ECFNMEIIGG REVSPHSRPF MASLQYGGDH ICGGVLIHPQ 
Human GZMK   .......S.F ..IV.A...H V......... K......... ...I....H. V......D.. 
MurineGZMK   .-R...WA.V S.V..V..SS ...HT..... ...Q...... ...I..RSK. .......... 
 
             61         71         81         91         101        111 
             .          .          .          .          .          .  
BovineGZMK   WVLTAAHCHL RFAKSQSSKV VLGAHSLSKN EASKQTFEIK KFIRFPGFAL APKSNDIMLV 
Human GZMK   ........QY ..T.G..PT. .......... ......L... ...P.SRVTS D.Q....... 
MurineGZMK   ........YS W.PRGH.PT. .......... .PM....... ...P.SRLQS GSA.H....I 
             
             121        131        141        151        161        171 
             .          .          .          .          .          .  
BovineGZMK   KLHTAAILNR HVQLLHPRAK NDIKAGTKCQ VVGWGATDPE GLSLSDTLRE VTVTVISRKT 
Human GZMK   ..Q...K..K ..KM..I.S. TSLRS....K .T.......D S.RP...... .....L...L 
MurineGZMK   ..R...E..K N.....LGS. .YLRD..... .T...T.K.D L.TA...... ....I....R 
 
             181        191        201        211        221        231 
             .          .          .          .          .          .  
BovineGZMK   CNSRDYYNHS PVITRTMLCA GDARGQKDSC QGDSGGPLVC KGAFHALVSG GPKCGDAKKP 
Human GZMK   ...QS...GD .F..KD.V.. ...K...... K.......I. ..V...I... .HE..V.T.. 
MurineGZMK   ...QS....K ....KD.I.. .......... K.......I. ..I......Q .Y...I.... 
   
             241        251        261        
             .          .          .        
BovineGZMK   GIYILLTRKF QAWIKSNLAP SHAD 
Human GZMK   ...T...K.Y .T......V. P.TN 
MurineGZMK   ...T...K.Y .T....K... .R.H  
 
Dot-Identical; Dash-Gap; Dark- Mature protein sequence; Yellow-Activation peptide           
 
(b). Percentage amino acid sequence identities (and nucleotide similarities) between 
species      
 BtGzmK HsGzmK MmGzmK 
BtGzmK  73 (81) 71 (75) 
HsGzmK   72 (78) 





Figure 3.6 Granzyme M – comparison of bovine, human and murine amino acid 
sequences 
(a). Alignment of amino acid sequences 
             1          11         21         31         41         51                    
             .          .          .          .          .          .                    
BovineGZMM   M-----LLLL VVLEALWAGG NTFETHIIGG RDAVPHSRPY MVSLQKSSGS HQCGGVLLHQ 
Human GZMM   MEACVSS..V LA.G..S-V. SS.G.Q.... .EVI...... .A...RN-.. .L.....V.P 
MurineGZMM   MEVCWS.... LA.KT...A. .R...Q.... .E........ .A....A-K. .V.....V.R 
 
             61         71         81         91         101        111 
             .          .          .          .          .          .  
BovineGZMM   NWVLTAAHCL TQPTQQLRLV LGLH---VLG EISPIYRIRK VVRHPEYKPV PHLENDLALL 
Human GZMM   K......... A.RMA..... ....---T.D SPGLTFH.KA AIQ..R.... .A........ 
MurineGZMM   K......... SE.L.N.K.. ....NLHD.Q DPGLTFY..E AIK..G.N-- HKY....... 
 
             121        131        141        151        161        171 
             .          .          .          .          .          .  
BovineGZMM   KLDGKVKPSR TIQPLALPRG -RQMVATGTR CSLAGWGLTH QPGNLARVLQ ELDVHVLDTR 
Human GZMM   Q......... ..R.....SK -..V..A... ..M....... .G.R.S...R ...LQ..... 
MurineGZMM   ...RR.Q..K NVK......K P.SKP.E..W ..T....M.. .G.PR..A.. ...LR....Q 
 
             181        191        201        211        221        231 
             .          .          .          .          .          .  
BovineGZMM   MCNNSRFWHG NISSHMICLA ADSKNQAPCK GDSGGPVVCK RGQVAG-ILS FSSENCTDIF 
Human GZMM   ........N. SL.PS.V... ....D..... ......L..G K.R.LARV.. ...RV..... 
MurineGZMM   ........N. VLIDS.L..K .G..S..... ......L..G K...D.-... ...KT..... 
 
             241        251        261         
             .          .          .           
BovineGZMM   KPPVAVAVAP YMPWIKKVLR HNGSPPSP- 
Human GZMM   .....T.... .VS..R..TG R-SA----- 
MurineGZMM   .....T.... .SS..R..IG R-W..Q.LV 
 
Dot-Identical; Dash-Gap; Dark- Mature protein sequence; Yellow-Activation peptide 
 
(b). Percentage amino acid sequence identities (and nucleotide similarities) between 
species               
 BtGzmM HsGzmM MmGzmM 
BtGzmM  70 (76) 64 (70) 





3.3.3 Validating expression of bovine granzymes and  perforin by 
RT-PCR analyses 
Based on the sequences identified above, pairs of PCR primers were designed to 
amplify the full-length coding region of each of the granzymes and also the perforin 
gene, which had been identified in the bovine genome (XM_585583). cDNA 
prepared from cultures of T. parva-specific CD8+ T cells established from animals 
641 and 011, which had been immunised by infection and treatment with T. parva, 
was used to test these PCR primers. PCR assays with the designed primers detected 
transcripts of the expected sizes for all 6 granzyme genes and perforin in cDNA from 
bovine CD8+ T cells (Figure 3.7). A single band was obtained for all except 
granzyme H and K, which each gave three bands, one of the predicted size and two 
smaller bands. To confirm the identity of the PCR products, they were sub-cloned 
into the pGEM-T vector and clones containing inserts of the correct size were 
selected and sequenced. Analysis of sequences obtained confirmed that they were all 
identical to those originally identified from the bovine genome. Sequencing of the 
additional bands obtained for granzyme H showed that they represent alternatively 
spliced forms of granzyme H, without exon 4 (562bp) and exons 2, 3 and 4 (265bp), 
respectively. The alternatively spliced forms of granzyme K were identified as 
transcripts without exon 4 (619bp) and exons 3 and 4 (468bp), respectively. In 
conclusion, all of the identified bovine granzyme genes are expressed at the mRNA 





Figure 3.7 PCR products obtained using primers designed to be specific for each 
of the bovine granzyme genes and perforin 
 
Lanes on the left contain negative controls (primers with no template) for the 
individual granzymes. Lanes on the right contain PCR products obtained with 
each set of primers with cDNA template of an uncloned T. parva-specific CD8+ 
T cell line (641) 7 day after 3rd stimulation (purity, 99%). The estimated sizes 
are; granzyme A - 838bp; granzyme O - 849bp; granzyme B - 818bp; granzyme 
H - 820bp,  562bp and 265bp; granzyme K - 889bp, 619bp and 468bp; granzyme 
M - 833bp; Perforin (PFN) - 1275bp.  
 
3.3.4 Chromosomal location of granzyme genes  
In humans and mice, granzyme genes are separated into loci on three chromosomes 
termed the trypsin-like, chymotrypsin-like and metas  loci (Smyth et al., 1996). 
Annotation of the bovine genome using the identified bovine granzyme orthologues 
revealed a similar organisation of granzyme genes to that described for human and 
mouse. Granzyme B is linked together with granzyme H and located on chromosome 
21. Granzyme A and K, as well as the novel granzyme gene O, are observed on the 
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same cluster on bovine chromosome 20, while granzyme M is located on 
chromosome 7. To provide comparative data from another artiodactyl species, the 
genomic location of granzyme genes in the pig was also examined and found to have 
a similar arrangement into 3 loci. The genome accession numbers for the genes are 
listed in table 3.6. 
 
Table 3.6 Summary of accession numbers of the identified genes found within 
the trypsin-like, chymotrypsin-like and metase loci of cattle and pig genome 
Species Chromosomal 
Loci Bos taurus (Bt) Sus scrofa (Ss) 




























The sequences matched in pig and cattle genome were named according to the 
orthologues suggested by Ensembl. Corr - Manually corrected sequence; ND - 
not detected. Gzm = granzyme; Cma1 = mast cell a-chymase; DDN = duodenase; 
CTSG = cathepsin G; ZAU1 = azurocidin 1; PRTN3 = proteinase 3; CFD = 
complement factor D.  
 
3.3.4.1 Trypsin-like locus 
In all 4 species examined, the trypsin-like locus contains the functional granzyme 
genes A and K, which are separated by between 74kb and 86kb on chromosomes 5, 
13, 20 and 16 in humans, mice, cattle and pig, respectively. The genes have a 
conserved gene orientation and arrangement in the 4sp cies.  
 
 
Figure 3.8 Comparison of the genomic organization of the human, murine, 
cattle and pig trypsin-like locus. 
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Bars indicate gene positions; arrows indicate transcriptional orientation; 
numbers indicate the length of locus. Functional genes are shown in black boxes 
and non-functional genes in grey. Intervals between genes are drawn to scale.  
 
 
In cattle and pig, the additional granzyme O gene is situated between the A and K 
genes and displays the same orientation. Interspecies comparison of the novel bovine 
and pig granzyme gene shows a high level of similarity both in nucleotide sequence 
(91%) and amino acid sequence (89%). The EST sequence data in both species (pig 
EST database reference 2241795172 ) together with RT-PCR analysis of cattle T 
cells in this study indicate that granzyme O is functionally expressed. Analysis of 
genome DNA sequence in the region between the granzyme A and K genes in human 
and mouse revealed a pseudogene in human (ENSG00000249454) and a truncated 
gene in mouse (ENSMUSG00000051002), which exhibit 89% and 66% nucleotide 
similarity to cattle granzyme O gene, respectively (Figure 3.9- b). The human 
granzyme O-like pseudogene comprises 4 exons that contain several premature stop 
codons, whereas the mouse truncated gene contains only 269bp of DNA sequence, 
which based on alignments appears to correspond to exon 4 in the bovine gene 
(Figure 3.9- a).  
 
Figure 3.9 Granzyme O and granzyme O-like genes – comparison of bovine, 
human murine and pig nucleotide sequences 
 (a). Alignment of nucleotide sequences 
           1          11         21         31         41         51                    
           .          .          .          .          .          .       
BovineGZMO ATGAATATTC CTTTTCCTTT CTCTTTTCCT CCTGCCATTT GTCTCCTTCT AATTCCTGGA 
PigGzmO    ...G.A.... .......... ..T....... G.......G. ........A. .......... 
HumanGZMO  .G...A...T T......C.. ......C... A..A....GC T......... .......... 
MurineGZMO ---------- ---------- ---------- ---------- ---------- ---------- 
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           61         71         81         91         101        111 
           .          .          .          .          .          .  
BovineGZMO GTT------- ---------- -TTTCCAGTA T--CCTGCGA GGGAAT---- ---TATAGGA 
PigGzmO    ...------- ---------- -......... .--....T.. C.....---- ---....... 
HumanGZMO  .A.AAGACAT GTTTTCATAG C.C.T..... .TG.TCAT.. .AA.G.AGAA TCC....T.. 
MurineGZMO ---------- ---------- ---------- ---------- ---------- ---------- 
 
           121        131        141        151        161        171 
           .          .          .          .          .          . 
BovineGZMO GGAAATGAAG TGGCCCCTCA CACAAGACGC TACATGGCTC TAATCAAAGG GCTGAAACTC 
PigGzmO    .......... ..T.A..C.. ......G... .........T ....TG.... .......G.. 
HumanGZMO  .......... ..CTA..... TG.....T.. .G..G.A... ...C...... ....G..A.. 
MurineGZMO ---------- ---------- ---------- ---------- ---------- ---------- 
 
           181        191        201        211        221        231 
           .          .          .          .          .          . 
BovineGZMO TGTGCAGGGG C-TTTAATCA AAGAAAACTG GGTGTTGACA GCCGCTCATT GTGACCTGAA 
PigGzmO    .......... .-...G.... .......... .......... ..T.....C. .......... 
HumanGZMO  ......A... .C...G..G. ..T....... ......A.TG ..T.....C. .--------- 
MurineGZMO ---------- ---------- ---------- ---------- ---------- ---------- 
 
            241        251        261        271        281        291 
           .          .          .          .          .          .  
BovineGZMO GGGCAATCCT CAAGTTATTC TTGGGGCCCA CTCTACATCC CATAAAGAGA AACTTGACCA 
PigGzmO    A.....C... .......... ....A..... .......... .......... ..TA...... 
HumanGZMO  -.....A.T. ...A...... .......... .......... ......C... .......... 
MurineGZMO ---------- ---------- ---------- ---------- ---------- ---------- 
 
           301        311        321        331        341        351                               
           .          .          .          .          .          .      
BovineGZMO AGTATTTTCC ATTAAAAAGG CAATTCCCTA CCCATGCTTT GATCCACAGA CATTTGAAGG 
PigGzmO    GAC....... .......... .......T.. T.....T... .......... .......... 
HumanGZMO  GAA.G..... .......... .G...T.... T.......A. .........C ....CAT.T. 
MurineGZMO ---------- ---------- ---------- ---------- ---------- ---------- 
   
           361        371        381        391        401        411 
           .          .          .          .          .          .  
                                    ---------------------Exon4-------------- 
BovineGZMO GGATCTTCAA CTACTTCAGC TGGAAGGTAA AGCAACTATG ACCAAAGCTG TAGGAATACT 
PigGzmO    .........G ..G....... .......... .......... .......... .......... 
HumanGZMO  .T.....T.. ..C....... ......T... ......C... .G........ ......-... 
MurineGZMO ---------- ---------- --------.. .........A .......T.. .G..G..C.. 
 
                  481        491        501        511        521        531 
           .          .          .          .          .          .  
---------------------------------------------------------------------------- 
BovineGZMO TCAGCTACCA AGAACAGAAG ACGATGTCAA ACCCCACACC AAGTGTCATG TGGCAGGATG 
PigGzmO    .A.......C .AC....G.A .A......G. .......... .......... .......... 
HumanGZMO  ...T...... .A.....G.C .G.....A.. ..TT...... G......... .......... 
MurineGZMO ...C..C... .AG.G..G.. .G..CT.G.. ......T... ........C. G......G.C 
 
           541        551        561        571        581        591 
           .          .          .          .          .          .  
---------------------------------------------------------------------------- 
BovineGZMO GGGAAGCACC AAAAAAGACG CATGTCAAAT GTC--TAATG CCTTGAGAGA AGCCAACG-- 
PigGzmO    .......... .G.......T .G..CA.... T..--A..CA .......... ..T....A-- 
HumanGZMO  .........A ....G....T ....CA..G. T.TGAA..CA .......... ..TG...AAA 
MurineGZMO AC.GG..CTG .TG.GG..-- -GCAC..GG. T..--CC.CA T......... ..T....C-- 
 
           601        611        621        631        641        651 
           .          .          .          .          .          .  
---------------------------------------------------------------------------- 
BovineGZMO --TTACAGTG ATAGATAGGA AAATATGCAA TGATGCCCAG CACTATAATT TTAATCCAGT 
PigGzmO    --....T... ......C.A. ....G..... .......... .......... .......... 
HumanGZMO  CA.C..TA.. ..G..CCAA. ...C...... ......AG.. .......... .C..G.TG.. 
MurineGZMO --.C..T... ..T...TTA. ..C.C..... CA..C.AA.. .GT..C.... .C..A.TGT. 
 
           661        671        681        691        701        711 
           .          .          .          .          .          .  
---------------------------------------------------------------------------- 
BovineGZMO TATTGATCTC AGTATGATCT GTGCTGGTGG TAGAAAAGGT GAAGATGATT CATGTGAAGG 
PigGzmO    ......C..T G......... ....A.T... .......... .......... .......... 
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HumanGZMO  .G....AAA. T.C....... .....A.... .........C .......C-- ---------- 
MurineGZMO CG.G..CAA. ..C.G.C.T. .......... C.CG.G...G TCTA.G.... .C...----- 
 
           721        731        741        751        761        771 
           .          .          .          .          .          .  
BovineGZMO GGATTCTGGA AGTCCTCTGA TATGTGATAA TGTTTTCAGA GGTGTCACTT CCTTTGGCAA 
PigGzmO    A......... .......... .......C.. CA........ ..G....... .......G.. 
HumanGZMO  ---------- ---------- ---------- ---------- ---------- ---------- 
MurineGZMO ---------- ---------- ---------- ---------- ---------- ---------- 
 
                781        791        801        811        821        831 
           .          .          .          .          .          . 
BovineGZMO GTGTGGTAAT CCCCAGAAGC CTGGCATCTA CATCCTCCTT ACCAAAAAAC ACCTCAACTG 
PigGzmO    .........C .......... .....G.... ...T.....C .......... .......... 
HumanGZMO  ---------- ---------- ---------- ---------- ---------- ---------- 
MurineGZMO ---------- ---------- ---------- ---------- ---------- ---------- 
 
           841        851        861 
           .          .          . 
BovineGZMO GATAAAGAAA ACCATTGCAG GAGCCATATA A 
PigGzmO    .......... .......... .......... G 
HumanGZMO  ---------- ---------- ---------- - 
MurineGZMO ---------- ---------- ---------- - 
 
Dot – Identical and Dash - Gap 
 
 
(b). Percentage nucleotide sequence similarities between species                                                         
 BtGzmO SsGzmO HsGzmO-like MmGzmO-like 
BtGzmO  90 (91) 89 (81) 66 
SsGzmO   82 (81) 67 
HsGzmO-like    68 
MmGzmO-like     
The nucleotide similarity values are for exon 4 and those in brackets are for the 
available coding region sequences  
 
3.3.4.2 Chymotrypsin-like locus 
The chymotrypsin-like locus is more complex. In human and mouse, the locus 
contains not only genes encoding granzymes B and H, but also a cluster of 
hematopoietic serine protease genes, including mast cell chymase (including 3 
subgroups, a-chymase in human and mouse and β-chymase and mast cell protease 8 
(Mcpt8), which are only found in mouse) and neutrophil cathepsin G, which exhibit 
gene sequence similarities and share similar substrate specificities with granzyme 
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genes (Gallwitz and Hellman, 2006). A preliminary map of the cattle chymotrypsin-
like locus, based on NCBI, Build 2.1 database released on October 2005, has been 
reported (Gallwitz et al., 2006). However, changes in the assembly of this region 
have been reported in the updated cattle genome; hence, the locus has been re-drawn 
according to the version of Ensembl, Btau_4.0 (released on 4 October 2007). The 
locus is identified on chromosome 21 in cattle. Although its overall size (192kb) is 
similar to that in human (129kb), the number of annotated functional genes in cattle 




Figure 3.10 Comparison of the genomic organization of the human, murine, 
cattle and pig chymotrypsin-like locus. 
Bars indicate gene positions; arrows indicate transcriptional orientation; 
numbers indicate the length of locus. Functional genes are shown in black boxes 
and non-functional genes in grey. Intervals between genes are drawn to scale. 
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Gzm = granzyme; Cma /Mcpt = mast cell chymase /mast cell protease; DDN = 
duodenase; Ctsg = cathepsin G.  
 
The cattle chymotrypsin-like locus contains 2 subgroups classified as α-chymase and 
cathepsin G (Ctsg) based on their phylogenetic relationship (Figure 3.13). In contrast 
to the presence of only one gene belonging to each group in human and mouse 
(Gallwitz and Hellman, 2006), there are two members of each group in cattle, which 
show a high level of predicted amino acid identity (94% and 78%, respectively): 
Cma1a and Cma1b representing α-chymase and Ctsg1 and Ctsg2 representing 
cathepsin G (as reported in (Gallwitz et al., 2006)); however, the gene sequences and 
chromosomal location of Ctsg genes differ from those in the previous report 
(Gallwitz et al., 2006). The positions of these genes relative to granzymes B and H 
and their orientation differ between human and cattle. Unlike the human locus, in 
which the Ctsg gene lies immediately downstream of the granzyme genes and the 
latter are in the same orientation, the two bovine Ctsg genes lie between the 
granzyme B and H genes, which are in a head-to-head orientation. This suggests that 
there has been one or more inversions in this region. 
 
A further 5 related genes sharing a high level of nucleotide similarity with granzyme 
B (64% to 66%) were found, one lying between the granzyme B and granzyme H 
genes and other 4 immediately downstream of granzyme H. However, none of them 
appear to be paralogous to granzyme B. One of these g n s was identified as a 
duodenase by Zamolodchikova et al in 1995 (Zamolodchikova et al., 1995a) and has 
been named as DDN1_BOVINE in Ensembl, Btau_4.0. Theother 4 genes are 
categorized as members of the duodenase family, based on their sequence similarity 
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to DDN1 and each other and their phylogenetic relationship (Figure 3.13) and have 
been named DDN2 – DDN5 accordingly following their order in the genome (Figure 
3.10). These 5 genes were previously reported as duodenases in (Gallwitz et al., 2006) 
and were named as BDMD1 – BDMD5 according to their close relationship to 
BDMD1 (a synonym of DDN1), but the gene sequences and chromosomal location 
of DDN2-DDN5 differ from those in the previous report (Gallwitz et al., 2006). So 
far, duodenase genes have only been reported in ruminants and no counterpart has 
been found in human and mouse. Comparisons of cDNA sequences show a high 
level of similarity between the DDN members. For example, the coding sequences of 
DDN2 and DDN1 are identical, except for one non-synonymous substitution at 
position 474 (A/T), suggesting a very recent gene duplication. All duodenase genes 
are predicted to be functional except for DDN5, which has several premature stop 
codons due to a frameshift mutation. Analysis of the available genomic data on the 
pig chymotrypsin-like locus reveals a gene order similar to cattle, with single Ctsg 
and DDN genes lying between the granzyme B and H genes, and with a Cma1 
fragmented gene (519bp) lying immediately downstream of granzyme H.  
 
3.3.4.3 Metase-locus 
The granzyme M gene found on chromosome 19 in human and chromosome 10 in 
mouse is linked downstream, in both species, with the neutrophil elastase gene 
cluster, which comprises azurocidin 1 (AZU1 - humans o ly), proteinase 3 (PRTN3), 
neutrophil elastase preproprotein (ELANE) and comple ent factor D (CFD) in 
human (Pilat et al., 1994). The counterpart of granzyme M in cattle is located on 
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chromosome 7, but no members of the neutrophil elastase gene cluster were found 
within the 160 kb of sequence downstream of this gene. 
 
Figure 3.11 Comparison of the genomic organization of the human, murine, 
cattle and pig metase locus. 
Bars indicate gene positions; arrows indicate transcriptional orientation; 
numbers indicate the length of locus. Functional genes are shown in black boxes. 
Dotted lines represent large regions of undermined sequence with the scaffolds. 
Intervals between genes are drawn to scale. Gzm = granzyme; ZAU1 = 
azurocidin 1; PRTN3 = proteinase 3; ELANE = neutrophil elastase 
preproprotein; CFD = complement factor D. 
 
BLASTN searches of the bovine genome using the nucleotide sequences of human 
AZU1, PRTN3, ELANE and CFD did not identify any sign ficant hits. In contrast 
searches of the EST database did identify single hihly matched sequences (covering 
>86% gene length and exhibiting >76% identity) for each of the genes 
(ZAU1/1907915542, PRTN3/1907973944, ELANE/1958311623 and 
CFD/1909258796). In human and mice two genes flanking each side of the elastase 
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gene cluster, PTBP1 and MIR3187 on one side and MED16 and C19orf22 on the 
other, are highly conserved and lie close to the elastase genes. These genes also are 
not included in the bovine genome assembly. In contrast to these genes, other genes 
flanking the metase locus show syntenic locations in cattle, mice and humans. It is 
most likely that the absence of the neutrophil elastase genes downstream from 
granzyme M may be due the incomplete genomic sequencing and assembly of this 
region. In pig, the cluster of neutrophil elastase genes was found on chromosome 2, 
but it was not possible to determine its proximity to the orthologue to granzyme M, 
as this gene has not been identified in the genome.  
 
 
3.3.5 Phylogenetic relationships between granzymes and related 
enzymes 
3.3.5.1 Relationship between genes within each geno me cluster 
Phylogenetic analysis of the nucleotide sequences of granzyme A, granzyme K and 
granzyme O located within the trypsin-like locus in human, mouse, cattle and pig 
identified three independent subgroups segregated according to granzyme gene, with 
the O subgroup being more closely related to A than K (Figure 3.12). In each case, 
interspecies comparisons showed that the bovine genwas most closely related to the 
pig orthologue and most divergent from the murine orthologue. The results suggest 
that the O gene diverged prior to speciation, possibly as a result of duplication of 




Figure 3.12 Phylogenetic relationships of human, mouse, cattle and pig trypsin-
like granzyme genes 
 
 
The nucleotide sequences were aligned by CLUSTAL W alignment with 
complete deletion of gaps for the analysis. The tree was constructed with the 
neighbour-joining algorithm using Mega 4.0 software. Numbers represent 
percentage bootstrap values out of 2,000 replications. Hs - Homo sapiens; Mm - 
Mus musculus; Ss - Sus scrofa; Bt - Bos taurus. 
 
Phylogenetic analyses of genes encoded in the chymotr psin-like locus in the 
different species broadly segregated the genes into four groups, namely the granzyme, 
cathepsin G, duodenase and chymase genes, which are expressed in mast cells and in 
mice are referred to as mast cell proteases (Mcpt). The chymase genes include two 
main subgroups, α-chymases in human, mouse and cattle and β-chymases which are 
only found in mouse. An additional mouse chymase, (Mcpt8), is phylogenetically 
distinct from both chymase subgroups. The 4 groups of genes exhibited a closer 
relationship across species than between the groups. Within the granzyme group, 
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human, bovine and pig granzyme B and H genes formed a subgroup, within which 
the bovine genes were most closely related to the respective pig orthologues, while 
the orphan mouse granzyme genes (D, E, F and G) formed a second subgroup. The 
murine granzyme B and C genes appeared to be in an intermediate position between 
these two subgroups. 
 
Figure 3.13 Phylogenetic relationship between genes within the human, mouse, 
pig and cattle chymotrypsin-like locus 
 
 
The cDNA sequences were aligned by CLUSTAL W alignment with complete 
deletion of gaps for the analysis. The tree was constructed with the neighbour-
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joining algorithm using Mega 4.0 software. The 4 main phylogenetic groups are 
labelled as granzymes, cathepsin G, duodenases and chymases (α- and β-
chymase). Numbers represent percentage bootstrap values out of 2,000 
replications. Hs - Homo sapiens; Mm - Mus musculus; Ss - Sus scrofa; Bt - Bos 
taurus. Gzm = granzyme; CMA /Mcpt = mast cell chymase /mast cell protease; 
DDN = duodenase; CTSG = cathepsin G.  
 
 
3.3.5.2 Relationship between granzyme proteins with in and between 
species 
A phylogenetic tree constructed from the translated amino acid sequences of all 
granzymes from human, mouse, cattle and pig is shown in figure 3.14 and the levels 
of amino acid identity between the granzymes are presented in table 3.7. In general, 
the levels of sequence identity correspond closely with the relationships observed in 
the phylogenetic tree. The latter demonstrates divergence into three broad groups, 
corresponding to the trypsin-like, chymotrypsin-like and metase proteins and to the 
chromosomal locations of the genes. This was reflect d by much lower sequence 










Figure 3.14 Phylogenetic relationship of granzymes from human, mouse, pig 
and cattle based on analysis of amino acid sequences 
 
 
The amino acid sequences translated from the cDNA sequences were aligned by 
CLUSTAL W alignment with complete deletion of gaps for the analysis. The 
tree was constructed with the neighbour-joining algorithm using Mega 4.0 
software. Numbers represent percentage bootstrap values out of 2,000 




Table 3.7 Percentage amino acid identities between mature protein sequences of 
bovine, human, murine and pig granzymes. 
 
Mature protein sequences of granzyme genes were aligned by Clustal W 
alignment with pairwise deletion of gaps for the analysis and then manually 
edited for improvement. Numbers representing the amino acid identity of 
granzymes within each subgroup are highlighted in grey. Hs - Homo sapiens; 





Overall, the findings support the view that the granzyme genes diverged before 
divergence of these mammalian species. Data on the nov l Granzyme O gene 
indicate that it arose from early duplication of granzyme A, with subsequent loss of 
function in human and mouse.  
 
 
3.3.6 Characteristic structural features of granzym e proteins  
To investigate their structural homologies and predict  substrate-binding specificity, 
multiple amino acid sequence alignments of human, mouse, cattle and pig granzymes 
were applied by using the Clustal W alignment and then manual manipulation for 
improvement (Figure 3.15). Sequence analysis reveald features of cattle and pig 
granzymes typical of the murine and human orthologues: highly conserved 
consensus sequences at positions 1-4 (IIGG) and 9-16 (PHSRPYMA); conserved 
signal sequence cleavage sites prior to the propeptide; conserved amino acids at the 
catalytic triad, ie. residues that form the active sit , His-45, Asp-95 and Ser-195; 3-4 









Figure 3.15 Amino acid sequence alignment of bovine, human, mouse and pig 
granzymes showing conservation of functionally relevant amino acid residues. 
                            
              ------Signal sequence-----   Propeptide 
                                      -3  -2                                         
Hs_GZMA       MRNSYRFLASSLSVVVSLLLIPEDVC * EK    
Mm_GZMA       MRNASGPRGPSLATLLFLLLIPEGGC * ER 
Bt_GZMA        MRNSSTFLAATLSIVVFLLIPEDLC * EK 
Ss_GZMA        MRNSSTFLAATLSIVIFLQIHEDFC * VE 
Bt_GZMO       MNIPFPFSFPPAICLLLIPGVFPVSC * EG   
Ss_GZMO       MEIPFPFFFPAAMCLLIIPGVFPVSC * DG 
Hs_GZMK         MTKFSSFSLFFLIVGAYMTHVCFN * ME 
Mm_GZMK         M-RFSSWALVSLVAGVYMSSECFH * TE 
Bt_GZMK         MTKFSSFFLCFLLAGTYMTPECFN * ME 
Ss_GZMK         MTTFSSFFLCFLIAGMYMTPECFN * ME 
Hs_GZMB               MQPILLLLAFLLLPRADA * GE 
Mm_GZMB               MKILLLLLTLSLASRTKA * GE 
Bt_GZMB               MKPLLLLVAFLLTPRAKA * GE 
Ss_GzmB             MQPLLLLLSLAFLLPPRAEA * GE 
Hs_GZMH               MQPFLLLLAFLLTPGAGT * EE 
Bt_GZMH           MQLLLLLMAFLLPPGLGEPFLS * EE 
Ss_GzmH           MQPVLLSLAFLLSPGLGWPFLA * EE 
Mm_GZMC               MPPVLILLTLLLPLRAGA * EE 
Mm_GZMD               MPPILILLTLLLPLRAGA * EE 
Mm_GZME               MPPVLILLTLLLPLGAGA * EE 
Mm_GZMF               MPPILILLTLLLPLRAGA * EE 
Mm_GZMG               MPPILILLTLLLPLRAGA * EE 
Mm_GZMN               MLPVLILLIFLLPVGDGA * EE                                  
Hs_GZMM          MEACVSSLLVLALGALSVG * SSFGTQ   
Mm_GZMM         MEVCWSLLLLLALKTLWAAG * NRFETQ 




              1          11         21         31         41         51                              
              .          .          .          .          .          .                                                    
Hs_GZMA       IIGGNEVTPH SRPYMVLLS- --LDRKTI-C AGALIAKDWV LTAAHCNL-- --NKRSQVIL 
Mm_GZMA       ....DT.V.. .....A..K- --.SSN..-. .....E.N.. .......V-- --G...KF.. 
Bt_GZMA       .....Q.... ........-- ---.GGN.-. .......... ......S.-- --.QK..I.. 
Ss_GZMA       .....P.... ........-- ---EG.N.-. .......... ......A.-- --..K..I.. 
Bt_GZMO       .......A.. T.R..A.I-- ---KGLKL-. .....KEN.. ......D.-- --KGNP.... 
Ss_GZMO       .......S.. T.R..A.I-- ---EGLKV-. .....KEN.. ......D.-- --KGNP.... 
Hs_GZMK       ....K..S.. ...F.ASIQ- --YGGHHV-. G.V..DPQ.. ......QYRF TKGQSPT.V. 
Mm_GZMK       ....R..Q.. ...F.ASIQ- --YRS.H.-. G.V..HPQ.. ......YSWF PRGHSPT.V. 
Bt_GZMK       ....R..S.. ...F.AS.Q- --YGGDH.-. G.V..HPQ.. ......H.RF AKSQS.K.V. 
Ss_GZMK       .V..R..S.. .K.F.ASIQ- --YSGHH.-. G.V..HPQ.. ......YYRF AKGQSAK.V. 
Hs_GZMB       ....H.AK.. .....AY.MI WDQKSLKR-. G.F..RD.F. ......WG-- ---SSIN.T. 
Mm_GZMB       ....H..K.. .....A...- IKDQQPEAI. G.F..RE.F. ......EG-- ---SIIN.T. 
Bt_GZMB       ....H.AK.. .....AY.QY WNQ.VQSR-. G.F.VRQ.F. .......G-- ---SSIK.T. 
Ss_GzmB       ....H.AK.. .....AY.QI QDQ.NRSR-. G.F..RE.F. ......WG-- ---SSIN.T. 
Hs_GZMH       ....H.AK.. .....AFVQF LQEKSRKR-. G.I.VR..F. ......QG-- ---SSIN.T. 
Bt_GZMH       ....H.AK.. .....AFVQF LGEKSWKR-. G.V..Q..F. ......RG-- ---SSIN.T. 
Ss_GzmH       ....H.AK.. .....AFVRF LDKESVKR-. G.V.VR..F. ......RG-- ---SSIN.T. 
Mm_GZMC       ......IS.. .....AYYEF LKVGG.KMF. G.F.VRDKF. ......KG-- ---SSMT.T. 
Mm_GZMD       ....HV.K.. .....AFVMS VDIKGNR.Y. G.F..QD.F. ......KNS- SVQSSMT.T. 
Mm_GZME       ....HV.K.. .....AFVKS VDIEGNRRY. G.F.VQD.F. ......RN-- ---RTMT.T. 
Mm_GZMF       ....H..K.. .....ARVRF VKDNG.RHS. G.F.VQDYF. ......TG-- ---SSMR... 
Mm_GZMG       ....H..K.. .....AFIKS VDIEG.KKY. G.F.VQD.F. ......RN-- ---RSMT.T. 
Mm_GZMN       V...H..K.. .....A.VVF LKVNGIGSS. G.F.VQDYF. ......IG-- ---SSMT.T. 
Hs_GZMM       ....R..I.. .....AS.Q- --RN-GSHL. G.V.VHPK.. ......LAQR --MAQLRLV. 
Mm_GZMM       ....R.AV.. .....AS.Q- --KA-.SHV. G.V.VHRK.. ......LSEP --LQNLKLV. 







              61         71         81         91         101        111 
              .          .          .          .          .          .  
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                                                99  
                                                S2   
Hs_GZMA       GAHSITREEP TKQIMLVKKE FPYPCYDP-A TREGDLKLLQ LMEKAKINKY VTILHLPKK- 
Mm_GZMA       .....NK-.. EQ..LT...A .......E-Y ......Q.VR .KK..TV.RN .A.......- 
Bt_GZMA       ....RNK... E....F.... ........-D .H.......K .NK..TL..N .A..Q...E- 
Ss_GZMA       ......KK.. E......... Y....F.Q-D .H.......K .NK..TL..N .AV.....V- 
Bt_GZMO       ....TSHK.K LD.VFSI..A I....F..-Q .F....Q... .EG..TMT.A .G..Q..RT- 
Ss_GZMO       ....TSHK.K YD.TFSI..A I....F..-Q .F....Q... .EG..TMT.A .G..K..NT- 
Hs_GZMK       ....LSKN.A S..TLEI..F I.FSRVTS-D PQSN.IM.VK .QTA..L..H .KM..-IRS- 
Mm_GZMK       ....LSKN.. M..TFEI..F I.FSRLQS-G SASH.IM.IK .RTA.EL..N .QL..-LGS- 
Bt_GZMK       ....LSKN.A S..TFEI..F IRF.GFAL-. PKSN.IM.VK .HTA.IL.RH .QL..-.RA- 
Ss_GZMK       ....LSKN.A S..TFEI..F I.F.RFTS-D PKSN.IM.VE .RKA..L.NH IQL..-.RS- 
Hs_GZMB       ...N.KEQ.. .Q.FIP..RP I.H.A.N.-K NFSN.IM... .ER...RTRA .QP.R..SN- 
Mm_GZMB       ...N.KEQ.K .Q.VIPMV.C I.H.D.N.-K .FSN.IM..K .KS...RTRA .RP.N..RR- 
Bt_GZMB       ...N.KQQ.R .Q.VIR.RRA ISH.D.N.-K NFSN.IM..K .ER...QTSA .KP.S..RA- 
Ss_GzmB       ...N.KKQ.E .Q.VIP.R.A IRH.D.NE-K RISN.IM... .ER...LT.A .KT.G..GA- 
Hs_GZMH       ...N.KEQ.R .Q.FIP..RP I.H.A.N.-K NFSN.IM... .ER...WTTA .RP.R..SS- 
Bt_GZMH       ...N.KQQ.R .Q.VIQ..RA IHH.D.N.-K .FSN.IM... .ER...QTSA .KP.S...A- 
Ss_GzmH       ...N.KKQ.E .Q.VIP.R.A IRH.D.NE-K RISN.IM... .ER...LT.A .KT.G..GA- 
Mm_GZMC       ...N.KAK.E .Q..IP.A.A I.H.D.N.-D D.SN.IM..K .VRN..RTRA .RP.N..RR- 
Mm_GZMD       ...N..AK.E .Q..IP.A.D I.H.D.NA-T IFYS.IM..K .ES...RT.A .RP.K..RS- 
Mm_GZME       ...N.KAK.E .Q..IP.A.A I.H.D.NA-T AFFS.IM..K .ES...RT.A .RP.K..RP- 
Mm_GZMF       ...N.RAK.E .Q..IP.A.A I.H.A..D-K DNTS.IM..K .ES...RT.A .RP.K..RP- 
Mm_GZMG       ...N.KAK.E .Q..IP.A.A I.H.AFNR-K HGTN.IM..K .ES...RT.A .RP.K..RP- 
Mm_GZMN       ...NLRAQ.E .Q..IP.N.A L.H.D.N.-L DHTN.IM..K .ES...GTRD .RP.K..GP- 
Hs_GZMM       .L.TLD---S PGLTFHI.AA IQH.R.K.VP AL.N..A... .DG.V.PSRT IRP.A..S.- 
Mm_GZMM       .L.NLHDLQD PGLTFYIREA IKH.G.N--H KY.N..A..K .DRRVQPS.N .KP.A..R.P 




              121        131        141        151        161        171 
              .          .          .          .          .          .  
Hs_GZMA       GDDVKPGTMC QVAGWGRTHN SA-SWSDTLR EVNITIIDRK VCNDRNHYNF NPVIGMNMVC 
Mm_GZMA       ........R. R......FG. KS-AP.E... .....V.... I...EK.... H....L..I. 
Bt_GZMA       .K..E...A. R.....QFY. NS-PV.KI.. ...V...... I...QS...Y .....L..I. 
Ss_GZMA       ........V. R.....KF.. NS-PR..I.. ...V.V.... I...KS...Y TT...L..I. 
Bt_GZMO       E.....H.K. H.....S.KK D.CQM.NA.. .A.V.V.... I...AQ.... ....DLS.I. 
Ss_GZMO       .K..E.H.K. H.....S.RK DSCKI.N... .....V.... M...AQ.... ....DLG.I. 
Hs_GZMK       KTSLRS..K. K.T...A.DP DSLRP..... ..TV.VLS.. L..SQSY..G D.F.TKD... 
Mm_GZMK       KNYLRD..K. ..T...T.KP DLLTA..... ..TV...S.. R..SQSY..H K...TKD.I. 
Bt_GZMK       KN.I.A..K. ..V...A.DP EGL.L..... ..TV.V.S.. T..S.DY..H S...TRT.L. 
Ss_GZMK       KN.IRA..K. ..I...A.DP DCL.P..... ..TV.V.S.. ...S.SY..H D.I.TKT.L. 
Hs_GZMB       KAQ....QT. S.....Q.AP LGKHSHT-.Q ..KM.VQEDR K.ES--DLRH -YYDSTIEL. 
Mm_GZMB       NVN....DV. Y......MAP MGKYSNT-.Q ..EL.VQKDR E.ES--YFKN -RYNKT.QI. 
Bt_GZMB       KAR....QT. S......DS- TDTYADT-.Q ..KLIVQEDQ K.EA--YLRN -FYNRAIQL. 
Ss_GzmB       KAR....QV. S.....QVE- RGIYTDT-.Q ..KL.LQKDQ E.DS--YLPN -YYN.NTQL. 
Hs_GZMH       KAQ....QL. S.....YVS- MSTLATT-.Q ..LL.VQKDC Q.ER--LFHG -NYSRATEI. 
Bt_GZMH       KAQ....EV. SL....KVA- LGTPATT-.Q ..EL.VQEDR ..ES--LNPR -NYSRATQI. 
Ss_GzmH       KAR....QV. S.....QVA- RGIQT.T-.Q .AKLRVQ.DV A.EF--PFPS GYYHRASQI. 
Mm_GZMC       NAH....DE. Y.....KVTP DGEFPKT-.H ..KL.VQKDQ ..ES--QFQS -SYNRA.EI. 
Mm_GZMD       NAR....DV. S.....SRSI NDTKA.AR.. ..QLV.QEDE E.KK--RFRY --YTETTEI. 
Mm_GZME       NAR....DV. S.....SRSI NDTKA.AR.. .AQLV.QEDE E.KK--RFRH --YTETTEI. 
Mm_GZMF       NAR....HV. S.......SI N.TQR.SC.. .AQLI.QKD. E.KK--YFYK --YFKTMQI. 
Mm_GZMG       NAR....DV. S.....K.SI N.TKA.AR.. .AQLI.QEDE E.KK--LWYT --YSKTTQI. 
Mm_GZMN       K.K.N..DV. S.....K.SI NTTEG.AL.E .AELI.QEN. E.KK--QFRH --YSKITEI. 
Hs_GZMM       RQV.AA..R. SM....L..Q GG-RL.RV.. .LDLQVL.TR M..NSRFW.G --SLSPS... 
Mm_GZMM       RSKPAE..W. ST....M..Q GG-PRARA.Q .LDLRVL.TQ M..NSRFW.G --.LIDS.L. 

















              181        191        201      211        221        231 
              .          .          .        .          .          .  
                     189 192                    216 218        226 
                      S1  S1                     S1 S3         S1 
Hs_GZMA       AGSLRGGRDS CNGDSGSPLL CE--GVFR GVTSFGLENK CGDPRGPGVY ILLSKKHLNW 
Mm_GZMA       ..D....K.. .......... .D--.IL. .I....G.-. ...R.W.... TF..D..... 
Bt_GZMA       ....Q..K.. .H.......I .K--DT.. .I.A..IPGR .......... T......... 
Ss_GZMA       ...PQ..K.. ......A..I ..--.I.. ...A...SE. .......... .......... 
Bt_GZMO       ..GRK.ED.. .E.......I .D--N... ......K--- ..N.QK..I. ...T...... 
Ss_GZMO       .VGRK.ED.. .E.......I .D--NI.. ......K--- ..N.QK.... ...T...... 
Hs_GZMK       ..DAK.QK.. .K....G..I .K--...H AIV.G.H.-- ..VATK..I. T..T..YQT. 
Mm_GZMK       ..DA..QK.. .K....G..I .K--.I.H ALV.Q.YK-- ..IAKK..I. T..T..YQT. 
Bt_GZMK       ..DA..QK.. .Q....G..V .K--.A.H ALV.G.PK-- ...AKK..I. ...TR.FQA. 
Ss_GZMK       ..DT..QK.. .Q....G..V .K--.A.N ALV.G.RK-- ...A.K..I. ....R.YQT. 
Hs_GZMB       V.DPEIKKT. FK....G..V .N--K.AQ .IV.Y.RN-- --NGMP.RAC TKV.-SFVH. 
Mm_GZMB       ..DPKTK.A. FR....G..V .K--K.AA .IV.Y.YK-- --.GSP.RAF TKV.-SF.S. 
Bt_GZMB       V.DPKTKKA. FQ....G..V .D--N.AQ .IV.Y.KR-- --.GST.RAF TKV.-SF.P. 
Ss_GzmB       V.DPKKKQAT FK....G..V .N--N.AQ .IV.Y.KK-- --.GTP.RAC TKV.-SF.P. 
Hs_GZMH       V.DPKKTQTG FK....G..V .K--D.AQ .IL.Y.NK-- --KGTP.... .KV.-HF.P. 
Bt_GZMH       V.DP.KVKTG FK....G..V .K--K.VH .IF.Y.KT-- --NGTP...F TQV.-HF.P. 
Ss_GzmH       V.NP.DMKT. FK....G..V .K--N.VQ .IF.Y.KM-- --.GTP...F TKV.-HF.P. 
Mm_GZMC       V.DSKIKGA. FEE...G..V .K--RAAA .IV.Y.QT-- --.GSA.Q.F TRVL-SFVS. 
Mm_GZMD       ..D.KKIKTP FK....G..V .D--NQAY .LFAYAKN-- --GTISS.IF TKVV-HF.P. 
Mm_GZME       ..D.KKIKTP FK....G..V .D--NKAY .LLAYAKN-- --RTISS..F TKIV-HF.P. 
Mm_GZMF       ..DPKKIQST YS....G..V .N--NKAY ..LTY..N-- --RTI....F TKVV-HY.P. 
Mm_GZMG       ..DPKKVQAP YE.E..G..V .D--NLAY ..V.Y.IN-- --RTIT...F TKVV-HF.P. 
Mm_GZMN       ..DPNKIEAP SK....G..V .N--NKAH ..L.YVKS-- --KKISS..F TKVV-HF.P. 
Hs_GZMM       LAADSKDQAP .K....G..V .GKGR.LA R.L..SSRV- .T.IFK.P.A TAVA-PYVS. 
Mm_GZMM       LKAGSKSQAP .K....G..V .GKGQ.-D .IL..SSKT- .T.IFK.P.A TAVA-PYSS. 
Bt_GZMM       LAADSKNQAP .K....G.VV .KRGQ.-A .IL..SS..- .T.IFK.P.A VAVA-PYMP.  
                                               ----L3 Loop-----  
            
              241        251             
              .          .                    
Hs_GZMA       IIMTIKGAV* ----- 
Mm_GZMA       .KKIM..S.. ----- 
Bt_GZMA       .VK.M.Q... ----- 
Ss_GZMA       .VN.M.H... ----- 
Bt_GZMO       .KK..A..I. ----- 
Ss_GZMO       .KK..A..I. ----- 
Hs_GZMK       .KSNLVPPHT N*--- 
Mm_GZMK       .KSKLAPSRA H*--- 
Bt_GZMK       .KSNLAPSHA D*--- 
Ss_GZMK       .KSKLAPSHQ N*--- 
Hs_GZMB       .KK.M.RY*- ----- 
Mm_GZMB       .KK.M.SS*- ----- 
Bt_GZMB       .KK.M.SL*- ----- 
Ss_GzmB       .KKIM.SL*- ----- 
Hs_GZMH       .KR.M.RL*- ----- 
Bt_GZMH       .KR.M.HL*- ----- 
Ss_GzmH       .KK.M.PL*- ----- 
Mm_GZMC       .KK.M.HS*- ----- 
Mm_GZMD       .SWNM.LL*- ----- 
Mm_GZME       .SRNM.LL*- ----- 
Mm_GZMF       .SRNM.LL*- ----- 
Mm_GZMG       .STNM.LL*- ----- 
Mm_GZMN       .STNM.LL*- ----- 
Hs_GZMM       .RKVTGRSA. ----- 
Mm_GZMM       .RKV.GRWSP QSLV* 
Bt_GZMM       .KKVLRHNGS PPSP* 
Hs - Homo sapiens; Mm - Mus musculus; Ss - Sus scrofa; Bt - Bos taurus. 
Multiple signal sequence cleavage sites are shown by an asterisk; conserved 
consensus sequences at the N-terminus at positions 1-4 (IIGG) and 9-16 
(PHSRPYMA) are shown in yellow; the three amino acids of the catalytic triad 
are shown in red; cysteine residues that form disulfide bonds are shown in blue; 
Substrate-determining residues in S1, S2 and S3 are shown in green. 
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Numbering of residues based on chymotrypsinogen amino acid sequence is used 
to refer to specific amino acids.  
 
 
Application of an algorithm based on a weight-matrix approach (von Heijne, 1986) 
indicates that the signal sequence cleavage site occurs between positions -3 and -2 in 
cattle and pig granzyme A, O, B and H. The algorithm failed to predict a cleavage 
site in granzyme K, but since Asn-3–Met-2 has been identified experimentally as the 
cleavage site in human granzyme K (Sayers et al., 1996) and is conserved in the 
bovine orthologue, this is likely to represent the cl avage site in the bovine protein. 
The residues forming the potential peptidase cleavage site, Gly(-7)-Asn(-6), deduced 
from the cattle granzyme M sequence, are identical o those in the mouse and rat 
proteins, which are cleaved at this site (Pilat et al., 1994; Smyth et al., 1995; Kelly et 
al., 1996), suggesting that a hexapeptide is cleaved from cattle granzyme M to 
generate the mature protein. Eight cysteine residue ar  conserved in the same 
respective positions in cattle and pig granzyme A, O, K and M and are predicted to 
form four internal disulfide bonds Cys30-Cys46, Cys162-Cys180, Cys191-Cys221 
and Cys130-Cys201. Six of these residues are also conserved in the corresponding 
positions in granzyme B and H; the lack of cysteine residues at positions 191 and 221 
in these granzymes, resulting in the absence of the disulfide bond in the vicinity of 
the enzyme active site, is a characteristic feature of the chymotrypsin family which 
distinguishes them from other serine proteases (Zamolodchikova et al., 2003). 
 
Like other proteases, the function of granzymes is determined by which substrate 
they cleave. In general, following specific docking i to the substrate binding cleft of 
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the protease, the substrate is cleaved after the cleavage residue (the amino acid at P1 
position in the substrate) through the proteolytic activity of the catalytic triad in the 
protease. The protease binding site typically interacts with at least three amino acids 
on each side of P1 in the substrate (nomenclature for amino acid positions in the 
substrate is Pn-P4-P3-P2-P1-P1'-P2'-P3'-P4'-Pn' (Schechter and Berger, 1967)). It is 
known that interaction of the substrate P1 residue with the S1 site of the protease 
(nomenclature for corresponding sites in the protease is Sn-S4-S3-S2-S1-S1'-S2'-S3'-
S4'-Sn' (Schechter and Berger, 1967)) determines “primary substrate specificity”, 
which is rigorously restricted to certain amino acids, whereas interaction of other 
substrate residues with the binding site of the protease determines “extended 
substrate specificity” that is less specific but has substantial influence on the 
proteolytic efficiency.  
 
Substrate specificity is determined by the 3-dimensional structure of the enzymes. 
Previously obtained data on the structure of murine a d human granzymes (Perona 
and Craik, 1995) and the use of homology molecular models provide the opportunity 
to predict the substrate specificity of granzymes from other species by analysis of the 
corresponding specificity-determining residues. Residues 189, 192, 216 and 226 
(based on chymotrypsinogen numbering) important for primary substrate specificity 
(Odake S 1991 and Kam C M 2000), deduced in cattle nd pig granzymes in this 




Table 3.8 Comparison of key amino acid residues in the substrate binding site 
and predicted enzymatic specificities of granzymes from different species 
 
 
Based on data from (Odake et al., 1991; Kam et al., 2000), with additional data 
on bovine and pig in red from the present study. Models from which data 
derived in original analysis: The molecular model of GzmA was constructed 
based on the crystal structure of bovine trypsin and RMCPII (Murphy et al., 
1988). The model for GzmB was based on structure ofRMCPII (Murphy et al., 
1988). GzmM was modelled based on the crystal struct re of α-chymotrypsin 
(Smyth et al., 1996). P1 specificity from human granzymes is derived from 
(Mahrus and Craik, 2005). The potential enzymatic function and P1 specificity 
of cattle and pig granzymes are highlighted by an asterisk. The sequence residue 
numbering is based on the chymotrypsinogen numbering. Hs - Homo sapiens; 
Mm - Mus musculus; Ss - Sus scrofa; Bt - Bos taurus. 
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Generally, three residues at positions 189, 216 and 226 are responsible for the 
primary substrate specificity in serine proteases (Perona and Craik, 1995). The 
presence of a negatively charged residue Asp189 is of great importance in 
determining the primary substrate specificity to trypsin-like enzymes (Ruhlmann et 
al., 1973). This amino acid is positioned at the bottom of S1 pocket and 
electrostatically interacts with the basic residue at P1 in the substrate. Gly residues at 
positions 216 and 226 help to provide access of the bulky lysine or arginine in the 
substrate to Asp189. As cattle and pig granzyme A, O and K share the identical 
specificity-determining triplet (Asp189-Gly216-Gly226) with their human and 
mouse counterparts, these novel enzymes most likelyhave the trypsin-like specificity 
and prefer to cleave after Arg or Lys residues.  
 
In chymotrypsin-like enzymes, the crucial role is shifted to the amino acid on 
position 226 that is situated at the back of the specificity pocket (Caputo et al., 1994; 
Edwards et al., 1999). This is associated with the absence of a disulfide bond in the 
vicinity of the enzyme active site, compared with other granzyme groups 
(Zamolodchikova et al., 2003). An uncharged amino acid is present at position 189 in 
all of chymotrypsin-like enzymes and it is observed in granzyme B and H in both 
cattle and pig. The small size of the uncharged residu  Gly226, present in all 
chymotrypsins, is thought to permit bulky hydrophobic side chains to be 
accommodated and cleaved (Edwards et al., 1999). Granzyme H has no direct rodent 
counterpart but is reported to have the typical chymotrypsin-like activity to cleave 
after Phe or Tyr at P1. The presence of conserved amino acids at Thr189, Gly216 and 
Gly226 (S1 subsite) in cattle and pig granzyme H are predictive of chymotrypsin-like 
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activity. However, the existence of a positively charged residue, Arg226, in bovine 
granzyme B suggests a unique specificity for the negatively charged acidic side-
chain of Asp in the substrate (Poe et al., 1991; Caputo et al., 1994; Waugh et al., 
2000). Experiments in which point mutations were introduced into mouse granzyme 
B have shown that replacement of Asp226 with Gly226 causes loss of Aspase 
specificity but facilitates hydrolysis of hydrophobic substrates (Caputo et al., 1994). 
As the Asn189-Gly216-Arg226 amino acid triplet within the S1 pocket of cattle and 
pig granzyme B are highly conserved with those in human and mouse, these enzymes 
are predicted to act on substrates containing the acidic residue Asp in P1.  
 
Structural studies of chymotrypsin A have indicated that the substrate specificity of 
granzyme M for the carboxyl terminal of long narrow hydrophobic amino acids, Met 
and Leu, is dependent on two key residues, Lys192 and Ser216. Replacement of 
Lys192 with Met and Ser216 with Gly in human granzyme M has been shown to 
result in a marked reduction in hydrolysis of substrates containing Met at P1, but the 
acquisition of chymase activity on Phe at P1 (Smyth et al., 1996). The presence of 
conserved amino acids Lys192 and Ser216 in cattle granzyme M indicates that it 
should have metase specificity similar to the human and murine counterparts.  
 
Comparison of predicted functions of related genes i  the chymotrypsin-like locus 
The bovine chymotrypsin-like locus contains a number of genes in addition to 
granzymes. It includes the duplication of non-granzyme genes (a-chymase and 
cathepsin G) and also a series of closely related genes, encoding enzymes termed 
duodenases, not detected in humans or mice. They show high sequence similarity to 
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granzyme B (64-66%) and in early studies one of these genes (DDN1, identified by 
Zamolodchikova et al in 1995) was erroneously reported as granzyme B 
(NM_174296). Therefore, the primary structure of duo enases was examined to 
investigate their potential enzymatic specificities n comparison with those of the 
chymotrypsin-like granzymes. The amino acids found in the three key specificity-
determining residues (189-216-226) in the S1 pocket of cattle and pig chymotrypsin-
like genes are shown in figure 3.16. 
 
Figure 3.16 Alignment of specificity-determining residues in the S1 pocket of 
chymotrypsin-like genes 
          189 191                   216 220  226                       189-216-226 
            S1                       S1       S1 
 
Hs_GzmB  IK.TS..... ....V.NK.. ........NN GM..RAC.KV .SFVH..KKT MKRY    T   G   R   
Mm_GzmB  TKRAS.R... ....V.KK.. A......YK. GS..RA..KV .SFLS..KKT MKSS    A   G   R 
Bt_GzmB  TK.AS.Q... ....V.DN.. .......KR. GST.RA..KV .SFL...KKT MKSL    A   G   R  
Ss_GzmB  .KQAT..... ....V.NN.. .......KK. GT..RAC.KV .SFL...KK. MKSL    A   G   R 
Hs_GzmH  ..QTG..... ....V.KD.. ...L...NKK GT..G.YIKV ..FL...KRT MKRL    T   G   G 
Bt_GzmH  .V.TG..... ....V.KK.V H..F...KTN GT..G...QV ..FL...KRT MKHL    T   G   G 
Ss_GzmH  DM.TS..... ....V.KN.V ...F...KM. GT..G...KV ..FL...KKT MKPL    T   G   G 
Mm_GzmC  IKGAS.EE.. ....V.KRA. A......QT. GSA.Q....V LSFVS..KKT MKHS    A   G   Q 
Mm_GzmD  .I.TP..... ....V.DNQ. Y.LFA.AKNG TISSGI..KV V.FL...SWN MKLL    T   A   G 
Mm_GzmE  .I.TP..... ....V.DNK. Y.LLA.AKNR TISSG...K. V.FL...SRN MKLL    T   A   G  
Mm_GzmF  .IQ.TYS... ....V.NNK. Y.VLT..LNR TIG.G...KV V..L...SRN MKLL    S   G   G 
Mm_GzmG  .VQAPYE.E. ....V.DNL. Y.V....INR TIT.G...KV V.FL...STN MKLL    A   G   G  
Mm_GzmN  .IEAPS.... ....V.NNK. H.VL..VK.K KISSG...KV V.FL...STN MKLL    A   V   G 
 
Bt_DDN1  .R.NS.S... ....V.N... ........N. GTT.D.Y... .SFLS..HST MRRY    N   G   D  
Bt_DDN2  .R.NS.S... ....V.N... ........N. GTT.D.Y... .SFLS..HST MRRY    N   G   D 
Bt_DDN3  .R.NS.S... ....V.N... ........D. GTT.D.Y... .SFLS..HST MRRY    N   G   D 
Bt_DDN4  .R.NS.S... ....V.D... ........K. GTT.D.Y... .SFLS..HST MRRY    N   G   D 
Bt_DDN5  *GRRL*MVTL .A..YVMVWP RALCPMDKIH LQMST--PES QGFSNGSKKQ *KCT    R   D   T  
Ss_DDN   .MNNS.L... ....V.K... .....F.KK. GS..S.Y.K. .SFL...KKT MRNH    N   G   S 
 
Bovine and pig sequences are labelled in red.  The triplet of S1 pocket residues 
at positions 189, 216 and 226 are highlighted in green and listed adjacent to the 
sequences to the right of the figure. Chymotrypsinogen numbering is used to 
refer to residue positions. Hs - Homo sapiens; Mm - Mus musculus; Ss - Sus 
scrofa; Bt - Bos taurus. 
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DDN1 was found to have unique amino acids Asn189 and Asp226 at two of the 
primary specificity determining residues in the S1 pocket. The presence of these 
amino acids suggests that DDN1 has both trypsin-like and chymotrypsin-like 
activities (Zamolodchikova et al., 1995a; Zamolodchikova et al., 1995b); the 
uncharged residue Asn at position 189 indicates chymotrypsin-like specificity while 
the negatively charged Asp at position 226 indicates acquisition of trypsin-like 
activity (Zamolodchikova et al., 1995b). The same structure-function relationship of 
duodenase has been reported for sheep mast cell prot ase (Smcp-1) (McAleese et al., 
1998). As the other functional duodenases DDN2-4 have the identical triplet (N-G-D) 
with DDN1 and sheep Smcp-1, these novel enzymes should exhibit similar 
specificity. In contrast, pig DDN has an uncharged r sidue Ser at position 226, 
suggesting that it does not have trypsin-like specificity. Overall, the duodenase genes 
in cattle, sheep and pig display similar key residues in the S1 pocket and are likely to 
have similar enzymatic activity. On the other hand, their functional sites show clear 
differences from granzyme proteins, indicating that these proteins have distinct 












The studies reported in this chapter have identified six classes of granzymes in cattle, 
A, O, B, K, H and M, based on analysis of genome and EST databases. Specific PCR 
protocols have been developed and optimised for all of these granzymes. Analysis of 
cDNA from un-cloned T. parva-specific CD8+ T cell lines using these PCR assays 
showed that all of the enzymes are expressed at the RNA level in activated CD8+ T 
cells. Consistent with findings in humans and mice, th  granzyme-encoding genes 
were located on 3 different loci within the genome, which correspond to different 
proteolytic enzymatic activities, namely trypsin-like, chymotrypsin-like and metase. 
Analysis of primary amino acid sequences suggested that the granzyme proteins have 
enzymatic specificities similar to their human and murine counterparts. 
 
The identified granzymes included a novel functional gr nzyme, termed granzyme O, 
not previously reported among the granzymes described in any species. A functional 
orthologue was also identified in the pig and non-fu ctional/truncated genes were 
present in human and mouse, indicating that this novel gene evolved by gene 
duplication before the human-mouse-cattle-pig species d vergence and subsequently 
became non-functional in humans and mice.  
 
Annotation of the genome loci containing the bovine granzyme genes has 
demonstrated that the gene organisation is essentially identical to that in human, 
mouse and pig. In each species, the genes are foundin three distinct chromosomal 
locations, each of which has similar gene organisation across the species (Table 3.9). 
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Analysis of phylogenetic trees has revealed the homol gous relationship between 
each subgroup of cattle and pig granzyme genes and their human and mouse 
counterparts. Comparison of mature protein sequences of all granzymes from human, 
mouse, cattle and pig has shown obviously higher levels of identity within each 
group between species (45%-91%) than between the groups (Up to 44%). All of 
these findings suggest that the granzyme family of genes in human, mouse, cattle and 
pig have evolved from common ancestors, and that differences in gene complement 
have arisen mainly due to differential deletion or loss of function. Thus, unlike cattle 
and pigs, humans and mice have lost granzyme O and, in contrast to the other species 
mice have lost granzyme H. In place of the latter, mice have an additional set of 
genes encoding granzyme C, D, E, F, G and N, which although no remnants are 
found in other species may also have been lost in a common ancestor of these species 
by a gene deletion event.  
 
The gene content and organisation of the trypsin-like and metase loci were similar to 
those in humans and mice, although a cluster of elastase genes and their flanking 
genes in the human and mouse metase locus were not ide tified in cattle. The latter 
may be due to incomplete or incorrect genome assembly. However, the findings 
indicate conservation of these loci following species divergence. In contrast, the 
chymotrypsin-like locus has expanded in gene content due to duplication of non-
granzyme genes (a-chymase and cathepsin G) and the pres nce of an additional set of 
closely related genes (duodenases), not detected either in the chymotrypsin locus or 
elsewhere in the human or mice genomes. Identification of a duodenase orthologue 
in pig has shown that the duodenase is not exclusively expressed in ruminant, 
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suggesting either that these may have been lost in human and mice or that they 
evolved later through gene duplication. These findings together with the expanded 
chymotrypsin-like locus of mice including the presenc  of Mcpt8 family and 
multiple β-chymases and granzymes in mouse (Gallwitz and Hellman, 2006), 
illustrate a massive change undertaken in this locus after human, mouse, cattle and 
pig divergence.  
 
Table 3.9 Summary of granzyme genes found in differnt mammalian species 
and their genomic locations 
 
Data on human and mouse granzymes was extracted from (Trapani, 2001). Pig 
granzyme M has not been detected but assembly of the region on chromosome 2 
predicted to contain the gene is incomplete.  
 
 
Analysis of primary amino acid sequences of bovine granzymes in relation to known 
crystal structures of human or murine orthologues by homology molecular models 
allows us to investigate the corresponding substrate specificity of granzymes within 
each group. These initial analyses of amino acid sequences of cattle granzymes 
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indicate that they have primary specificities comparable with their human and mouse 
counterparts, but their extended substrate specificities appear to show some 
differences.  
 
To date, crystal structures of human granzyme A, B, Pro-K and M have been 
reported by several groups but structures for K and H have not been described so far 
(Estebanez-Perpina et al., 2000; Hink-Schauer et al., 2002; Bell et al., 2003; Hink-
Schauer et al., 2003; Wu et al., 2009). The crystal structures, coupled with results of 
biological experiments and structural modelling, provide information on residues that 
are critical for interacting with the substrates. For example, a crystallography study 
of granzyme A by Bell (2003) has shown that the specificity for a basic residue of 
the S1 pocket is primarily due to the side chain of Asp189 at the bottom of the pocket 
(Bell et al., 2003), whereas the primary specificity of granzyme B for Asp occurs 
through a salt bridge with Arg226, anchored at the back of the S1-specificity pocket 
of granzyme B (Estebanez-Perpina et al., 2000; Waugh et al., 2000). Crystal structure 
comparison of the active form of granzyme M with the inactive Asp86Asn-GzmM 
mutant has revealed that a peptide loop (L3 - residues 214-226) is most important in 
determining substrate specificity M (Wu et al., 2009). Mahrus and Craik (2005) 
provided experimental evidence to support the respective substrate specificities of 
human granzyme A, B, K, H and M, using positional scanning of synthetic 
combinatorial libraries of 4-amino acid peptides (Mahrus and Craik, 2005). The 
results of these studies suggest that homology molecular modelling is a reliable and 
productive method for identifying differences in fie substrate specificity of related 
granzymes and novel orthologues of the same granzyme. Comparison of the 
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substrate-determining amino acid residues in bovine granzymes with those in 
orthologues in other species, predict that cattle granzymes have primary substrate 
specificities identical to their human and mouse counterparts. The findings indicate 
that the novel granzyme O is most likely to have trypsin-like activity, consistent with 
the specificity of the other granzymes (A and K) in the same gene locus. The trypsin-
like specificity of granzyme A, O and K is also consistent with the idea that these 
genes arose by duplication before primate/rodent/cattle/pig species divergence. 
Although phylogenetic analysis shows that granzyme B and C are most closely 
related in mouse, as are granzymes B and H in human, cattle and pig, experiments 
have demonstrated that the mechanism of cell death induced by granzyme C is quite 
different from the classical apoptosis induced by granzyme B (Johnson et al., 2003). 
Although the enzymatic function of granzyme C is still unknown, these findings 
indicate that the substrate specificity of granzyme C is distinct from that of granzyme 
B.  
 
Although both human granzyme A and K have the trypsin-like specificity 
characterised by cleavage after basic residues Arg or Lys (Mahrus and Craik, 2005), 
they display highly restricted substrate specificites that only partially overlap 
(Bovenschen et al., 2009). This was demonstrated by screening a library comprising 
1,000 fully randomized 15-amino acid peptides; no clear consensus sequence was 
found near the cleavage site, although both granzymes were shown to prefer P1Arg 
(Bovenschen et al., 2009). Cattle and pig granzyme A, O and K are predicted to have 
the identical primary substrate specificity (trypsin-like activity). However, 
comparison of extended specificity-determining residues at S2 and S3 of granzyme A, 
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O and K in both cattle and pig (shown in table 3.8) revealed different amino acids 
both between granzymes and between species orthologues, indicating differences 
between species in the extended substrate specificities of these granzymes. Although 
human and mouse granzyme B exhibit high sequence similarity, including conserved 
primary substrate-determining residues, and both are aspases, they exhibit divergent 
substrate preferences. This is a consequence of differences in the residues that 
determine extended substrate specificity. Using a ph ge display substrate assay, 
human and mouse granzyme B were shown to have distinct ubstrate preferences at 
the key P4, P2 and P2’ substrate residues because of the presence of divergent 
residues at the corresponding granzyme binding sites (Kaiserman et al., 2006). The 
detection of divergent amino acids in the S2 and S3 extended specificity-determining 
residues in cattle and pig granzyme B suggests that they may also have different 
substrate preferences than those of the human and mouse orthologues.  
 
The bovine chymotrypsin-like locus contains a number g nes closely related to 
granzymes, including genes encoding duodenases, which located adjacent to 
granzyme B and one of which (DDN1) was previously erroneously reported as 
granzyme B. However, comparison of their amino acid sequences revealed different 
primary specificity-determining residues in the S1 pocket predicted to result in 
enzymatic functions distinct from granzyme B. Compared to the aspase activity of 
granzyme B, comparison with other chymotrypsin-like proteins indicates duodenase 
genes are likely to have dual specificity with trypsin-like as well as chymotrypsin-
like activity. DDN1 was originally isolated from duodenal mucosa (Antonov et al., 
1992; Zamolodchikova et al., 1995a). It is found in epithelial cells and the ducts of 
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Brunner’s gland and is a potential activator of enteropeptidase, as indicated by its 
ability to hydrolyse recombinant bovine pro-enteropeptidase, which is an important 
enzyme in the digestive protease cascade (Zamolodchikova et al., 1997).  
 
In conclusion, work described in this chapter has identified the complement of 
functional granzyme genes in cattle, developed PCR assays to examine their 
expression and demonstrated that they are all expressed in activated antigen-specific 
CD8+ T cells. Comparisons of their amino acid sequences with orthologues in other 
species have identified differences in residues that determine extended substrate 
specificities, suggesting that they differ in their protein substrate specificities. These 
findings provide the basis for further work to examine their role in killing of target 





















Chapter 4   Expression and characterization of bovi ne 
granzyme B 
 
4.1 Introduction  
 
Cell-mediated killing by cytotoxic T-lymphocytes (CTL) is an important immune 
response against viral infection, intra-cellular bacteria and neoplastic cells. One 
important mechanism used by CTL is induction of apoptosis of target cells by 
granule exocytosis, involving release of several toxic granzymes and a membrane 
disrupting protein perforin. Granzyme B is the best-characterized and most potent 
member of the granzyme family and is considered to be the major initiator of 
granule-mediated apoptosis. This protease induces target cell apoptosis by several 
pathways, including mitochondrial-mediated mechanisms, via direct cleavage of 
‘BH3-only’ members of the Bcl-2 family, by enzymes such as BH3-interaction 
domain death agonist (Bid), which result in mitochondrial permeabilization (Heibein 
et al., 2000; Alimonti et al., 2001; Pinkoski et al., 2001; Sutton et al., 2003), 
activation of caspases (Darmon et al., 1995; Martin e  al., 1996; Quan et al., 1996) 
and direct cleavage of downstream substrates (Andrade et al., 1998; Casciola-Rosen 
et al., 1999; Browne et al., 2000; Thomas et al., 2000; Sharif-Askari et al., 2001; 
Adrain et al., 2006). As granzyme B is highly active, expression of this molecule is 
regulated to avoid enzymatic activity during the post-translational modification 
process. Typically, granzyme B is translated as an in ctive zymogen containing a 
leader peptide of 18 amino acids, followed by a conserved dipeptide/GE. Activation 
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of the zymogen requires cleavage of the dipeptide/GE by dipeptidyl peptidase 
I/cathepsin C within the granules (McGuire et al., 1993).  
 
Granzyme B is a 32-kDa serine protease with a structu e closely resembling that of 
chymotrypsin and characterized as an Aspase because of it  preference for substrate 
cleavage after aspartic acid residues (Poe et al., 1991). Granzyme B is the only 
known serine protease with this specificity in mammals (Atkinson and Bleackley, 
1995), although cleavage after aspartic acid residu also occurs in cysteine proteases 
of the ICE family (caspases) (Duan et al., 1996), which are inactive zymogens under 
normal cellular conditions but can be activated during apoptosis. The preferred 
substrate sequence at the P4-P3-P2-P1 (amino-terminal to the proteolytic cleavage 
site) for human granzyme B cleavage is I-E-P-D defined by a combinatorial 
chemistry approach (Thornberry et al., 1997), but optimal substrate recognition also 
involves features extending carboxyl terminal to the proteolytic cleavage, P1’-P2’-
P3’-P4’(Waugh et al., 2000; Rotonda et al., 2001; Sun et al., 2001).  
 
Although native granzyme B from NK cell granules has been purified to 
homogeneity and characterized as an Aspase based on it activity on synthetic 
substrates, the purification procedure, involving biochemical and immunological 
methods, is time-consuming and has yielded limited amounts of active granzyme B 
(Odake et al., 1991; Poe et al., 1991; Trapani et al., 1993). As other members of the 
chymotrypsin-like subfamily (granzyme H and other hmatopoietic serine proteases 
such as mast cell chymase and neutrophil cathepsin G) are of similar size and exhibit 
similarity in amino acid sequence (50-70%), they may contaminate preparations of 
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native granzyme B. However, studies by Caputo et al in 1993 and Smyth et al in 
1995 have enabled a system to produce this enzymatically active granzyme B by 
preparation of recombinant DNA constructs that can be expressed in mammalian 
COS-7 cells (Caputo et al., 1993; Smyth et al., 1995). In this eukaryotic expression 
system, deletion of nucleotide sequences encoding an amino-terminal dipeptide is 
required because of the absence of cathepsin C in COS-7 cells (Caputo et al., 1993; 
Smyth et al., 1995). 
                                                                                                                                                                                                                
This chapter describes the preparation of recombinant cDNA constructs of cattle 
granzyme B for production of functionally active protein, and testing of the 
enzymatic activity and substrate specificity of theprotein. The reactivity of six anti- 














4.2 Materials and Methods 
 
4.2.1 Preparation of cDNA  
Total RNA was extracted from an un-cloned T.parva-specific CD8+ T cell line from 
the cow 011 and cDNA was synthesized from RNA using the Reverse Transcription 
system as described in section 2.3.1- 2.3.3.  
 
4.2.2 Site-directed mutagenesis strategies  
4.2.2.1 Wild-type cattle granzyme B cDNA 
Wild-type cattle granzyme B cDNA was amplified by High fidelity PCR, using 
primers flanking the full-length cattle granzyme B coding sequence as follows:  
5’- CATCCTGGGCAGTCTTTCTA-3’ (Forward);  
5’- CCTGCAGTGTGATTCTGGAT-3’ (Reverse).  
The High fidelity PCR protocol was composed of 10pmol of primers, 1.2 unit Pfu 
DNA polymerase (3units/ul, Promega), 5ul of 10x Buffer with MgSO4 (200nM Tris-
HCl, 100mM KCl, 100mM (NH4)2SO4, 20mM MgSO4, 1mg/ml nuclease-free BSA 
and 1% Triton X-100, Promega), 10mM dNTP, 0.5ug of cDNA template and 
nuclease-free water to give a final volume of 50ul. The programme used was as 
follows: 95°C for 2 min, 30 cycles of 95°C for 1min followed by 55°C for 0.5 min 
and 72°C for 2.5 min, and a final extension period of 72°C for 5 min. The PCR 
product was analysed by electrophoresis as described in section 2.3.5. 
 
 111 
4.2.2.2 Cloning of the purified cDNA 
Blunt-ended PCR products of the predicted size were purified (section 2.3.6) and 
then a single adenosine was added to the 3’-ends of a d uble stranded DNA molecule 
(Zhou and Gomez-Sanchez, 2000). The TA cloning reaction was composed of 
0.5unit BIOTAQ (5 units/ul Bioline, London, UK), 1ul SM-0005 buffer (Appendix 
C.5), 4ul of purified DNA (30ng/ul), and nuclease-fr e water to give a final volume 
of 10ul. The reaction was incubated at 72°C for 30 min and then transferred to ice.  
 
The A-tailed granzyme B cDNAs were subcloned into a linearized T-vector which 
has single 3’-T overhangs on both ends (section 2.3.7). The plasmid DNA was 
extracted from selected colonies and purified using the Wizard Mini-preps DNA 
Purification System (section 2.3.8). To identify the presence of inserts, the plasmid 
DNA was digested with EcoR1 (section 2.3.9). Plasmid products purified from 
clones containing inserts were submitted to DBS Genomic (Durham University) for 
nucleotide sequencing (2.3.10). 
 
4.2.2.3 Dipeptide/GE knockout of cattle granzyme B cDNA 
The deletion of six nucleotides encoding the dipeptid  of cattle granzyme B cDNA 
was performed by PCR splice overlap extension (PCR-SOE) based on procedures 
described for human granzyme B (Smyth et al., 1995), as discussed by Ling and 
Robinson in an overview of DNA mutagenesis (Ling and Robinson, 1997). 
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Figure 4.1 Schematic illustration of the “overlap extension PCR” for 
introducing a deletion into granzyme B cDNA. 
Two PCR assays were initially performed to generate two overlapping 
fragments that carry the 6 nucleotide deletion in the overlapping segment. 
These two fragments were mixed, denatured and anneal d to produce mutant 
DNA templates and amplification of the extended mutant DNAs was performed 
with flanking primers in a further PCR.  
 
Principle: 
The scheme for generating the dipeptide-deleted mutant is summarised in figure 4.1. 
Firstly, two PCRs were performed to generate two DNA fragments with overlapping 
sequence containing the target site for mutagenesis. Forward and reverse mutagenic 
internal primers extending across the site and from which the 6 nucleotides had been 
omitted, were used. The sequences of these internal p imers for cattle granzyme B 
were as follow: 5’- CAAAGGCAATCATCGGGGGCCATG-3’ (Forward); 5’- 
CCCGATGATTGCCTTTGCCCTGGG-3’ (Reverse). External primers flanking the 
full-length coding region of cattle granzyme B were as follow: 5’- 
CATCCTGGGCAGTCTTTCTA - 3’ (Forward); 5’- 
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CCTGCAGTGTGATTCTGGAT - 3’ (Reverse). The PCR reaction was composed of 
10 pmol of primers, 1.2 unit Pfu DNA Polymerase (3units/ul, Promega), 5ul of 10x 
Buffer with MgSO4, 10mM dNTP, 0.5ug of cDNA template and nuclease-free water 
to give a final volume of 50ul. The programme used was as follows: 95°C for 2 min, 
30 cycles (95°C for 1min, 45°C for 0.5 min, 72°C for 2.5 min) and a final extension 
period of 72°C for 5 min. The PCR products were analysed by electrophoresis as 
described in section 2.3.5. 
 
Secondly, PCR products of the two overlapping DNA fragments were purified, 
mixed, denatured and annealed in a PCR-ready buffer to produce mutant DNA 
templates. Amplification of the extended mutant DNAs was achieved by using the 
pair of external primers in a further PCR. The PCR reaction was composed of 10 
pmol of primers, 1.2unit Pfu DNA Polymerase (3units/ul, Promega), 5ul of 10x 
Buffer with MgSO4, 10mM dNTP, 5ng of each purified DNA fragments and 
nuclease-free water, to give a final volume of 50ul. The programme used was as 
follows: 95°C for 2 min, 30 cycles (95°C for 1min, 45°C for 0.5 min, 72°C for 2.5 
min) and a final extension period of 72°C for 5 min. The PCR product was analysed 
by electrophoresis as described in section 2.3.5. PCR products of the predicted size 
were purified, TA cloned and sub-cloned into the T-vector as described above in 
section 4.2.2.2.  
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4.2.2.4 Introduction of a Ser195Ala substitution at  the active site in the 
Dipeptide/GE knockout granzyme B cDNA  
Substitution of Ser with Ala at the active site of dipeptide-knockout cDNA was 
performed by ‘megaprimer’ PCR mutagenesis (Picard et al., 1994; Tyagi et al., 2004), 
as summarised in figure 4.2.  
 
 
Figure 4.2 Schematic representation of the “megaprimer PCR” for introducing 
a mutation into granzyme B DNA. 
An initial 5 cycles of a PCR reaction containing a standard concentration of 
mutagenic internal primer and a limiting concentration of a flanking primer 
was followed by a prolonged extension step to generate mutant mega fragments. 
The other flanking primer was added to the mutant templates and the PCR 
reaction subjected to a further 25 cycles to generate full-length product 
containing the mutation.  
 
Principle: 
This procedure is based on first introducing the desired mutation into a terminal 
fragment of the cDNA (in this case the 5’ end) in an initial PCR reaction and then 
using this fragment as a megaprimer in a second PCRreaction to obtain the mutated 
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full-length cDNA. The first round of this ‘Megaprimer’ PCR protocol uses a limiting 
concentration of the standard unmodified reverse primer in combination with a 
standard concentration of an internal mutagenic forward primer incorporating 
substitutions to achieve the amino acid change. The PCR protocol incorporates a 
prolonged additional extension period.  
Two different internal mutagenic forward primers incorporating the mutation were 
designed and tested in the first step due to the GC rich nature of the primer binding 
site; their sequences were:  
Primer1, 5’-AGAAAGCTTCCTTTCAGGGGGACGCGG-3’; or Primer2, 5’- 
ACGCGGGGGGCCCTCTCGTGTGTGACAAT-3’; these were used with e 
reverse primer 5’- CCTGCAGTGTGATTCTGGAT-3’; The PCR reaction was 
composed of 50pmol of internal mutagenic forward prime , 2.5pmol of external 
reverse primer, 1.2 unit Pfu DNA Polymerase (3units/ul, Promega), 5ul of 10x 
Buffer with MgSO4, 10mM dNTP, 1ul of dipeptide-knockout cattle granzyme B 
cDNA containing plasmid (60ng/ul) and nuclease-free water to give a final volume 
of 50ul. The first round PCR programme used was as follows: 95°C for 2 min, 5 
cycles (95°C for 1min, 55°C for 0.5 min, 72°C for 2.5 min) and an additional 
extension period of 72°C for 35 min.  
 
In the second round of PCR, 50pmol of the external forward primer, 5’- 
CATCCTGGGCAGTCTTTCTA - 3’ was added into the same tube and the 
programme was resumed under the following conditions: 95°C for 2 min, 25 cycles 
(95°C for 1min, 55°C for 0.5 min, 72°C for 2.5 min) and a final extension period of 
72°C for 10 min. The PCR product was analysed by electrophoresis as described in 
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section 2.3.5. PCR products of the predicted size were purified, TA cloned and sub-
cloned into the T-vector as described above in section 4.2.2.2.  
 
4.2.3 Mammalian expression vector construction 
4.2.3.1 PCR amplifications of Granzyme B cDNAs lack ing a stop codon 
(TGA) 
Forward and reverse PCR primers were designed to inc rporate unique SalI and 
BamH1 sites on the ends of the functional granzyme B cDNA and the corresponding 
controls and to eliminate the 3’ stop codon, in order to express the protein with a c-
terminal peptide tag. The forward primer containing six nucleotides encoding the 
SalI restriction site and the reverse primer containing six nucleotides encoding a 
BamH1 site with a stop codon (TGA) deletion were as follows:  
5’- CCAGGTCGACCATCCTGGGCAGTCTTTCTA-3’ (SalI, Forward); 5’- 
CCTGGGATCCGAGGCTTTTCATGGTTTTCTTTATCCAGGGC-3’ (BamH1, 
Reverse). These primers were used in a high fidelity PCR protocol composed of 
10pmol of primers, 1.2 unit Pfu DNA Polymerase (3units/ul, Promega), 5ul of 10x 
Buffer with MgSO4, 10mM dNTP, 1ng of plasmid templates and nuclease-fre  water 
to give a final volume of 50ul. The programme used was as follows: 95°C for 2 min, 
30 cycles (95°C for 1min, 55°C for 0.5 min, 72°C for 2.5 min) and a final extension 
period of 72°C for 5 min. The PCR product was analysed by electrophoresis as 
described in section 2.3.5.  
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4.2.3.2 Incorporation of granzyme B cDNAs into the pFLAG-CMV tm-5a 
expression vector 
PCR products of the predicted size were purified andouble digested by using 
restriction endonuclease reactions (BioLabs Inc, New England) to generate the SalI 
and BamH1 sticky-end cDNAs. The reaction was composed of 1ug DNA, 5ul of 10x 
NEBuffer 3, 0.5ul of 100x BSA, 2ul SalI (20,000 units/ml), 2ul BamH1 (20,000 
units/ml) and nuclease-free water to give a final volume of 50ul. The reaction was 
incubated at 37°C for 3h and stored at -20°C. The pFLAG-CMVtm-5a expression 
vector (Sigma, Cat.E7523) was double digested with SalI and BamH1 and the 
restriction endonuclease reaction was performed at 37°C for 3h.  
 
Double digested cDNAs and pFLAG-CMVtm-5a expression vector of the expected 
size were gel purified and ligated together by using T4 DNA ligase. The reactions 
were composed of 50ng modified pFLAG-CMVtm-5a expression vector, 26ng sticky-
end granzyme B cDNA, 1ul T4 DNA ligase (3 weiss units/ul), 5ul 2x Rapid ligation 
Buffer and DDW to give a final volume of 10ul. The reaction was performed at 4°C 
overnight. The products were then transferred into JM109 High Efficiency 
Competent Cells and the cells were plated onto duplicate LB/ampicillin plates. The 
plates were incubated overnight at 37°C.  
 
Colonies containing appropriate inserts were identifi d by PCR amplification with 
primers specific for flanking vector sites. Selected colonies were picked and streaked 
onto new LB agar plates with 100ug/ml ampicillin. The plates were incubated for 4h 
or overnight at 37°C. The expanded colonies were havested, added into 96-well V 
 118 
bottom plates with 50ul of nuclease-free water and denatured by heating at 95°C for 
5 min. The cellular debris were sedimented by centrifugation at 13,000 x g for 5 min 
and the aqueous phase containing plasmid DNAs was used as template in further 
PCR amplification. The primers flanking the multiple cloning region of the pFLAG-
CMVtm-5a expression vector were as follows: 
5’-AATGTCGTAATAACCCCGCCCCGTTGACGC- 3’ (N-CMV-30, Forward);  
5’-TATTAGGACAAGGCTGGTGGGCAC-3’(C-CMV-24, Reverse); 
Annealing of the primers was performed at 55°C. Thereaction and programme were 
performed as described in section 2.3.4 and PCR products were analysed by 
electrophoresis as described in section 2.3.5.  
 
The colonies containing inserts were selected from the streaked plates and each 
transferred into a 30 ml flask with 6ml LB and 100ug/ml ampicillin. The clones were 
expanded overnight (section 2.3.7) and the plasmid DNA was purified (section 2.3.8) 
and sent to DBS Genomic (Durham University) for sequencing (section 2.3.10) 
 
4.2.3.3 Plasmid DNA Preparation-(Maxi-preps) 
The EndoFree Plasmid Maxi Kit (QIAGEN, Cat.12362) was used to prepare the 
purified Maxi-preps. Colonies containing inserts of the correct sequence and 
orientation were picked from the streaked plate, added into a starter culture of 5ml 
LB with 100 ug/ml ampicillin and incubated for 8h at 37°C with vigorous shaking at 
300rpm. The starter cultures were then added into 150ml fresh LB with 100 ug/ml 
ampicillin and incubated overnight for 37°C with vigorous shaking at 300 rpm. The 
bacterial cells were pelleted by centrifugation at 6000 x g for 15 min at 4°C, 
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suspended in 10ml buffer P1 with 100ug/ml RNase A, lysed by the addition of 10ml 
Buffer P2 at room temperature for 5 min and precipitated  by the addition of 10ml 
chilled Buffer P3. The lysates were immediately poured into the barrel of a QIAfilter 
Cartridge at room temperature for 10min, filtered into a 50ml tube by gently 
inserting the plunger into the QIAfilter Maxi Cartridge and then mixed with 2.4ml 
Buffer ER for 30min on ice. Following equilibration with 10ml Buffer QBT and 
addition of filtered lysates by gravity flow, a QIAGEN-tip 500 was washed twice in 
30ml Buffer QC. DNA was eluted in 15ml Buffer QN and precipitated in 10.5ml 
isopropanol at room-temperature by centrifugation at 15,000 x g for 30min at 4°C. 
The DNA pellet was washed with 5ml of endotoxin-free 70% ethanol at room 
temperature, centrifuged at 15,000 x g for 10min and ir-dried for 20min, re-
dissolved in 500ul of endotoxin-free Buffer TE and stored at -20°C until use. 
 
4.2.4 Cell culture and transfection  
4.2.4.1 Growth of COS cells and 293T cells  
COS cells and  293T cells were maintained in the culture medium containing DMEM 
(Invitrogen) supplemented with 10% FCS, 5x10-5M 2-Mercaptoethanol, 4mM 
glutamine, 100U/ml penicillin and 100ug/ml streptomycin, passaged every 3-4 days 
by diluting 1:5 in the culture medium and cultured at 37°C under 5% CO2.  
 
To remove COS cells or 293T cells adherent to the bottom of 75cm2 flasks, the cells 
were gently washed with 10ml 1x PBS/EDTA (Appendix C.11) and the washing 
medium was discarded. Following addition of 9ml 1x PBS/EDTA and 1ml of 0.25% 
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Trypsin-EDTA (Invitrogen) at 37°C for 5 min, the COS cells or 293T cells in 
suspension were harvested into 15ml Falcon tubes, centrifuged at 1200 x g for 5min 
and suspended in 5ml culture medium. One ml of cell suspension was added to 15ml 
fresh culture medium in a 75mm flask and maintained at 37°C under 5% CO2. 
 
4.2.4.2 Transient transfection in COS cells  
COS cells (3x106-4x106) in 20ml culture medium without antibiotics were seded in 
a 75cm2 flask one day before transfection. The transient transfection was performed 
by using the Lipofectaminetm 2000 reagent (Invitrogen, Cat.11668-027) according to 
the manufacturer’s protocol. The pFLAG-CMVtm-5a vector only(60ug) and vectors 
containing three cattle granzyme B recombinant cDNAs containing the wild type 
(60ug), the dipeptide knockout (60ug) and the knockout with an additional 
Ser195Ala substitution (40ug) were firstly diluted in 2ml Opti-MEN I Reduced 
Serum Medium without serum (Invitrogen) and mixed gently. Then 80ul 
Lipofectaminetm 2000 was diluted in 2ml Opti-MEN I Reduced Serum Medium 
without serum, mixed gently and incubated for 5min at room temperature. The 
diluted DNA and Lipofectaminetm 2000 were combined together and incubated for 
20min at room temperature to form the DNA- Lipofectaminetm 2000 complexes. 4ml 
of complexes were then added to a 75cm2 flask containing cells at 90-95% 
confluency and the complexes removed by replacing the culture medium without 
antibiotics 4-6h after transfection. Cells were cultured at 37°C under 5% CO2 for 48h 
to allow expression of the transgene. Transfected cells were harvested after 48h, 




4.2.4.3 Detection of transfection efficiency   
Cytospin smears of cells were examined to test for expression of transfected DNA 
products. Aliquots of 150-200ul of PBS-washed cells (8x104) in PBS were added 
into a cytospin cuvette with cleaned glass slides, spun for 5 min at 800rpm in a 
Shandon Cytospin 3 Centrifuge (Block Scientific, Inc) and the resultant smears air-
dried for 5-10 min. Cells were then fixed with acetone for 5-10 min, air-dried for 5-
10 min and the location of the cytocentrifuged cells marked by a Liquid Blocker 
Super Pap Pen.  Following addition of 50ul anti-FLAG M2 antibody (1:500 dilution; 
IgG1; Sigma) cells were incubated for 20 min at room temperature in a moist 
atmosphere and washed three times with PBS. 50ul FITC-conjugated anti-mouse 
polyvalent immunoglobulins (G,A,M) antibody diluted 1:100 (Sigma) was added and 
cells were incubated for 20 min at room temperature in a moist atmosphere and then 
washed three times with PBS. Following removal of excess PBS, slides were 
mounted with the DakoCytomation Fluorescent Mounting Medium 
(DakoCytomation). Duplicate slides were examined on a Leitz Laborlux S 
microscope (Leica Mikroskopie und Systeme GmbH, Germany) and images recorded 
using a DXC-390P 3CCD Color Video camera (Sony Corporation, Japan) and 
analysed using the Scion Image 1.62c software (Wayne Rasband, National Institutes 
of Healthe, USA).  
 
4.2.5 Production of cell lysates 
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The cell lysis protocol was performed as described y Piuko et al. (2007) for equine 
granzyme B. Aliquots of 1ml of PBS-washed cells adjusted to 2x106cells/ml in PBS 
were centrifuged at 180 x g for 10 min and the pellet was lysed by using 0.2ml lysis 
buffer (1%Triton X-100, 50mM Tris, pH8.0 and 2ul of Benzonase Nuclease 25U/ml, 
Purity>99%, Merck). Following incubation on ice for 20min, lysed cells were 
centrifuged for 10min at 0°C at 21,000 x g to pellet c ll nuclei and other cell debris. 
Supernatants were harvested and either stored at -70°C or immediately subjected to 
activity assay. 
 
4.2.6 Assay of protease activity 
The protease activity protocol was performed as described by Piuko et al. (2007) for 
equine granzyme B. In duplicate, aliquots of 25ul of ysis supernatant, granzyme B 
substrate VIII, Ac-IEPD-pNA, (Calbiochem, Cat.368067) in a final concentration of 
300uM and the reaction buffer (0.1M Hepes, pH 7.0; 0 3M NaCl; 1mM EDTA) in a 
total volume of 250ul/well were added into the wells of Falcon™ 96-Well Flat 
bottomed Microplates (BD, Cat. 353072). The chymotrypsin substrate I, Suc-GGF-
pNA (Calbiochem, Cat.230912), was used as a negative control for the substrate 
specificity. The reaction was composed of 25ul of lysis supernatant, 1mM Suc-GGF-
pNA in the final concentration and the reaction buffer (50mM Tris, 100mM NaCl, 
pH8.0) in a total volume of 125ul. Mixtures were incubated at 37°C for 4h and the 
colour reaction generated by cleavage of the pNA substrate measured at a 




4.2.7 Inhibition of protease activity in lysates 
The specific granzyme B inhibitor IV, Ac-IEPD-CHO (Calbiochem, Cat.368056) 
was tested for its ability to inhibit cattle granzyme B activity as described by Piuko et 
al. (2007) for equine granzyme B. In duplicate, aliquots of 25ul of lysis supernatant 
containing released bovine granzyme B were pre-incubated with 10uM Ac-IEPD-
CHO at 37°C for 0.5h. Following the addition of 300uM granzyme B substrate VIII, 
Ac-IEPD-pNA and the reaction buffer (0.1M Hepes, pH7.0; 0.3M NaCl; 1mM 
EDTA), mixtures in a total volume of 250ul were incubated at 37°C for 4h and the 
colour reaction generated by cleavage of the pNA substrate measured at a 
wavelength of 405nm by using a Synergy™ HT Multi-Mode Microplate Reader 
(BioTek). 
 
4.2.8 Cross-reactivity of antibodies specific for e quine granzyme 
B 
An expression construct containing human granzyme B cDNA, pcDNA3.1-hsGzmB, 
and six anti-eqGzmB monoclonal antibodies produced in mice were kindly provided 
by Dr. Martin Muller (Deutsches Krebsforschungszentrum, Heidelberg, Germany). 
First, 293T cells were transiently transfected with either cDNA3.1-hsGzmB (80ug) 
or Bt-pFLAG-SOE (60ug) using the Lipofectaminetm 2000 reagent as described in 
section 4.2.4.2 and following incubation for 48 hours, cytospin staining was 
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performed to determine the transfection efficiency and to test reactivity of the 
monoclonal antibodies as described above in section 4.2.4.3.  
Following incubation of smears with the monoclonal antibodies (mAbs) (Table 4.1) 
they were washed and incubated FITC-conjugated anti-mouse polyvalent 
immunoglobulins (G, A, M) antibody diluted 1:100 (Sigma).  
 
Table 4.1 Monoclonal antibodies used for staining cytospin preparations of 










SZ EqGzmB 1:10 NDa 
8-5B EqGzmB 1:10 0.57ug/ul 
8D8 EqGzmB 1:10 0.56ug/ul 
7-7D EqGzmB 1:10 1.0ug/ul 
108 EqGzmB 1:10 0.63ug/ul 
Anti-pFLAG M2 pFLAG tag epitope 1:500 1mg/ml 










4.3 Results  
 
4.3.1 Site-directed PCR mutagenesis  
To obtain the functional recombinant granzyme B, deletion of an amino-terminal 
dipeptide is required (Caputo et al., 1993; Smyth et al., 1995). The splice overlap 
extension (SOE) PCR mutagenesis was developed to delete 6 nucleotides encoding 
the GE dipeptide to allow expression of the activated cattle granzyme B. Control 
constructs without the dipeptide deletion and with the deletion and an additional 
Ser195 to Ala substitution in the active site, generated by ‘megaprimer’ PCR 
mutagenesis, were also produced (Table 4.2). cDNAs prepared from a culture of T. 
parva-specific CD8+ T cells established from an animal th t had been immunised by 
infection and treatment with T. parva, was used as the template.  
 
Table 4.2 Bovine granzyme B cDNA constructs and predicted functional 
activities 
cDNA type  Structure Predicted Function 
Wild-type  (WT) Not activated No 
Dipeptide/GE-deleted         activated  Yes 
Dipeptide/GE-deleted  with additional 
Ser195Ala substitution  





Wild-type granzyme B 
The use of High fidelity PCR with flanking primers successfully generated a PCR 
product of the expected size (818bp) for the coding region of the wild-type granzyme 
B gene (Figure 4.3- A). To confirm the identity of the PCR product, it was sub-
cloned into the pGEM-T vector and 3 clones containing inserts of the correct size, 
WT-1, 2 and 5, were selected for sequencing (Figure 4.3- B). Analysis of sequences 
obtained from WT-1 and 2 confirmed that they are idntical to those originally 





Figure 4.3 PCR amplification of wild-type bovine granzyme B cDNA. 
(A). High fidelity PCR performed using proof reading taq (Pfu) with cDNA 
template of an uncloned T. parva-specific CD8+ T cell line (011) 7 day after 3rd 
stimulation (purity, 99%) , yielded a product of the expected size (818bp) at an 
annealing temperature of 55°C. (B). Analysis of clones of the PCR product (1-5) 
revealing products of the expected size in 3 of the clones (1, 2 and 5). 
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Dipeptide/GE-deleted granzyme B  
To complete the splice overlap extension (SOE) PCR mutagenesis, three individual 
high fidelity PCR assays were required. Two partially overlapping PCR fragments 
carrying the 6 nucleotide deletion in the overlapping segment were successfully 
produced using complementary internal primers each containing one end of flanking 
primer and the other end of internal mutagenic prime  (Figure 4.4- A and B). 
Generation of the full-length mutated sequence requi d two further steps. First, the 
selected overlapping fragments were mixed, denatured and annealed to produce 
mutant DNA templates. In the second step, amplificat on of the extended mutant 
DNAs with flanking primers successfully generated a PCR product of the expected 
size (812bp) (Figure 4.4- C). To confirm the authenicity of the PCR products, 
purified PCR product was sub-cloned and 3 clones containing inserts of the correct 
size, SOE-2, 4 and 5, were selected for sequencing (Figure 4.4- D). Analysis of 
sequences obtained from SOE-4 and 5 confirmed that the 6 nucleotides encoding the 
dipeptide/GE were deleted and that the remainder of the sequence was identical to 








Figure 4.4 Amplification of dipeptide/GE deleted mutant of granzyme B cDNA 
by splice overlap extension PCR. 
 
Results are presented for high fidelity PCR assays performed at a range of 
annealing temperatures (45-65°C) by using: (A). A forward flanking primer and 
the reverse internal mutagenic primer, giving a fragment of the expected size 
(89bp); (B). A forward internal mutagenic primer and the reverse flanking 
primer, giving a fragment of the expected size (741bp); (C). Use of flanking 
primers to amplify full length mutated cDNA, using a mixture of the products 
from (A) and (B) as template (expected size 812bp); (D). Analysis of subclones of 
the product obtained in step (C), revealing three clones containing inserts of the 
correct size (arrows).  
 
 
Granzyme B with dipeptide/GE deletion and additional Ser195 to Ala substitution 
Production of the dipeptide/GE knockout cDNA plasmid allowed further 
manipulation to generate a substitution of Serine with Alanine at the active site. 
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Using the SOE-4 clone as template, ‘Megaprimer’ PCR assays were performed by 2-
round high fidelity PCR reactions in the single PCR tube. Because of the high GC 
content of the targeted sequence, two different internal mutagenic primers were 
tested (Primer1 and Primer2). Mega fragments of the expected size (213bp for 
primer1 and 194bp for primer2) were amplified with each of the forward internal 
mutagenic primers when used with a limiting concentration of reverse flanking 
primer during the first 5 cycles and completed by a prolonged additional extension 
time. Use of the mega fragment as the reverse primer and addition of the forward 
flanking primer in a second round PCR, produced a mutated product of the expected 
size (812bp) (Figure 4.5- A, Lane 2 and 4 Top). As only the 5’- 3’ chain of the mega 
fragments can be used as the reverse primer, the complementary mega fragments still 
remained in the mixture (Figure 4.5- A, Lane 2 and 4 Bottom). To confirm the 
identity of the PCR product obtained with both primer1 and primer2, they were sub-
cloned and 8 clones containing inserts of the corret size, SMAPrimer1 -1, 2, 3 and 4 
and SMAPrimer2 -2, 5, 12 and 8, were selected for sequencing (Figure 4.5- B). 
Analysis of sequences obtained from SMAPrimer1-2 and SMAPrimer2-12 confirmed the 
success of the Ser195 to Ala substitution and in each case the remainder of the 





Figure 4.5 Amplification of dipeptide/GE deletion granzyme B cDNA containing 
an additional Ser195 to Ala substitution using ‘Megaprimer’ PCR. 
 
(A). Results of first round PCR amplification using two different forward 
internal mutagenic primers (Primer1 and Primer2) and the same reverse 
flanking primer at the limiting concentration are shown in lanes 1 and 3. Mega 
fragment products of the expected size (213 and 194bp, respectively) were not 
detectable. Residual plasmids with DNA inserts (expected size over 3000bp) are 
detectable (arrows). PCR products obtained following addition of the forward 
flanking primer to amplify full-length mutated cDNA  (using the 5’- 3’ chain of 
mega mutants from 1st round PCR reaction as the reverse primer) are shown in 
lanes 2 and 4. A product of the expected size (812bp) together with amplified 
remaining mega fragments (213bp and 194bp, lanes 2 and 4 respectively) were 
obtained (arrows). (B). Analysis of clones of the full-length product revealing 




4.3.2 Construction of recombinant cDNAs  
To construct recombinant cDNAs for expression in mam alian cells, three DNA 
clones representing the wild-type GzmB (WT-1), the dipeptide deletion mutant 
(SOE-4) and the dipeptide mutant with the point mutation in the active site 
(SMAPrimer1-2), were first sub-cloned from the pGEM-T vector using primers 
designed to add SalI BamH1 5’ and 3’ restriction sites and to eliminate their stop 
codon (TGA). High fidelity PCR assays with these primers yielded products of the 
expected sizes (Figure 4.6- A). The resultant DNAs were sub-cloned and 2 clones of 
each containing inserts of the correct size, pFLAG-SOE-1 and 3, pFLAG-SMA-1 
and 3 and pFLAG-WT-1 and 2, were selected for sequencing (Figure 4.6- B). 
Analysis of sequences obtained from pFLAG-SOE-1 and 3, pFLAG-SMA-1 and 3 
and pFLAG-WT-2 confirmed that they were all successfully sub-cloned into the 








Figure 4.6 Production of cDNA clones of each of the 3 granzyme B cDNA 
constructs suitable for expression in the pFLAG expression vector. 
 
(A). High fidelity PCR assays were performed on each of the 3 granzyme B 
cDNA constructs using primers designed to create a SalI restriction site at the 5’ 
end and to create a BamH1 site and remove the stop codon (by deleting 3 
nucleotides) at the 3’ end. Products of the expected sizes - 829bp for SOE-4 and 
SMAprimer1-2 and 835bp for WT-1 – were obtained. (B). Inserts were amplified 
from cloned plasmid DNAs following insertion into the pFLAG vector by 
conventional PCR using a pair of pFLAG-CMVtm-5a vector sequencing 
primers, CMV30 and CMV24. Two clones of each construct containing inserts 
of the correct size (1000bp for SOE-4, SMAprimer1-2 and 1006bp for WT-1) were 




Figure 4.7 Predicted amino acid sequences from nucleotide sequences of three 
recombinant forms of bovine granzyme B cDNA, aligned with the reference 
sequence from the genome database. 
 
Bovine_GZMB-CDs – the full length cDNA from bovine genome 
(corr_ENSBTAG00000010057); Bovine_WT-flag - pFLAG-CMVtm-5a vector 
containing wide type granzyme B; Bovine_SOE-flag - pFLAG-CMVtm-5a 
vector containing functional granzyme B; Bovine_SMA-flag - pFLAG-CMVtm-
5a vector containing functional granzyme B with Ser195 to Ala mutation. Dot-
Identical; Dash-Gap; Leader peptide is highlighted in red; Dipeptide/GE is in 
yellow; Ser195Ala is in black; FLAG epitope-tag sequence of the pFLAG-




4.3.3 Expression in COS cells  
As a large quantity of DNA was needed for the transie t transfection, pFLAG-
CMVtm-5a vector without inserts (mock) and with insert  (pFLAG-WT-2, pFLAG-
SOE-1 and pFLAG-SMA-1) were first prepared in Maxi-preps and the resultant 
DNAs transfected into COS cells. The efficiency of transfection was determined by 
staining cells in cytospin preparations with a monoclonal anti-FLAG M2 antibody 
that detects the FLAG epitope-tag sequence, GSGTDYKDDDK. Figure 4.8 shows 
staining of transfected cells, with negative controls including an isotype-control 
antibody and mock-transfected cells. Transfection effici ncy was very similar, 33-
35%, in all preparations. Clear expression of pFLAG-WT-2, pFLAG-SOE-1 and 










Figure 4.8 Immunofluorescence staining of COS cells transiently transfected 
with different recombinant granzyme B cDNAs in the pFLAG expression 
plasmid. 
 
Cells transfected with unmodified cDNA (pFLAG-WT), cDNA containing the 
GE dipeptide deletion (FLAG-SOE) and cDNA containing both the GE 
dipeptide deletion plus an alanine substitution at position 195 (pFLAG-SMA), 
as well as mock-transfected cells, were stained with he anti-FLAG M2 antibody 
(IgG1, 1:500). In addition cells transfected with FLAG-SOE stained with an 
irrelevant isotype control primary antibody were shown (Isotype control). The 
transfection efficiency of pFLAG-SOE, pFLAG-WT and pFLAG-SMA was 








4.3.4 Functional characterization and inhibition of  cattle 
granzyme B  
To examine the functional activities of the recombinant versions of cattle granzyme 
B, substrate assays were performed using a substrate, AC-IEPD-pNA containing a 
tetrapeptide, which has been shown to be recognized sp cifically by human, rat, 
mouse and equine granzyme B (Caputo et al., 1993; Smyth et al., 1995; Xia et al., 
1998; Piuko et al., 2007). The enzymatic activities of COS cell lysates prepared 48 
hours following transfection with mock, pFLAG-SOE, pFLAG-WT and pFLAG-
SMA are shown in figure 4.9. Transfection with the unmodified cattle granzyme B 
yielded a signal close to the background level produce  by mock transfection. In 
contrast, lysates from cells transfected with the dipeptide/GE knockout granzyme B 
exhibited dramatically increased enzymatic activity, whereas the additional 
substitution of Ser with Ala at the active site resulted in a complete loss of activity. 
As a substrate-specific control, the chymotrypsin substrate Suc-GGF-pNA was used 
in the assay and no signal was detected with any of cattle granzyme B constructs. 
Given this specificity and the similar transfection efficiency (33-35%) achieved with 
the different constructs, it is concluded that the observed high level of enzymatic 
activity generated by cells transfected with the dipeptide deletion mutant is 
attributable to granzyme B. The results also confirm that cattle granzyme B has a 
similar structure-function relationship to the human, mouse, rat and equine 
























Figure 4.9 Enzymatic activity of different recombinant forms of bovine 
granzyme B tested on a granzyme B-specific substrate AC-IEPD-pNA and a 
control substrate Suc-GGF-pNA. 
 
COS cells were transiently transfected with unmodifed granzyme B cDNA 
(pFLAG-Wt), cDNA with the GE dipeptide deleted (pFLAG-SOE) or cDNA 
containing a deletion of the dipeptide and an alanie substitution at position 195 
(pFLAG-SMA) and lysates of the transfected cells collected after 48 hours were 
incubated with the substrates for 4 hours. Controls consisted of lysates of cells 
transfected with pFLAG without an insert (MOCK) and  buffer (No cells) added 
to the substrate. Colour reaction generated after 4 hours by cleavage of the pNA 
substrate were measured at a wavelength of 405nm using a Synergy™ HT 
Multi-Mode Microplate Reader (BioTek) 
 
 
To test whether a granzyme B-specific inhibitor is able to inhibit the enzymatic 
activity of the functional bovine granzyme B, enzymatic activity of the cell lysate 
used above was measured in the presence or absence of AC-IEPD-CHO (Thornberry 
et al., 1997; Harris et al., 1998). The presence of this specific inhibitor dramatically 
reduced the activity of the cattle granzyme B prepaation by about 4 fold, close to the 
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background level (Figure 4.10). The substantial loss f enzymatic function indicates 
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Granzyme B + - +












Figure 4.10 Inhibition of the activated recombinant cattle granzyme B by the 
specific inhibitor AC-IEPD-CHO. 
 
Functional cattle granzyme B (expressed in pFLAG-SOE) was produced by 
transient transfection of COS cells and cell lysates prepared after 48 hours used 
to test the enzymatic activity of lysates on the substrate AC-IEPD-pNA, in the 
presence or absence of the specific inhibitor AC-IEPD-CHO (10uM). Colour 
reaction generated after 4 hours by cleavage of the pNA substrate were 
measured at a wavelength of 405nm by using a Synergy™ HT Multi-Mode 









4.3.5 Equine antibodies cross-react  
One of the six murine anti-eqGzmB monoclonal antibod es (XIXG7) kindly provided 
by Dr. Martin Muller has been demonstrated previously to cross-react with human 
granzyme B by a western-blot assay (Piuko et al., 2007). To test whether any of the 
six antibodies cross-react with the functional form of cattle granzyme B used in the 
enzyme activity assay, they were tested for recognition of transfected cells by 
immunofluorescence staining of cytospin preparations (Figure 4.11). Positive 
controls confirmed expression of cattle pFLAG-SOE in approximately 20% of cells 
following transfection, using M2 antibody to the pFLAG epitope tag, and expression 
of human granzyme B in a small percentage of cells (<10%) transfected with 
pcDNA3.1-1 (kindly provided by Dr. Martin Muller), using the anti-eqGzmB XIXG7 
antibody. However, none of six anti-eqGzmB monoclona  antibodies stained cells 
expressing the functional cattle granzyme B, even when used at twice the 





Figure 4.11 Reactivity of 6 anti-eqGzmB monoclonal antibodies with 293T cells 
transfected with a vector (Bt-pFLAG-SOE) expressing the active form of bovine 
granzyme B. 
 
Cytospin preparations of the cells were stained by indirect immunofluorescence 
with the 6 anti-eqGzmB monoclonal antibodies, X1XG7(1:50), SZ(1:10), 8-
5B(1:10), 8D8(1:10), 7-7D(1:10) and 108(1:10) shown in panels (d) - (i), or with 
the anti-FLAG M2 antibody (panel b). Staining of cells transfected with human 
granzyme B (Hs-pc-DNA3, kindly provided by Dr. Martin Muller) with the 
monoclonal antibody XIXG7 is shown in panel (c) and staining of untransfected 
cells with the anti-FLAG M2 antibody as a negative control is shown in panel 






4.4 Discussion  
 
In human and mouse, granzyme B is thought to be the most potent effector molecule 
used by CTL to induce apoptosis of virally infected and tumour cells. The substrate 
specificities and biological activities of granzyme B in these species are well 
characterized (Heusel et al., 1994; Shresta et al., 1995; Thornberry et al., 1997; 
Kaiserman et al., 2006; Casciola-Rosen et al., 2007; Cullen et al., 2007). However, at 
the beginning of my study, no information on the biological activity of bovine 
granzyme B or its specificity was available. Therefo , it was difficult to investigate 
its role in killing mediated by CTL in cattle. As a first step to examining the activity 
of bovine granzyme B, this study set out to obtain expressed recombinant protein, 
first to determine whether processing of the translted polypeptide to generate 
functional protein is similar to that observed with the human and mouse orthologues 
and, second, to obtain initial information on the enzymatic activity of the mature 
protein. Several attempts to produce biologically active human granzyme B in 
baculovirus, bacteria and yeast had failed (cited by Smyth et al., 1995). However, the 
successful generation of recombinant human and mouse granzyme B by expression 
in mammalian COS cells (Caputo et al., 1993; Smyth et al., 1995) provided a 
potential system for investigating production of active bovine granzyme B. The 
success of the eukaryotic expression system is likely to relate to its ability to generate 
protein with appropriate post-translational modificat ons such as protein folding, 
disulfide bond formation and glycosylation, although direct evidence for this is not 
available. No specific antibodies were available to detect bovine granzyme B protein. 
Hence, to enable us to detect the recombinant bovine granzyme B expressed in COS 
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cells, a vector containing an antibody epitope tag w s chosen to express the protein. 
The study incorporated production of a version of the protein with a point mutation 
in the predicted active site to further test the spcificity of the activity.  
 
The results of these studies demonstrated successful xpression of biologically active 
granzyme B from cattle. This work is the first description of the biological activity of 
a member of the granzyme family in cattle. The demonstration that deletion of the 
dipeptide/GE is a prerequisite for activation of cattle granzyme B in COS cells 
indicates that processing of the translated polypeptid  is similar to that described for 
humans and mice (Caputo et al., 1993; Smyth et al., 1995). Moreover, the finding 
that mutation of Ser195, one of the triad at the catalytic site (His, Asp and Ser), 
causes the loss of enzyme activity of activated cattle granzyme B confirms the 
involvement of this residue in the active site of the bovine enzyme (Caputo et al., 
1994).  
  
The activity of the recombinant mature granzyme B protein was also examined 
employing a substrate assay using a peptide substrate, AC-IEPD-pNA containing an 
aspartic acid residue, which in other species acts s a specific substrate for granzyme 
B. The demonstration of strong activity against this substrate confirms that cattle 
granzyme B displays Aspase activity, which is a characteristic feature of granzyme 
B, as no other known serine protease in mammals has the cleavage preference for 
Asp-containing substrates (Poe et al., 1991). The GzmB inhibitor, AC-IEPD-CHO, is 
a known non-cell-permeable compound that inhibits human and rat granzyme B 
(Thornberry et al., 1997; Harris et al., 1998) by binding to residues at P4-P3-P2-P1 
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(amino-terminus with the proteolytic cleavage site) of active granzyme B, thus 
competitively blocking its enzymatic function. The effective inhibitory capacity of 
AC-IEPD-CHO for cattle granzyme B provides further evidence that the functional 
activity is attributable to granzyme B. Overall, these results indicate that the 
expressed product of the isolated granzyme B gene has functional properties 
characteristic of the granzyme B subfamily.   
 
Although one of six anti-eqGzmB monoclonal antibodies tested in these experiments 
had previously been reported to cross-react with human granzyme B, none of these 
antibodies was found to react with the bovine protein. As there was no available 
information on the epitope specificity of these antibodies (Piuko et al., 2007), it is 
possible that only two different epitopes may have be n recognized. However, the 
development of a system for expressing granzyme B provides a means of producing 
protein for generating specific antibodies in future studies.  
 
In the absence of specific antibodies, the granzyme B substrate assay established in 
these studies provides a potentially valuable tool t  determine and quantify the 
expression of functional cattle granzyme B in CD8+ T cells. Moreover, the 
demonstration that AC-IEPD-CHO is an effective inhibitor of cattle granzyme B in 
vitro also allows investigation of the enzyme specificity. However, this inhibitor is 
not cell-permeable and therefore cannot be used to examine granzyme B activity in 
intact cells. Therefore, other cell-permeable inhibitors of granzyme B need to be 
tested. These aspects are further investigated in chapters 5 and 6 of this thesis.  
 144 
Chapter 5   Expression of perforin and granzymes by  
Theileria-specific CD8+ T cells in relation to their 
killing activity 
 
5.1 Introduction  
 
Class I MHC (MHCI)-restricted CD8+ T cell responses are important in mediating 
immunological control of many intracellular pathogens, including viruses, bacteria 
and parasites (Wong and Pamer, 2003). The importance of CD8+ T cells in immunity 
to T. parva has been confirmed by demonstrating that immunity could be transferred 
from immune to naïve twin calves with CD8+ T cells (McKeever et al., 1994). 
Recently, a number of antigens recognised by T. parva-specific CD8+ T cells have 
been identified (Graham et al., 2006; Graham et al., 2007; Graham et al., 2008) and 
responses in individual animals have been shown to be focused on a few highly 
dominant antigens (Taracha et al., 1995; MacHugh et al., 2009). However, 
experiments attempting to immunise cattle with these antigens using prime-boost 
strategies have given poor protection against parasite challenge (Graham et al., 2006). 
In contrast to the strong cytotoxic activity of CD8+ T cells induced by infection and 
treatment, immunisation of cattle with 5 defined T. parva antigens induced CD8+ T 
cells with weak cytotoxic activity (Graham et al., 2006). This suggests that strong 
cytotoxicity in the specific CD8+ T cell response may be required for protection.  
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The predominant pathway used by CD8+ T cells to kill pathogen-infected cells is 
granule exocytosis (Kagi et al., 1994; Walsh et al., 1994; Nickell and Sharma, 2000), 
involving release of a membrane disrupting protein perforin and a number of 
granzymes (5 in human and 10 in mouse), which are co-localized in the lytic 
granules. Perforin and granzymes induce apoptosis of target cells in a synergetic 
manner, perforin generating membrane pores that allow delivery of the granzymes 
into the cytosol of target cells where they initiate cell death by cleaving a number of 
protein substrates (Redelman and Hudig, 1980; Hudig et al., 1991). Granzyme 
expression in other species has shown to be primarily restricted to lymphoid lineage 
cells such as T lymphocytes and natural killer cells, but not B cells (Anthony et al., 
2010; Bovenschen and Kummer 2010). Studies of mouse and human CD8+ T cells 
indicate that granzyme B is the most potent effector granzyme in T cell-mediated 
killing of virally infected cells and tumour cells. It is reported to be predominantly 
expressed in CD8+ T cells with effector function (Lieberman, 2003; Takata and 
Takiguchi, 2006; Chattopadhyay et al., 2009; Harari et al., 2009). Serine protease 
inhibitor 9 (serpinB9 / PI-9), an endogenous inhibitor of human granzyme B has 
been reported to be expressed broadly in many tissues, with high and stable levels in 
cytotoxic T cells, antigen-presenting cells, a number of endothelial and mesothelial 
cells and at immune privileged sites (Sun et al., 1996; Bladergroen et al., 2001; 
Buzza et al., 2001; Hirst et al., 2001). It is localized in the cytoplasm and nucleus of 
cells (Bird et al., 2001) and protects cytotoxic T cells and bystander cells from 
misdirected granzyme B (Bird et al., 1998).  
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Studies in mice have indicated that the perforin and granzyme genes can be 
differentially regulated in activated CD8+ T cells (Kelso et al., 2002). Thus, 
differences in cytolytic function of T. parva-specific CD8+ T cell responses might be 
related to differential expression of these granule enzymes (especially granzyme B). 
Recent work in the Roslin laboratory has revealed that CD8+ T cell clones that share 
epitope specificity have markedly different levels of cytotoxic activity against the 
same target epitope (Dr. Tim Connelley, personal communication). 
 
The aim of this chapter is to investigate whether heterogeneity in cytotoxic function 
is related to differential expression of granzymes and/or perforin by T. parva-specific 















5.2 Materials and Methods 
 
5.2.1 Animals and cell lines  
Freshly isolated PBMC established from naïve animals 1683 and 1693 were 
generated as described in section 2.2.1. Uninfected lymphoblasts were established 
from the same animals by stimulation of PBMC with ConA for 3 days (section 
2.2.2). Seven Theileria parva-infected cell lines of different cell surface phenotypes - 
641, 468, 109, 011, F44-951, F31-951 and 592 TPM - were provided by Drs Niall 
MacHugh and Timothy Connelley.  
 
CD8+ T cell clones established from animals 641 and 633, homozygous for the A18 
class I MHC haplotype, were kindly provided by Ms Victoria Carroll. The 
autologous T. parva-infected cell line, 641TPM (MHC A18/A18), was used as 
infected target cells in cytotoxicity assays with these clones. A T. annulata-infected 
cell line from the same animals incubated with synthetic peptide representing the 
target epitope, (641TAA-pulsed-Tp1214-224,100ng/ml) was used to investigate killing 
of peptide-pulsed target cells, as described in section 2.2.8.  
 
An uncloned T. parva-specific CD8+ T cell line established from animal 592, 
homozygous for the A10 class I MHC haplotype, was generated as described in 
section 2.2.4 and used with the autologous T. parva-infected cell line (592TPM-
MHC A10/A10), as an antigen-specific stimulator to examine the kinetics of 
expression of granule enzymes.  
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5.2.2 Standard RT-PCR  
The expression of genes encoding bovine granzymes, perforin and serine protease 
inhibitor 9 (serpinB9 / PI-9) was investigated. PI-9 is an intracellular inhibitor of 
granzyme B, which protects cytotoxic T cells and bystander cells from misdirected 
granzyme B. cDNA prepared from T. parva-infected cell lines of different 
phenotypes and resting PBMC and ConA-stimulated PBMC from two animals (1683 
and 1693) was prepared and analysed by RT-PCR as described in section 2.3.1- 2.3.5. 
A further two cDNAs prepared from ConA-stimulated cell lines (1706 and  1707) 
that had subsequently been maintained by passage in culture with IL-2 were kindly 
provided by Dr Timothy Connelley and also used in these assays. PCR primers for 
the full-length coding region of PI-9 gene, identified in the bovine genome 
(NM_001075859), were designed using the Primer3 programme. The sequences of 
these primers were as follows: forward primer- 5’- ACCTGGTTTCCAATGTCAGG 
-3’ and reverse primer - 5’- CTGGGGACACAGGGAAGG -3’. The primers were 
tested with cDNA prepared from a culture of T. parva-specific CD8+ T cells. The 
identity of the resultant PCR product (1270bp) was confirmed by sequencing as 
described in section 2.3 (data not shown). Primers used for granzymes and perforin 
were listed in table 3.3.  
 
5.2.3 Semi-quantitative PCR 
A semi-quantitative reverse transcriptase PCR was used to investigate the relative 
levels of expression of bovine granzymes and perforin in selected CD8+ T cell lines. 
A PCR for the house-keeping gene GAPDH was used as a control employing the 
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following primers: forward primer -  5’-ACC CCT TCA TTG ACC TTC AC-3’ and 
reverse primer - 5’-TTC ACG CCC ATC ACA AAC ATG-3’. Primers for 
granzymes were redesigned using DNAsis Max 2.0 software to obtain a single-band 
product under the same annealing temperature for each gene. This was achieved for 
all except granzyme K, which gave three bands, one of the expected size and two 
smaller bands. The sequences of primers are listed n table 5.1. The primers for 
granzyme genes and GAPDH were tested with cDNA prepared from a culture of T. 
parva-specific CD8+ T cells. The identity of the PCR products were confirmed by 
sequencing as described in section 2.3 (data not shown). Primers used for perforin 
were listed in table 3.3. The PCR reactions were composed of 20pmol of 
granzymes/perforin primers and 10pmol of GAPDH primers, 2.5 units BIOTAQ (5 
units/ul Bioline, London, UK), 2.5ul SM-0005 buffer, 2ul cDNA (derived by 
Reverse Transcription of RNA samples as described in section 2.3.3) and nuclease-
free water to give a final volume of 25ul. The reaction programme was as following: 
94°C for 3 min, 30 cycles (94°C for 1.5 min, 55°C for 1.5 min, 72°C for 1.5 min) 
and a final extension period of 72°C for 10 min. The Semi-quantified PCR products 
were analysed by 1.5% agarose gel electrophoresis and the density of the specific 
bands was measured by computer software (KODAK 1D 3.6 version). 
 
Table 5.1 PCR primers designed to amplify bovine granzyme sequences from 
cDNA 
Primers Sequences  ( 5’---3’ ) 
GzmA   (For) TGA CTC CTC ATT CAA GAC CCT A 
GzmA   (Rev) CCA GTTGAG GTG TTT CTT TGA G 
GzmO   (For) TTC CTC CTG CCA TTT GTC TC 
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GzmO   (Rev) AGG CTT CTG GGG ATT ACC AC 
GzmB   (For) ACT GGA ATC AGG ATG TCC AGA G 
GzmB   (Rev) TTT GGG TCC CCC ACA CAC AG 
GzmH   (For) GGC TTT CGT TCA GTT TCT GG 
GzmH   (Rev) GAG TCA CCC TTG AAG CCG 
GzmK   (For) AGC CGG GAC TTA CAT GAC TC 
GzmK   (Rev) AGG TTT CTT GGC ATC ACC AC 
GzmM   (For) AGA TCC AAG ATG CTG CTC CT 
GzmM   (Rev) GAT GTC GGT GCA ATT CTC AG 
 
 
5.2.4 Cytotoxicity Assay  
A standard 4h 111In-release assay was performed as described in section 2.2.8.  
 
5.2.5 CD8+ T cell line lysate preparation  
Cell lysates for analysis of granzyme B content were prepared as described by Ewen 
et al., (2003) and Piuko et al., (2007). Aliquots of 1ml of PBS-washed CD8+ Tcells 
adjusted to 1x106cells/ml in PBS were centrifuged at 180 x g for 10 min and the 
pellet was lysed by addition of 50ul of a lysis buffer composed of 1%Triton X-100 in 
50mM Tris, pH8.0 and 0.5ul of Benzonase Nuclease (25U/ml, Purity>99%, Merck). 
Following incubation on ice for 20min, lysed cells were centrifuged for 10min at 0°C 
at 21,000 x g to pellet cell nuclei. Supernatants were harvested and either stored at -
70°C or immediately used in activity assays. 
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5.2.6 Granzyme B release by CD8+ T cells   
Samples containing released granzyme B were prepared as described by Ewen et al., 
(2003). Aliquots of 1x106 effector cells were distributed into the wells of 96-well V-
bottomed plates together with 5x105 target cells in a total volume of 200ul phenol-
red-free complete media (Invitrogen, RPMI1640, Cat:11835-063). Control wells 
containing effector cells and medium were also included. Plates were briefly 
centrifuged for 1 min at 120xg and then incubated in a humidified incubator in an 
atmosphere of 5% CO2 at 37°C. After incubation for 4h, supernatants were obtained 
by centrifuging for 10 min at 400xg.  
 
5.2.7 Granzyme B enzymatic assay  
Measurement of granzyme B activity in samples was performed as described by 
Ewen et al. (2003). Aliquots of 10ul of cell lysates or 40ul of culture supernatants 
were added in duplicate to wells of Falcon™ 96-well flat-bottomed Microplates (BD, 
Cat. 353072) together with 200uM granzyme B substrate VIII, Ac-IEPD-pNA, 
(Calbiochem, Cat.368067) and reaction buffer (0.1M HEPES, pH7.0; 0.3M NaCl; 
1mM EDTA) in a total volume of 100ul/well. Wells containing reaction buffer and 
substrate control were also included as controls. Mixtures were incubated at 37°C for 
4h and the colour reaction generated by cleavage of the pNA (p-nitroaniline) 
substrate measured at a wavelength of 405nm using a Synergy™ HT Multi-Mode 
Microplate Reader (BioTek) 
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5.2.8 Statistical analysis  
The statistical analysis was performed using Minitab software (Minitab® 15.1.20.0, 
Minitab Inc.). The correlation between variables was nalysed by Pearson’s 





















5.3 Results  
 
5.3.1 Expression of granule enzymes and protease in hibitor 9 by 
resting and activated lymphocytes 
To investigate the transcript expression of bovine granule enzymes and PI-9, resting 
PBMC and ConA-stimulated PBMC from two animals (1683 and 1693) were 
examined by PCR (Figure 5.1- 5.2 and Figure 5.4). Transcripts of granzymes A, K H 
and M were detected in both resting PBMC, but granzymes O and B and PI-9 were 
not expressed. By contrast, all granzyme transcripts except granzyme K were 
observed in the corresponding ConA-stimulated PBMC; PI-9 transcripts were also 
detected in these cells. A similar profile of expression was obtained for another two 
ConA-stimulated PBMC (1706 and 1707) maintained by further stimulation with IL-












5.3.2 Expression of granule enzymes and PI-9 in T. parva-infected 
cell lines 
Previous studies have shown T. parva can infect and transform CD4+ T cells, CD8+ 
T cells, γδ+ T cells and B cells at similar frequencies in vitro (Baldwin et al., 1988). 
Six T. parva-infected cell lines of different phenotypes were examined by PCR for 
expression of transcripts of granule enzymes and PI-9 (Figure 5.3 and 5.4). Infected 
cell lines of different T cell subtypes (CD4+, CD8+ and γδ+) all expressed 
transcripts for perforin and granzyme A and displayed variable expression of the 
other granzymes. In contrast, there is no detectable expression of perforin or any of 
the granzymes in a B cell line infected with T. parva. The granzyme inhibitor PI-9 
was found to be consistently expressed in all of the T. parva-infected cells. An 
additional weaker band of slightly smaller size was obtained in four infected cell 
lines (641, 109, 011 and 592 TPM) which had the most abundant PCR product. The 
identity of this PCR product was not determined, but it may be an alternatively 











Table 5.2 Summary of relative levels of expression of genes encoding granule 
enzymes and PI-9 in resting and activated PBMC and in T. parva-infected cell 
lines of different phenotypes, determined by RT-PCR 
Cells Animal A O B H K M PFN PI-9 
1683 ++ - - + -/+ + ++ - PBMC 
1693 + - - -/+ -/+ -/+ ++ - 
1683 +++ ++ ++ ++ - + ++ + ConA Blast 
1693 +++ ++ ++ + - -/+ ++ + 
1706 ++ + - - - -/+ ++ + ConA line 
1707 + + - - - -/+ + + 
641 +++ -/+ +++ +++ -/+ + ++ +++ CD8+ TPM 
109 ++ -/+ ++ + -/+ + ++ +++ 
011 ++ -/+ ++ + NT + + ++ CD4+ TPM 
F44-951 ++ - - - -/+ - ++ ++ 
γδ+ TPM F31-951 +++ +++ - - -/+ - +++ ++ 
B+ TPM 592 - - - - - - - ++ 
PBMC = freshly harvested blood mononuclear cells; ConA blasts = PBMC 
harvested 3 days after stimulation with ConA; ConA line = PBMC stimulated 
with ConA and subsequently passaged in medium containing recombinant IL-2; 
TPM = cell lines infected with T. parva. NT = not tested. The intensity of PCR 
products in agarose gels was assessed visually: ranging from very weak (-/+) to 






Figure 5.1 PCR products obtained for each of the bovine granule enzymes from 
(A). resting PBMC from two animals and (B). an uncloned T. parva-specific 
CD8+ T cell line (641). 
 
A.                                                                    B. 
 
 
The sizes of the PCR products obtained were: granzyme A - 838bp; granzyme O 
- 849bp; granzyme B - 818bp; granzyme H - 820bp; granzyme K - 889bp; 
granzyme M - 833bp; Perforin (PFN) - 1275bp; (B). Negative controls (primers 
with no added cDNA template) are included in the uper left of panel B and 








Figure 5.2 PCR products obtained for each of bovine granule enzymes and PI-9 




PCR products for each of granule enzymes and PI-9 (sizes as described in figure 
5.1) are shown in the upper part of the panel. The negative and positive controls 
shown in the bottom part of the panel represent PCR products obtained without 
and with cDNA template respectively from cDNA of an uncloned T. parva-
specific CD8+ T cell line (641) 7 days after stimulation with irradiated 








Figure 5.3 PCR products obtained for each of the bovine granule enzymes from 
six T. parva-infected cell lines of different surface phenotypes and from ConA-




The sizes of the PCR products are given in the legend to figure 5.1. Positive 
controls, labelled + in the set of PCRs for each enzyme, consisted of primers 
with cDNA template of an uncloned T. parva-specific CD8+ T cell line (641). The 
negative controls, consisting of PCR assays with no added template, are shown 







Figure 5.4 PCR products obtained for PI-9 from cDNA of T. parva-infected lines 




Results are shown for 6 T. parva-infected cell lines, IL-2-maintained ConA lines 
from two animals (1706 and 1707), PBMC from two animals stimulated for 3 
days with ConA (1683 and 1693) and an uncloned T. parva-specific CD8+ T cell 
line (641) (labelled +). Results obtained with the PI-9 PCR are show in the 
upper part of the panel and those for the GAPDH control in the lower part. 
Negative controls for PI-9 and GAPDH (labelled -), without added template, are 






5.3.3 Kinetics of expression of granule enzyme transcript s in un-
cloned CD8+ T cells  
The kinetics of expression of mRNA for bovine granzymes and perforin by an 
uncloned CD8+ T cell line were examined following stimulation with autologous T. 
parva-infected cells, using semi-quantitative PCR assays. A CD8+ T cell culture 
established from animal 592; these T cells were stimulated with a B cell line infected 
with T. parva (Muguga) to avoid detection of granzyme transcripts derived from 
stimulator cells. A sample of cDNA prepared from this parasitized line prior to the 
assay was confirmed as negative for perforin and granzyme transcripts (data not 
shown). Analysis of the T. parva-specific T cell line by flow cytometry confirmed 
that it was predominantly CD3+, CD8+, CD4- and TCRγδ-. Following antigenic  
stimulation, T cell proliferation developed between days 2 and 7, during which the 
numbers of CD8+ cells in the culture increased at least 10-fold and their propo tion in 
the whole population increased from 54% to 99.5% (the negative cells representing 
surviving stimulator cells). Cells collected from the stimulated cultures were 
examined by semi-quantitative PCR on days 2, 5, 7, 9 12, 14 after stimulation. 
 
The results revealed some differences in the kinetics of expression of the different 
mRNA species (Figure 5.5). Granzyme O showed high levels of expression at all 
time points, granzymes A and B showed high levels btween days 2 and 7, while 
granzymes H, K and M showed low or undetectable expression on day 2 and 
gradually increased thereafter. The expression of perforin showed high levels 
between days 7 and 9.  
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Figure 5.5 Time course of granzymes and perforin mRNA expression in an 
uncloned T. parva-specific CD8+ T cell line (592) following stimulation with 
autologous irradiated parasitized cells. 
 
A. Agarose gels showing the PCR products for individual enzymes and the 
GAPDH control. Days after antigenic stimulation are shown at the top of each 
panel. A negative control (-), without added template, and a positive control (+), 
consisting of primers with cDNA template of an uncloned T. parva-specific 
CD8+ T cell line (641) day 7 after 3rd stimulation are included for each enzyme; 
B. Changes in quantity of PCR product (vertical axis) at different times 
following antigenic stimulation, normalised in relation to that of the GAPDH 








The density of the bands was measured by Kodak 1D software (version 3.6) and 
results (vertical axis) are expressed as ratios of the density of the specific bands 
to that of the corresponding GAPDH bands.  
 
 
5.3.4 Relationship of killing levels and granule enzyme t ranscript 
profiles  
To determine whether the levels of killing by CD8+ T cells are related to expression 
of particular granule enzymes, CD8+ T cell clones drived from the same animals 
but exhibiting different levels of killing were analysed using a semi-quantitative 
PCR. Dr Tim Connelley provided the cDNA and cytotoxicity data for these T cell 
clones. A standard time point of 7 days was chosen for analysis of cDNA, based on 
the results of the kinetics study as described above. The T cell clones had also been 
assayed for cytotoxicity on day 7. Two sets of cloned CD8+ T cell lines derived from 
different animals (641 and 1011) were examined; each set of lines expressed 
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identical TCRβ chains and recognised the same epitope but exhibited d fferent levels 
of cytotoxic activity (data provided by Dr. Timothy Connelley). The levels of 
cytotoxicity on autologous parasitized cells and on n -parasitised cells pulsed with 
peptide epitope are shown in figure 5.6. Of the 4 clones examined from animal 641, 
two showed no cytotoxic activity whereas the other 2 gave 19-32% killing of 
parasitized cells and 80% killing of peptide-pulsed targets. Two of the T cell clones 
from animal 1011 gave high levels of killing (64-75%) of both parasitized and 
peptide-pulsed target cells while the other two clones gave low levels of killing 
(<40%). Transcripts for perforin and all of the granzymes were detected in all 8 T 
cell clones (Figure 5.7 and 5.8). Amongst the 641 clones, perforin expression was 
higher in the clones with killing activity compared to the non-killing clones. In the 
1011 clones, those displaying high levels of cytotoxicity had higher granzyme A 
expression than clones with low cytotoxicity, but there was no obvious difference in 
the level of perforin expression. Overall, there was no consistent pattern of Gzm/PFN 











Figure 5.6 Cytotoxic activity of T. parva-specific CD8+ T cell clones, 4 from 
animal 641 (A) and 4 from animal 1011 (B), assayed on autologous T. parva-
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The clones were also tested on MHC-mismatched T. parva-infected targets and 





Figure 5.7 Relationship of killing levels and granule enzyme transcript profiles 
in CD8+ T cell clones (641). 
 
A. Agarose gels showing the PCR products for individual enzymes and the 
GAPDH control. A negative control (-), without added template, and a positive 
control (+), consisting of primers with cDNA template of an uncloned T. parva-
specific CD8+ T cell line (641) are included for each enzyme; B. Changes in 
quantity of PCR product (vertical axis) in different T cell clones, normalised in 










The density of the bands was measured by Kodak 1D software (version 3.6) and 
results (vertical axis) are expressed as ratios of the density of the specific bands 




Figure 5.8 Relationship of killing levels and granule enzyme transcript profiles 
in CD8+ T cell clones (1011). 
 
A. Agarose gels showing the PCR products for individual enzymes and the 
GAPDH control. A negative control (-), without added template, and a positive 
control (+), consisting of primers with cDNA template of an uncloned T. parva-
specific CD8+ T cell line (641) are included for each enzyme; B. Changes in 
quantity of PCR product (vertical axis) in different T cell clones, normalised in 












The density of the bands was measured by Kodak 1D software (version 3.6) and 
results (vertical axis) are expressed as ratios of the density of the specific bands 
to that of the corresponding GAPDH bands.  
 
 168 
5.3.5 Relationship of killing levels and granzyme B  protein 
expression 
To further investigate whether the different levels of killing by CD8+ T cells is 
related to expression of granzyme B or degranulation, twelve Tp1214-224–specific 
CD8+ T cell clones derived from two T. parva-immune animals (641 and 633), 
kindly provided by Ms Victoria Carroll were examined for levels of granzyme B 
enzymatic activity (Ewen et al., 2003). In a separate ssay, these T cells gave 
variable levels of killing of autologous parasitized target cells and Tp1214-224 peptide-
pulsed target cells but did not kill MHC-mismatched parasitized target cells, 
indicating that they are antigen-specific and MHC rest icted (data not shown).  
 
MHC-homozygous T. parva-infected cells, 641TPM and 468TPM (MHC A18/18) 
were used as a source of stimulator cells for the 641 and 633 CD8+ T cell clones, 
respectively. In earlier experiments, RT-PCR assays h d demonstrated expression of 
granzyme B transcripts in the 641TPM line. To determine the possible contribution 
of granzyme release from these stimulator cells to the T cell assays, lysates prepared 
from the 641TPM and 468TPM cell lines at different intervals up to 14 days after 
gamma-irradiation were analysed for granzyme B activity. No significant granzyme 
B activity was detected in the 468TPM line at any time point, while the 641TPM 
contained very low levels on days 0, 4 and 6 but was negative thereafter (Figure 5.9). 
A further experiment was undertaken to examine granzyme B release from the T. 
annulata-infected  cell line (641TAA) used to present peptides to the CD8+ T cell 
lines. Consistent with the RNA analyses, no granzyme B was detected in lysates 
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from this line, whereas 641TPM again exhibited low levels of granzyme B (Figure 
10). 
 
Figure 5.9 Granzyme B enzymatic activity in lysates of two T. parva-infected cell 
































Aliquots of 5x105 of gamma-irradiated T. parva-infected cells were cultured in 
2ml SCM for the indicated times Granzyme B enzymatic activity in cell lysates 
was assayed by measuring the colour reaction generated after 4 hours 
incubation with the pNA substrate using a Synergy™ HT Multi-Mode 
Microplate Reader (BioTek).  
 
Figure 5.10 Granzyme B activity in lysates prepared from T. parva-infected 
(TPM) and T. annulata-infected (TAA) cell lines from animal 641 





















Aliquots of 1x106 of Theileria-infected cells in 1 ml were lysed and assayed for 
granzyme B enzymatic activity by measuring the colour reaction generated 
after 4 hours incubation with the pNA substrate using a Synergy™ HT Multi-
Mode Microplate Reader (BioTek).  
 
 
A pilot experiment was performed with five 641 CD8+ T cell clones to examine 
whether the levels of killing activity on [111In]-labelled autologous 641TPM were 
associated with the granzyme B content of the cells. Since the T cell clones were 
assayed for cytotoxicity on day 7 after stimulation, this time point was also chosen 
for analysis of granzyme B activity in CD8+ T cell lysates. Figure 11- A shows the 
levels of killing obtained with the clones when tested at effector to target ratios of 2:1 
and 4:1. Although the levels of killing observed at the two effector to target ratios 
differed slightly, the relative ranking of cytotoxic activity between the clones was 
similar. Interestingly, when the granzyme B content of lysates from these lines was 
examined they displayed a clear trend, namely that those CD8+ T cell clones with the 
highest levels of granzyme B showed the highest killing of autologous T. parva-









Figure 5.11 Cytotoxicity activity (A) and granzyme B activity (B) of five T. 

























Five cloned 641 CD8+ T cell lines (1x104cells/well) were tested in a 4-hour 
cytotoxicity assay with [111 In]-labelled autologous T. parva-infected target cells 
at effector to target ratios of 2:1 and 4:1.  
 
B. 






















Aliquots of 1x106 CD8+ T cells were lysed and granzyme B enzymatic activity 
assayed by measuring the colour reaction generated after 4 hours incubation 





To further investigate this observation, experiments were undertaken using a larger 
set of 12 Tp1214-224–specific CD8+ T cell clones (including the 5 clones used in the 
previous experiment). Degranulation was also assessed by measuring granzyme B 
released into the supernatant following incubation with 641TAA pulsed with Tp1214-
224 peptide. A standard effector to target ratio of 2:1 was used. Since the T cell clones 
were assayed for cytotoxicity on day 7 after stimulation, this time point was also 
chosen for analysis of granzyme B activity in CD8+ T cell lysates. The levels of 
cytotoxicity on autologous parasitized cells and on cells pulsed with epitope peptide 
ranged from 1% to 47% and from 5% to 93%, respectivly (Figure 5.12). The levels 
of granzyme B in cell lysates of these CD8+ T cell clones and in supernatants 



















Figure 5.12 Cytotoxic activity of T. parva-specific CD8+ T cell clones assayed 
with (A) autologous T. parva-infected cell target cells and (B) autologous T. 
annulata-infected target cells pulsed with Tp1214-224 peptide 
A. 














































CD8+ T cell lines (1x104cells) were tested in a 4-hour cytotoxicity assay with the 
respective [111 In]-labelled target cells. T. annulata-infected targets were 
incubated with 100ng/ml of the Tp1214-224 peptide. A standard effector to target 




Figure 5.13 Granzyme B activity in, (A) cell lysates from 12 T. parva-specific 
CD8+ T cell clones and, (B) in supernatants of the same 12 clones following 





















Aliquots of 1x106 CD8+ T cells were lysed and granzyme B enzymatic activity in 
lysates assayed by measuring the colour reaction generated after 4 hours 
incubation with pNA substrate using a Synergy™ HT Multi-Mode Microplate 






















Aliquots of 1x106 CD8+ T cells were incubated for 4 hours with autologous T. 
annulata-infected cells with Tp1214-224 peptide added at 100ng/ml. Supernatants 
were harvested and granzyme B activity measured as described for (A) above.  
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The values for all of the data are presented in table 5.3 and plots of cytotoxicity 
versus levels of granzyme B in cell lysates or supernatants and their statistical 
associations are presented in figure 5.14- 5.16. When t e levels of granzyme B 
activity in lysates are plotted against killing of parasitized cells, there is a statistically 
significant positive correlation (r=0.732, p=0.007) (Figure 5.14- A). The levels of 
granzyme B activity in lysates or in supernatants al o showed a statistically 
significant positive correlation with killing of cells pulsed with epitope peptide (the 
former, r=0.679, p=0.015; the latter, r=0.599, p=0.039) (Figure 5.14- B and 5.15), 
although these associations were weaker than those ob rved with killing of 
parasitized cells. When the levels of granzyme B activity in lysates are plotted 
against its release, a strong positive correlation was observed (r=0.953, p=0.000) 











Table 5.3 Summary of cytotoxicity and granzyme B dat  on 12 T. parva-specific 
















641.24 3 47 93 0.22 0.19 
641.19 3 43 92 0.30 0.33 
641.20 3 36 88 0.07 0.07 
641.25 3 33 79 0.13 0.05 
641.27 NT 26 78 0.25 0.19 
631.23 NT 25 64 0.16 0.10 
641.28 NT 19 79 0.22 0.20 
641.30 NT 16 50 0.05 0.02 
641.18 1 15 64 0.00 0.00 
641.11 1 13 71 0.03 0.01 
641.26 NT 8 29 0.02 0.03 
633.21 NT 1 5 0.00 0.02 
Data on the TCRVβ genes expressed by individual T cell clones are cited from 















Figure 5.14 Correlation of granzyme B cellular activity with (A) levels of killing 
of Theileria-infected target cells by CD8+ T cell clones and, (B) levels of killing 
of peptide-pulsed target cells by the same CD8+ T cell clones 
A. 
























S c a tte r p lo t o f  P e r ce ntage  c y to tox ic i ty  v s  G zmB  ce l lu la r  a c tiv i ty  
 
Correlation coefficient=0.732; P value=0.007   
 
B.  
























S ca tte rp lo t o f  P e r centage  cy to tox ic ity  v s  G zmB  ce l lu la r  a c tiv i ty  
 






Figure 5.15 Correlation of granzyme B release by CD8+ T cell clones following 
stimulation with irradiated parasitized cells and their levels of killing of peptide-
pulsed target cells. 
























S c a tte r p lo t o f  P e r ce nta ge  c y to tox ic i ty  v s  G zmB  r e le a s e
 
Correlation coefficient=0.599, P value=0.039. 
 
Figure 5.16 Association of levels of granzyme B cellular activity of CD8+ T cell 





















S catterplot of GzmB re lease  vs  GzmB ce l lula r  activ ity  
 
Correlation coefficient=0.953, P value =0.000 
 
Since cytotoxicity activity and granzyme B release by CD8+ T cells had been 
measured using target cells loaded with a relatively high concentration of epitope 
peptide (100ng/ml), further experiments were undertaken to test the minimal 
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concentrations of peptide required to mediate cytotoxicity. Based on preliminary 
experiments, 100-fold dilutions of Tp1214-224 peptide, ranging from 0.0001ng/ml to 
1ng/ml, were tested (Figure 5.17). Three of the 641CD8+ T cell clones, including 
one (641.20) that tended to have low levels of granzyme B content but relatively 
strong killing, were used. The granzyme B content in hese three T cell clones and 
their cytotoxic activity against autologous T. parva-infected cells (641) were 
examined at the same day (7 day after the last stimulation) (Table 5.4). All 3 clones 
showed a similar cytotoxicity profile, with killing of between 52% and 63% of 
targets pulsed with 1ng/ml of peptide decreasing to undetectable levels at 
0.0001ng/ml of peptide. However, the levels of granzyme B release at the highest 
peptide concentration (1ng/ml) differed for the 3 clones, and the values were similar 
to those obtained with 100ng/ml in the previous experiments. Nevertheless, the 
decrease in levels of killing observed with lower peptide concentrations was 
associated with a progressive decrease in granzyme B release by all 3 clones. As in 
the previous experiments, clone 641.20 showed low levels of granzyme B release but 
relatively strong killing.  
 





Granzyme B activity 
(405nm) 
Cytotoxicity (%) against autologous T. 
parva-infected cells  
641.19 3 0.17 28 
641.20 3 0.09 33 
641.24 3 0.14 35 
The assays were carried out on the same day as the assays described in figure 
5.17. The data on expressed TCRVβ genes are cited from the reference 
(Macdonald et al.) 
 180 
 
Figure 5.17 Influence on target peptide density on levels of cytotoxicity and 
granzyme B release by 3 T. parva-specific T cell clones. 
 
(A). cytotoxicity assayed on T. annulata-infected target cells incubated with 
different concentrations of Tp1214-224 peptide. (B). granzyme B concentrations in 
supernatants of the same T cell clones following incubation with peptide pulsed 
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These results indicate that although there is a statistic lly significant association 
between the levels of killing activity of different T. parva-specific CD8+ T cell 
clones and granzyme B protein cell content and releas , this correlation is not 
absolute. It suggests that other factors in addition t  granzyme B, which vary 





















5.4 Discussion  
 
Several studies in other species have shown differential expression and discordant 
regulation of granule enzymes in different subpopulation of lymphocytes, both at the 
transcription level (Grossman et al., 2003) and protein expression (Sedelies et al., 
2004; Bade et al., 2005; Bratke et al., 2005). Transcripts of perforin and all except 
granzymes B and O were detected in resting PBMC. Granzymes B and O were 
expressed in ConA-activated PBMC, indicating that the expression of these two 
granzyme is activation-dependent. In contrast, while granzyme K was expressed in 
resting PBMC, there was no detectable transcript in Co A-activated cells. This might 
relate to a more restricted cellular expression of this granzyme K, although in 
humans expression of granzyme K at the protein level has been reported in T cells, 
CD56bright NK cells and a subpopulation of NKT cells (Bade et al., 2005; Bratke et al., 
2005). Granzyme expression was also detected in T. parva-infected cell lines of 
different T cell subtypes, but not in infected lines of B cell origin, reflecting their 
lineage-restricted expression to T lymphoid lineage nd NK cells (Anthony et al., ; 
Bovenschen and Kummer). Therefore, although infection with T. parva results in 
altered expression of some host proteins, the presenc  of granzyme expression 
appears to be consistent with the origin of cells.  
 
PI-9 acts as an endogenous inhibitor of human granzyme B. It protects CTL and 
bystanders against the actions of granzyme B (Sun et al., 1996; Bladergroen et al., 
2001; Buzza et al., 2001; Hirst et al., 2001; Bird et al., 1998). Several studies have 
reported that expression of PI-9 in tumour cell lines gives rise to resistance to 
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perforin/ granzyme B-mediated killing activity by CTL and NK cells (Medema et al., 
2001; Bladergroen et al., 2002; Bots et al., 2006; Jiang et al., 2006), although this 
conclusion remains controversial (Godal et al., 2006). Expression of PI-9 in cattle is 
activation-dependent, as it detected in ConA-activated but not resting PBMC. Of 
particular interest was the observation that all of T. parva-infected cell lines 
examined consistently expressed higher levels of PI-9 transcripts than ConA-
activated lines and uncloned CD8+ T cell lines (used as a positive control). This 
conclusion is based on visual comparison of the intnsi y of PCR products in agarose 
gels and needs to be examined by fully quantitative PCR to accurately determine the 
relative differences in expression. Theileria parva has been shown to protect infected 
cells from Fas/Fas ligand-induced apoptosis by upregulating a number of anti-
apoptotic proteins (Guergnon et al., 2003; Kuenzi et al., 2003). Further studies are 
required to determine whether enhanced expression of PI-9 in T. parva-infected cells 
reduces their sensitivity to perforin/granzyme-mediated killing in comparison to 
uninfected cells.  
 
Levels of transcripts for perforin and granzymes detect d in 8 cloned CD8+ T cell 
lines with a semi-quantitative assay showed no consistent pattern of expression that 
correlated with the levels of killing of T. parva-infected target cells. One possible 
reason for this finding is that the PCR method used to measure Gzm/Prf expression 
may not be sufficiently quantitative to detect significant differences. This could be 
overcome by using a quantitative PCR. Alternatively, proteins of perforin and the 
granzymes are synthesized and stored in lytic granule after the initial activation when 
CTL precursor recognizes the target (Griffiths, 1995). It is therefore possible that 
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several CD8+ T cells which do not have active GzmB RNA transcriptions may still 
have proteins of perforin and the granzymes and are c pable to mediate the 
cytotoxicity by immediately releasing them upon therecognition of the same target. 
Hence there may be no directly relevant expression pattern of perforin/ granzymes 
between the gene and protein. It is also possible that the cells within the cloned 
populations are heterogeneous in their patterns of Gzm/PFN expression and that only 
certain combinations of expression give effective killing. This would not be detected 
by examining the whole population. A study of mouse CD8+ T cells has reported 
that granzyme and perforin genes are differentially expressed in single CD8+ cells 
within cloned populations (Kelso et al., 2002). The ability of the different clones to 
preload and/or degranulate their effector molecules following recognition of the 
target cells might also vary.  
 
Granzyme B has been shown to be the most potent effector molecule utilized by 
CD8+ T cells to kill infected cells in human and mouse. However, the lack of 
specific antibodies for bovine granzyme B as described in chapter 4 makes it difficult 
to investigate its expression at the protein level to examine its role in CD8+ T cell 
killing in cattle. An alternative approach is to measure the specific enzymatic activity 
of granzyme B. Ewen et al (2003) established a sensitive and reliable method to 
measure murine and human granzyme B activity in cell lysates and supernatants 
employing a peptide substrate, AC-IEPD-pNA. Work described in chapter 4 of this 
thesis demonstrated that AC-IEPD-pNA acts as a substrate for bovine granzyme B, 
thus providing an assay to detect and quantify the expression of functional bovine 
granzyme B in CD8+ T cells in relation to their cytotoxic activity.  
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The levels of granzyme B enzymatic activity in cell lysates of 12 cloned CD8+ T cell 
lines, as well as levels released into supernatants during target cell killing, showed 
statistically significant correlations with the levels of killing of T. parva-infected 
cells and peptide-pulsed cells by the CD8+ T cell lines. The results indicate that the 
amount of granzyme B released during killing reflects the level of granzyme B 
content of the T cells and the statistical associations of both parameters with levels of 
cell killing suggest that granzyme B is likely to be involved in killing of the target 
cells. However, this correlation was not absolute. For example, clone 641.20, which 
had low levels of granzyme B content and release, actually displayed relatively 
strong killing. This suggests that other factors, in addition to granzyme B, that vary 
between T cells clones may contribute to the cytotoxic activity of CD8+ T cells. Co-
expression of more than one granzyme has been shown to enhance cytotoxic activity 
in vitro. For example, co-transfection of rat basophilic leukemia (RBL) cells with 
granzyme A and granzyme B in the presence of perforin resulted in enhanced killing 
of tumour targets in a synergistic manner (Nakajima et al., 1995). Also, human 
granzyme H, which itself can mediate cytotoxicity (Fellows et al., 2007), has been 
reported to augment granzyme B-mediated killing of adenovirus-infected cells 
(Andrade et al., 2001; Andrade et al., 2007; Waterhouse and Trapani, 2007). It was 
shown to directly restrict the replication of virus by cleaving and inactivating an 
essential viral protein (DNA binding protein/ DBP) and also enhanced granzyme B-
induced death by neutralizing the viral inhibitor of granzyme B (L4-100K assembly 
protein) (Andrade et al., 2001; Andrade et al., 2007). Recent studies in vitro have 
demonstrated the ability of human granzyme M to rapidly induce cell death of tumor 
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cells, which displayed a unique cell death-morphology (Kelly et al., 2004; 
Bovenschen et al., 2008; Cullen et al., 2009). In addition to directly killing target 
cells, granzyme M has been reported to hydrolyse PI-9 and inactivate its inhibitory 
function for granzyme B (Mahrus et al., 2004). These findings have shown the 
potential for other granzymes to cooperate with granzyme B in achieving CD8+ T 
cell-mediating cell death. Further investigation of these interactions in cattle is 
hampered by the current lack of specific antibodies and biological assays to measure 
other bovine granzyme proteins.  
 
It has been observed that T cell clones that give poor killing of T. parva-infected 
cells show substantially increased levels of killing against peptide-pulsed cells, 
particularly at high peptide concentration. The strong correlation between granzyme 
B content and its release detected in 12 cloned T cell lines indicated that there was no 
difference in degranulation ability among these clones. However, the higher levels of 
cytotoxicity detected against peptide-pulsed compared to infected targets indicates 
that the peptide ligand concentration can influence the extent of degranulation by the 
T cells. This was confirmed by showing increased levels of granzyme B release by T. 
parva-specific T cells exposed to targets incubated with increasing concentrations of 
peptide. Recent studies in mice have revealed that the strength of T cell receptor 
signal regulates the polarization of lytic granules to the immunological synapse and 
that a high threshold of signalling is required forull recruitment of granules to the 
synapse, implying a fine level of control of granule-mediated cell death by CD8+ T 
cells (Jenkins et al., 2009). Thus, in addition to effector molecules, the strength of T 
cell signalling also influences the efficiency of killing of target cells.  
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Chapter 6   Granzyme B is an important mediator 
involved in killing of Theileria-infected cells by 
specific CD8+ T cells 
 
6.1 Introduction  
 
It has been well established that the CD8+ T cell response against cells infected with 
T. parva schizonts is important in mediating immunological ontrol of the infection 
(Morrison et al., 1987; Goddeeris et al., 1990; McKeever et al., 1994). Despite the 
evidence that CD8+ T cells are involved in mediating immunity, the mechanism by 
which they act against the parasitized cells is not well understood. CD8+ T cells in 
other species have been shown to act as effectors by eleasing soluble mediators, 
such as IFN-γ (Boehm et al., 1997), TNF-α (Vassalli, 1992) and interleukins (Biron, 
1994), which induce killing of the intracellular pathogens. However, previous 
experiments have provided evidence that the schizont stage of Theileria parva in 
infected leukocytes is not susceptible to IFN-γ or TNF-α (DeMartini and Baldwin, 
1991). CD8+ T cells can also directly kill pathogen-infected cells by inducing rapid 
apoptosis, utilising either Fas/Fas ligand interaction which results in classical 
caspase-dependent apoptosis (Nagata and Golstein, 1995) or the granule exocytosis 
pathway, which involves release of perforin and granzymes (Henkart and Sitkovsky, 
1994). Studies in mice have shown that the perforin-based cytotoxicity of CD8+ T 
cells is the predominant effector mechanism employed by CD8+ T cells against a 
number of intracellular pathogens (Kagi et al., 1994a; Walsh et al., 1994; Nickell and 
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Sharma, 2000). Perforin is a pore-forming protein, which facilitates delivery of 
granzymes into the cytosol of target cells, and thus plays an essential role in 
lymphocyte-mediated cytotoxicity. Although the precis  delivery mechanism is still 
under debate, expression of perforin is absolutely required for killing by CTL granule 
exocytosis, as indicated by absence of killing activity in T cells from perforin-
deficient mice (Kagi et al., 1994b; Kojima et al., 1994; Lowin et al., 1994). Purified 
perforin alone has been shown to induce direct lysis of target cells under some 
conditions; however, induction of DNA damage of thesame cells only occurred in 
the presence of granzymes (Hayes et al., 1989; Shi et al., 1992a; Shi et al., 1992b). 
Granzymes, a subfamily of serine proteases, comprise a small group of enzymes (5 in 
human and 10 in mouse), with various primary substrate specificities. Granzyme A 
and B are the most abundant granzymes and have been studied in most detail. In 
vitro studies by the Lieberman group showed that purified human granzyme A 
induces target cell death via damage of the inner mitochondrial membrane and DNA 
nicking (Lieberman and Fan, 2003). However, the physiological significance of these 
findings remains controversial (Metkar et al., 2008; Trapani and Bird, 2008; Pardo et 
al., 2009), and several investigators have reported that granzyme A-deficient mice 
have no defect of CTL/NK-mediated cytotoxicity, suggesting that granzyme A does 
not play an essential role in cell mediated cytotoxicity (Ebnet et al., 1995; 
Mullbacher et al., 1996; Riera et al., 2000). In contrast, there seems to be little 
dispute that granzyme B is a potent inducer of apoptosis and an important mediator 
of cytotoxicity. In vitro studies have shown that granzyme B is critical for the rapid 
induction of target cell lysis and DNA fragmentation by CD8+ T cells generated 
from granzyme B-deficient mice (Heusel et al., 1994). Granzyme B induces 
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apoptosis by two main pathways: one involving direct activation of caspases and the 
other by triggering mitochondrial outer membrane permeabilization via cleaving the 
pro-apoptotic protein, BH3-interaction domain death gonist (Bid). The truncated 
Bid protein initiates mitochondrial-dependent apoptosis via activating Bax and/or 
Bak and promotes their oligomerization within the mitochondrial outer membrane, 
which results in permeabilization of mitochondria and release of cytochrome c 
(Kuwana et al., 2002). Recent studies have shown that the pathways utilised by 
granzyme B to mediate killing are species-dependent. Mouse granzyme B directly 
activates caspases to promote apoptosis, whereas human granzyme B acts by a Bid-
dependent pathway (Kaiserman et al., 2006; Cullen et al., 2007). Despite the finding 
that GzmA/B-deficient CD8+ T cells are defective inducers of classical apoptosis, 
they can still mediate target cell death in some systems, suggesting that other 
granzymes may be operating via alternative pathways (Simon et al., 1997; 
Mullbacher et al., 1999; Davis et al., 2001; Waterhouse et al., 2006).  
 
The studies described in this chapter, investigated th  role granule exocytosis and 
specifically granzyme B in killing of T. parva-infected target cells by testing a series 








6.2 Materials and Methods 
 
6.2.1 Animals and cell lines  
Selected CD8+ T cell clones established from two cattle (592 and 641) homozygous 
for the A10 or A18 class I MHC haplotypes were kindly provided by Dr Tim 
Connelley and Ms Victoria Carroll, respectively. An u -cloned CD8 T cell culture 
established from animal 011 was generated as describ d in section 2.2.4. Three 
autologous T. parva-infected cell lines, 641TPM (MHC A18/A18), 011TPM and 
592TPM (both MHC A10/A10), were used as infected target cells in cytotoxicity 
assays. T. annulata-infected cell lines from the same animals loading with a specific 
peptide epitope, 641TAA-pulsed-Tp1212-224 and 592TAA-pulsed-Tp249-59, were used 
to investigate killing of peptide-pulsed-target cells, as described in section 2.2.8.  
 
6.2.2 Inhibitors of proteins involved in the exocyt osis pathway 
Ten inhibitors specific for four molecules involved in the exocytosis pathway were 
used in this chapter. The properties of these inhibtors are shown in Table 6.1. 
Concanamycin A, CMA (SIGMA, Cat. C9705) is an inhibitor of perforin (PFN) 
activity. Four inhibitors of granzyme B were tested: GzmB inhibitor I (Calbiochem, 
Cat.368050), GzmB inhibitor II (Calbiochem, Cat.218773), GzmB inhibitor III 
(Calbiochem, Cat.218840) and GzmB inhibitor IV (Calbiochem, Cat.368056). They 
all contain short peptide sequences that bind to amino acids at the active sites of 
granzyme B and thus act as competitive inhibitors of enzymatic function. Of these, 
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GzmB inhibitor IV, used in previous experiments described in section 4.3.4, is a non-
cell-permeable competitive inhibitor containing a 4-amino acid sequence (IEPD). 
The other three granzyme B inhibitors tested are cell-permeable and also act as 
competitive inhibitors. GzmB inhibitor I contains a three-amino acid peptide (AAD) 
(Odake et al., 1991; Shi et al., 1992a), and GzmB inhib tor II and III have a same 4-
amino acid peptide (IETD). The IETD sequence in the latt r two inhibitors also binds 
to caspase 8 and has caspase 8 inhibitory activity (Thornberry et al., 1997; Harris et 
al., 1998; Martin et al., 1998; Sweeney et al., 1998). Caspase inhibitor I 
(Calbiochem, Cat.627610), containing a 3 amino acid peptide (AAD), is a broad 
competitive inhibitor of caspases, acting on several caspases involved in apoptotic 
pathways (Garcia-Calvo et al., 1998). It reacts with active sites on most caspases and 
irreversibly inactivates their activity; the negative control of caspase inhibitor I, 
cathepsin B inhibitor I (Calbiochem, Cat.342000), was also included (Sarin et al., 
1997). Bax, a pro-apoptotic member of the Bcl-2 family, plays an important role in 
mitochondrial-dependent apoptosis (Korsmeyer et al., 1999). It is activated via 
cleaving by truncated Bid protein and involved in inducing permeabilization of 
mitochondria and release of cytochrome c (Kuwana et al., 2002). Two inhibitors Bax 
Channel Blocker (Calbiochem, Cat.196805) and Bax-inhibiting Peptide, V5 











Table 6.1 Inhibitors tested in the current study and their properties 
Inhibitor 
Target 





PFN CMA NT - + - 
Inhibitor 
I 





































Bis TFA  3,6-Dibromocarbazole 
Piperazine Derivatives of 
2-Propanol  










BIP-NC H-IPMIK-OH - + NT 
+, yes, -, no; NT, not determined; NC, negative control; Amino acid sequence of 
the inhibitor peptide is highlighted in red. Z = benzyloxy-carbonyl group; AC = 
acetyl group; OMe = O-methyl ester group; CHO = aldehyde group; CMK = 
chloromethyl ketone; FMK = fluoromethyl ketone.  
 
 
6.2.3 Inhibition of enzymatic granzyme B activity i n CD8+ T cell 
lines 
The cell-permeable granzyme B inhibitors, GzmB inhibitor I, GzmB inhibitor II and 
GzmB inhibitor III (described above), were tested for their abilities to inhibit cattle 
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granzyme B activity in CD8+ T cell lines. Z-VAD-FMK, a pan-caspase inhibitor was 
used as negative control for the inhibition specificity, whereas a non-cell-permeable 
GzmB inhibitor IV, AC-IEPD-CHO, which was found to substantially inhibit cattle 
granzyme B activity in lysates in section 4.3.4, was used as a positive control.  
 
6.2.3.1 Inhibition of enzymatic granzyme B activity  in CD8+ T cell lines 
Aliquots of 1ml of CD8+ T cells adjusted to 1x106cells/ml were centrifuged at 180 x 
g for 10 min and re-suspended in 150ul SCM. Following addition of 50ul of each 
inhibitor to the CD8+ T cells (GzmB inhibitor I, 80uM; GzmB inhibitor II, 80uM; 
GzmB inhibitor III, 40uM; caspase inhibitor I, 80uM), the cells were incubated for 1 
hour in a humidified incubator in an atmosphere of 5% CO2 at 37°C. Cells were then 
washed, pelleted and lysed as described in section 5.2.5. In duplicate, aliquots of 
10ul of lysate supernatant, granzyme B substrate VIII, Ac-IEPD-pNA (Calbiochem, 
Cat.368067) at a final concentration of 200uM and the reaction buffer (0.1M Hepes, 
pH7.0; 0.3M NaCl; 1mM EDTA) in a total volume of 100ul/well were added into the 
wells of Falcon™ 96-Well Flat bottomed Microplates (BD, Cat. 353072). Mixtures 
were incubated at 37°C for 4h and the colour reaction generated by cleavage of the 
pNA (p-nitroaniline) substrate measured at a wavelength of 405nm by using a 
Synergy™ HT Multi-Mode Microplate Reader (BioTek).  
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6.2.3.2 Positive control - Inhibition of enzymatic granzyme B activity in 
lysates 
The inhibition of the enzyme in lysates (section 4.2.7) was used as a positive control 
for experiments with CD8+ T cell lines. The protocol was modified slightly as 
follows:  CD8+ T cells (1x106cells) were washed, pelleted and lysed as described in 
section 5.2.5. In duplicate, aliquots of 10ul of lysates were pre-incubated with 10uM 
GzmB inhibitor IV (Ac-IEPD-CHO) at 37°C for 30min. Granzyme B substrate VIII 
(Ac-IEPD-pNA) at a final concentration of 200uM and the reaction buffer were 
added to give a total volume of 100ul, which was incubated at 37°C for 4h. The 
colour reaction generated by cleavage of the pNA substrate was measured at a 
wavelength of 405nm by using a Synergy™ HT Multi-Mode Microplate Reader 
(BioTek). 
 
6.2.4 Cytotoxicity assay with inhibitors  
An 111In release cytotoxicity assay was used as described in section 2.2.8, but with 
some adaptations: 
 
6.2.4.1 Cisplatin-induced apoptosis  
Cisplatin, cis-diamminedichloroplatinum II, an important chemotherapeutic agents, 
has been shown to induce cancer cell death through apoptosis (Dive and Hickman, 
1991). The drug was kindly provided by Dr Kyoko Hayashida (Hokkaido University, 
Japan) and was used to induce cell lysis of Theileria-infected cells. Aliquots of 50ul 
of two-fold dilutions of cisplatin in SCM were distributed in duplicate into wells of 
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96-well V-bottomed plates to give concentrations ranging from 75uM to 2.4mM and 
100ul of 111In labelled target cells (5x105) was added to each well. Hence, the final 
concentration of cisplatin ranged from 25uM to 800uM. Spontaneous release and 
maximal release of isotope were determined by adding 100ul cytotoxicity medium 
and 100ul 0.2%Tween respectively to the 50ul aliquots of cells. After 4, 20, 24 and 
48 hour incubation, 75ul supernatant were harvested from each well and measured 
for radioactivity.  
 
6.2.4.2 CD8+ T cell-induced apoptosis  
Aliquots of 50ul of each inhibitor were pre-incubated in duplicate with 100ul effector 
cells (1x105-6.25x103 cells) or 50ul 111In labelled target cells (5x103 cells) for various 
times and at different concentrations as specified b low for the individual inhibitors. 
Following pre-incubation, aliquots of 100ul of effector cells or 50ul of 111In labelled 
target cells were added to wells containing pre-incubated target cells and effector 
cells respectively, to give a total volume of 200ul/well. Spontaneous release and 
maximal release from untreated target cells were det rmined by adding 150ul of 
cytotoxicity medium and 150ul 0.2% Tween 20 respectiv ly to 50ul aliquots of target 
cells. After 4-hour incubation, 100ul supernatant was harvested from each well and 
measured for radioactivity.  
 
For the inhibition of perforin activity, effector cells were pre-incubated with ten fold 
dilutions of CMA at final concentrations ranging from 0.1ug/ml to 1000ug/ml for 2 
hour at 37 °C. For the inhibition of granzyme B activity, effector cells were pre-
incubated for 1 hour at 37°C with the following inhibitors: GzmB inhibitor I (80uM); 
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GzmB inhibitor II (80uM), GzmB inhibitor III (40uM) and the negative control, 
caspase inhibitor I (80uM). For inhibition of caspae activity, 111In labelled target 
cells were pre-incubated with caspase inhibitor I (80uM) and the negative control, 
cathepsin B Inhibitor I (80uM) for 1 hour at 37°C. For inhibition of Bax activity, 
111In labelled target cells were pre-incubated for 1h at 37°C with 2 fold dilutions of 
Bax Channel Blocker at final concentrations ranging from 2.5uM to 20uM or Bax-
inhibiting Peptide, V5 and its negative control at final concentrations ranging from 


















6.3 Results  
 
6.3.1 Theileria-infected cell death induced by CD8+ T cells is 
mediated by granule exocytosis pathway  
To investigate whether killing of Theileria parva-infected cells by CD8+ T cell is 
mediated by granule enzymes, concanamycin A (CMA), an inhibitor of vacuolar type 
H+-ATPase was used (Kataoka et al., 1996). CMA induces degradation of perforin 
by raising the pH of the lytic granule in which acidification is essential for 
maintaining its structure and function (Kataoka et al., 1994). An uncloned CD8+ T 
cell line derived from animals 011 and 3 cloned CD8+ T cell lines from animal 592, 
harvested 7 days after the last antigen stimulation, were pre-incubated with various 
concentrations of CMA for 2 h and tested in a 4-hour cytotoxicity assay with [111In]-
labelled autologous Theileria-infected target cells. In preliminary experiments, these 
T cell lines were shown to kill autologous parasitized target cells but not MHC-
mismatched parasitized target cells and also killed Tp249-59 peptide-pulsed target 
cells, indicating that they are antigen-specific and MHC restricted (data not shown). 
CMA completely inhibited the cytolytic activity of all cell lines tested when added at 
concentrations of 10ng/ml or greater and had no effect on background release from 
the target cells indicating that it did not adversely affect their viability (Figure 6.1- A 
and B). The results indicate that the killing of bovine CD8+ T cells specific for T. 
parva-infected cells is dependent on perforin, implying that it is mediated by release 
of granule enzymes.  
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Figure 6.1 Inhibition of the cytotoxic activity of (A). an un-cloned CD8+ T cell 
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Effector with peptide-pulsed
target




An un-cloned CD8+ T cell line (1x105cells) from animal 011 was pre-incubated 
with various concentrations of CMA for 2h and tested in a 4-hour cytotoxicity 
assay with [111In]-labelled autologous 011TPM and MHC-matched (592) TAA-
infected target cells pulsed with TP249-59 peptide (1000ng/ml). Labelled target 
cells alone were also incubated with CMA in the assay. A standard effector to 

























Three cloned CD8+ T cell lines (2.5x104cells) from animal 592 were pre-
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incubated with various concentrations of CMA for 2h and tested in a 4-hour 
cytotoxicity assay with [111In]-labelled autologous 592TPM. The labelled target 
cells alone were also incubated with CMA in the assay. A standard effector to 
target ratio of 5:1 was used. 
 
 
6.3.2 Theileria-infected cell death induced by CTL granule 
exocytosis is granzyme B-dependent 
Although the capacity of the GzmB inhibitor IV, AC-IEPD-CHO to inhibit bovine 
granzyme B in cell lysates was successfully demonstrated in section 4.3.4, this 
inhibitor is inactive when added to viable cells due to its non-cell-permeable 
property. To address the problem, three additional cel -permeable granzyme B 
inhibitors (GzmB inhibitor I, GzmB inhibitor II and GzmB inhibitor III) were tested 
for their abilities to inhibit cattle granzyme B activity in two 641 CD8+ T cell clones 
(used in the previous experiments in section of 5.3.5). Z-VAD-FMK, a pan-caspase 
inhibitor, which has no effect on granzyme B activity and does not inhibit cytotoxic 
activity of human/mouse CD8+ T cells, was used as anegative control (Sarin et al., 
1996). GzmB inhibitor IV was included as a positive control in assays of CD8+ T 
cell lysates. Figure 6.2 shows the results of an experiment in which lysates of CD8+ 
T cells in the presence or absence of inhibitors were assayed for GzmB activity using 
a specific substrate assay. As demonstrated in section 4.3.4, the presence of inhibitor 
IV (AC-IEPD-CHO) dramatically reduced the granzyme B activity of the lysates of 
both clones to levels that were close to the background level obtained by addition of 
assay buffer alone to the substrate. The presence of GzmB inhibitors I and II had no 
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effect on the granzyme B activity in either of the clones. In contrast, GzmB inhibitor 
III reduced the activity of granzyme B activity in lysates from both CD8+ T cell lines 
by approximately 50%, indicating a capacity to inhibit cattle granzyme B enzymatic 
activity. The negative control inhibitor Z-VAD-FMK has no effect on cattle 
granzyme B activity, as observed in other species.  
 
Figure 6.2 Effect of pre-incubation with granzyme B inhibitors on the granzyme 































Two cloned CD8+ T cell lines (1x106cells) derived from animal 641 were pre-
incubated for 1 hour with indicated concentrations of GzmB inhibitors I, II and 
III and a negative control, Z-VAD-FMK, and tested in a 4-hour substrate assay.  
As a positive control, lysates of CD8+ T cell lines (1x106cells) were also pre-
incubated with GzmB inhibitor IV for 30min and tested in the same substrate 
assay.  
  
To further investigate the role of granzyme B in killing of target cells by T. parva-
specific CD8+ T cells, the GzmB inhibitors used above were pre-incubated for one 
hour with three 641 CD8+ T cell clones (including the two clones from which lysates 
were tested and one (641.20) that tended to have low levels of granzyme B content 
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but relatively strong killing as described in section 5.3.5) and tested in a 4-hour 
cytotoxicity assay with [111In]-labelled target cells. The 3 clones exhibited lvels of 
killing between 28% and 35% when assayed on autologous parasitized target cells at 
an effector to target ratio of 2:1). Preincubation with GzmB inhibitor III (40uM) 
completely inhibited the cytolytic activity of all CD8+ T cell lines and had no effect 
on the viability of the target cells, as indicated by low levels of spontaneous isotope 
release (Figure 6.3). GzmB inhibitors I and II and the negative control inhibitor (Z-
VAD-FMK) did not have any effect on killing by any of the CD8+ T cell lines. 
Hence, the inhibitory effects on viable CD8+ T cells are consistent with those 
obtained by testing CD8+ T cell lysates. Although GzmB inhibitor III is also an 
inhibitor of caspase 8, which is involved in an early stage of apoptosis in target cells, 
the lack of inhibition by the pan-caspase inhibitor Z-VAD-FMK, indicates that the 
GzmB inhibitor III is not acting via caspase 8.  
 
Figure 6.3 Effect incubation with GzmB inhibitors on the cytotoxic activity of 3 






























) 641 TPM vs 641.19
641 TPM vs 641.20
641 TPM vs 641.24
641 TPM
 
Three cloned CD8+ T cell lines (1x104cells) from animal 641 were pre-incubated 
for 1 hour with indicated concentrations of GzmB inhibitors and a negative 
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control, Z-VAD-FMK and tested in a 4-hour cytotoxicity assay with [111In]-
labelled autologous 641TPM target cells. The labelld target cells alone were 
also incubated with these inhibitors in the assay. A standard effector to target 
ratio of 2:1 was used 
 
Since GzmB inhibitor I (Z-AAD-CMK) had been shown to be effective at inhibiting 
human and murine granzyme B activity in lysates (Odake et al., 1991) and blocking 
cell apoptosis induced by granzyme B (Gorak-Stolinska et al., 2001; Saito et al., 
2008), further experiments were undertaken to test different concentrations of the 
inhibitor and different incubation times.  An un-cloned CD8+ T cell line established 
from animal 011 and both autologous infected target cells (011TPM) and peptide-
pulsed target cells (592TAA-pulsed-Tp249-59) were used.  Pre-incubation of the 
CD8+ T cells with various concentrations (ranging from 0.1uM to 100uM) of Z-
AAD-CMK for 0.5 hour had no inhibitory affect on the killing activity with either of 
the target cells (Figure 6.4- A). Pre-incubation times ranging from 0.5h to 4h also 
had no detectable effect on killing at any of the time points (Figure 6.4- B). The 
results show that GzmB inhibitor I, a known inhibitor for both human, mouse and rat 
granzyme B, has no effect on either cattle granzyme B activity or killing activity of 








Figure 6.4 Effect of GzmB inhibitor I, Z-AAD-CMK on  cytolytic activity of an 
un-cloned T. parva-specific CD8+ T cell line (A). after 0.5-h incubation and (B). 
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An un-cloned CD8+ T cells (1x105cells) from animal 011 was pre-incubated for 
0.5 hour or 4 hours with various concentrations of GzmB inhibitor I, Z-AAD-
CMK, and tested in a 4-hour cytotoxicity assay with [111In]-labelled autologous 
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011TPM and MHC-matched (592) TAA-infected target pulsed with TP249-59 
peptide (1000ng/ml). Z-VAD-FMK, the pan-caspase inhibitor, served as 
negative control. Labelled target cells alone were also incubated with Z-AAD 
and Z-VAD. A standard effector to target ratio of 20:1 was used. 
 
 
In conclusion, these findings reveal that the GzmB inhibitor III, Z-IETD-FMK 
specifically and effectively blocks the activity ofcattle granzyme B and also inhibits 
killing of target cells by bovine CD8+ T cells, indicating that granzyme B is an 
important mediator of killing of T. parva infected cells by specific CD8+ T cell.  
 
6.3.3 Theileria-infected cell death mediated by granzyme B is 
independent of caspases 
Granzyme B, implicated above in the killing of Theileria-infected cells by CD8+ T 
cells, has been shown in other species to act by caspase-dependent and/or caspase-
independent pathways (Lieberman, 2003). To examine the role of caspases in cell 
killing, experiments were undertaken to test the ability of the pan-caspase inhibitor 
Z-VAD-FMK and its control Z-FA-FMK to block killing. In contrast to previous 
experiments in which this inhibitor was pre-incubated with effector cells (as a 
negative control), these experiments involved pre-incubation with the target cells. 
Firstly, the ability of Z-VAD-FMK to block apoptosi of Theileria-infected cells  
induced by drug cisplatin, which causes apoptotic cell death in tumor cells (Sarin et 
al., 1997; Lau, 1999), was examined. Two parasitised cell lines, one infected with T. 
parva (468TPM) and one with T. annulata (641TAA) and two uninfected CD8+ T 
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cell clones (641.18 and 641.25) were used as target cells following incubation with 
various concentrations of cisplatin for a range of times (4h, 20h, 24h and 48h). Only 
one of the 4 lines (641TAA) showed significant cell lysis when tested in a 111In 
release assay, and cell death was not observed before 24 hour (Figure 6.5). Figure 
6.6- A and B show that cisplatin (100uM and 200uM) induced 20-30% cell death of 
641TAA after incubation of 24 hour and this was blocked specifically by Z-VAD-
FMK. A shortcoming of these experiments is that thelonger incubation periods 
resulted in high levels of spontaneous isotope releas  from the cell lines reducing the 
ability to detect specific lysis. Notably, this spontaneous release was partially 
inhibited by Z-VAD-FMK, suggesting that this spontaeous cell death was also 
caspase-dependent.  
 
Figure 6.5 Kinetic studies of the ability of the pro-apoptotic drug cisplatin to 

























111In-labelled T. annulata-infected cells (641TAA) (5x105/well) were incubated 
for indicated times (4h, 20h, 24h and 48h) with various concentrations of 
cisplatin and radioactivity released was measured. A further 3 cell lines, a T. 
parva-infected line 468TPM and two CD8+ T cell clones 641.18 and 641.25, were 
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also used as target cells in this experiment, but the cell viability of these lines 
beyond 4 hours was too low to give interpretable results. 
 
 
Figure 6.6 Inhibition of cytolysis of Theileria annulata-infected cells induced by 
cisplatin, by incubation with Z-VAD-FMK for 24 hour : (A). Cisplatin added at 



















































111In-labelled T. annulata-infected cells (641TAA, 5x105/wells) were incubated 
for 24 hour with cisplatin (100um or 200uM) in the presence or absence of Z-
VAD-FMK or Z-FA-FMK and radioactivity released was measured. Labelled 
target cells alone were also incubated with Z-VAD-FMK (80uM) or Z-FA-FMK 
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(80uM) for 24 hour and the values of cytotoxicity were -43% and -15% 
respectively.   
  
To examine the role of caspases in CD8+ T cell-mediat  killing, the same 111In-
labelled 641TAA target cell loaded with a specific peptide epitope was pre-incubated 
with Z-VAD-FMK (80uM) for 1 hour and tested in a 4-hour cytotoxicity assay with 
two epitope-specific CD8+ T cell clones (used in the previous experiment in section 
5.3.5). Inclusion of the perforin and granzyme B inhibitors (CMA and Z-IETD-
FMK) confirmed that killing by these cell lines is mediated by granule exocytosis; 
figure 6.7 shows that CMA completely blocked the cell d ath of both cell lines at 
10ng/ml and that Z-IETD-FMK dramatically reduced killing by about 70%. 
However, Z-VAD-FMK did not affect the killing activity of either CD8+ T cell clone. 
The inhibitors had no effect on the viability of the target cells in these assays. Thus, 
although Z-VAD-FMK specifically blocked lysis of Theileria-infected cells induced 
by the pro-apoptotic agent cisplatin, it had no inhibitory effect on the granzyme B-
dependent killing of T. parva-specific CD8+ T cell lines. In conclusion, these results 
suggest that granzyme B-mediated killing of Theileria-infected cells by specific 











Figure 6.7 Effect of a pan-capase inhibitor, Z-VAD-CMK, on the susceptibility 



























111In-labelled Tp1 peptide-pulsed target cells (641TAA + TP1214-224, 100ng/ml) 
was pre-incubated with Z-VAD-FMK (80uM) for 1h and tested in a 4-hour 
cytotoxicity assay with two Tp1-specific cloned  CD8+ T cell lines (1x104cells) 
from animal 641. As controls, effector cells pre-incubated with the perforin 
inhibitor CMA (10ng/ml) for 2h or the granzyme B inhibitor Z-IETD-FMK 
(40uM) for 1h were tested in the same experiment. Labelled target cell alone 
were also incubated with these inhibitors in the assay. A standard effector to 









6.4 Discussion  
 
The results of work described in this chapter provide evidence that killing of 
Theileria-infected cells by cattle CD8+ T cells is mediated by the granule exocytosis 
pathway and that cattle granzyme B plays a pivotal role for induction of cell death.  
Cytotoxicity of CD8+ T cell lines was completely abolished by concanamycin A, an 
inhibitor of perforin, which is membrane pore-forming protein released from 
cytolytic granules. An inhibitor (GzmB inhibitor IV, AC-IEPD-CHO) shown to 
inhibit granzyme B activity in T cell lysates was not tested on intact T cells, as it is 
known to be membrane-impermeable. However, one of 3 additional membrane-
permeable granzyme B inhibitors (GzmB inhibitor III, Z-IETD-FMK) was shown to 
inhibit the cytotoxic activity of CD8+ T cell lines by 70-100%. This compound 
functions as a competitive inhibitor that inhibits human and rat granzyme B 
(Thornberry et al., 1997; Harris et al., 1998) by binding to residues at P4-P3-P2-P1 
(amino-terminal to the proteolytic cleavage site) of active granzyme B, thus 
competitively blocking its enzymatic function. In contrast, another two inhibitors 
(Inhibitor I and II) had no inhibitory effect on bovine granzyme B. GzmB inhibitors 
II (AC-AAVALLPAVLLALLAP IETD-CHO) and III (Z-IE(OMe)TD(OMe)-FMK) 
contain the identical 4-amino acid sequence (IETD) to bind the active sites of 
granzyme B but Inhibitor III contains the ester groups (OMe) which contribute to cell 
permeability. Hence, poorer permeability of bovine cells might account for the lack 
of inhibitory activity of Inhibitor II. GzmB inhibitor I (Z-AAD-CMK) contains 
distinct amino acid sequence (AAD), which might be unable to bind effectively to 
bovine granzyme B. 
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Previous studies of mechanisms of killing by mouse CD8+ T cells showed that cells 
derived from granzyme B-deficient mice induced tumor cell lysis with reduced 
efficiency in a 4 hour 51Cr release assay but that levels of killing comparable to those 
obtained with wild-type CD8+ T cells could be achieved by incubation for 18 hours 
(Heusel et al., 1994). It revealed that granzyme B is required for the rapid induction 
of cell death and also suggested that other granzymes (eg. granzyme A) might be 
involved in the late onset killing. In the absence of gene knockout animals, 
determining the role of granzyme B in killing at different times is difficult. Although 
CD8+ T cells utilize pre-formed granule enzymes to kill target cells, de novo 
synthesis of granzyme B proteins occurs 4-6 hours after ntigen stimulation (Isaaz et 
al., 1995; Wolint et al., 2004) and therefore late onset killing initiated by newly 
synthesised granzyme B cannot be distinguished from that mediated by other 
granzymes. Moreover, the 111In release cytotoxicity assay used in our lab gave high
spontaneous isotope release from labelled target cells with longer incubation, 
increasing from under 10% at 4 h to 30-40% during 18- 24 hour, resulting in reduced 
sensitivity to detect specific lysis.  
 
Although activation of caspases was originally thought to be important in granzyme 
B-mediated cell death, studies by many groups reveal d that their requirement was 
not absolute. An in vitro study of mouse CD8+ T cells showed that apoptotic nuclear 
damage induced by granule exocytosis was abrogated by the caspase inhibitor Z-
VAD-FMK, whereas lysis of the cells was unaffected. In contrast, target cell lysis 
induced by the pro-apoptotic drug cisplatin was specifically blocked by this inhibitor 
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(Sarin et al., 1997). Similar results have been obtained in studies with purified human 
granzyme B, caspase inhibition preventing granzyme-induced DNA damage but not 
cell lysis (Trapani et al., 1998). These observations are consistent with the results of 
the present study, which showed that Z-VAD-FMK inhibited cisplatin-induced 
apoptosis of Theileria-infected cells, but did not inhibit granzyme B-mediated 
cytolytic activity of cattle CD8+ T cells, although DNA damage of the cells has not 
been examined. T. parva has been shown to protect infected cells from apoptosis by 
utilizing NF-κB activation to induce the expression of anti-apoptotic proteins such as 
FLIP, which functions as a catalytically inactive form of caspase-8, and X-
chromosome-linked inhibitor of apoptosis protein (XIAP) as well as c-IAP, which 
block caspase-9 and also downstream executioner caspase  (caspase 3 and 7) 
(Kuenzi et al., 2003). Studies by Guergnon et al. 2003 showed that drug-induced 
parasite death in Theileria-infected cells resulted in apoptosis involving activation of 
caspases 9 and 3 and was inhibited by Z-VAD-FMK (Guergnon et al., 2003). These 
findings demonstrated the requirement of the parasite for retaining cell viability and 
confirmed that the Z-VAD-FMK inhibitor is active in bovine cells. Inhibition of 
killing by T. parva-specific CD8+ T cell clones by GzmB inhibitor III in the current 
study demonstrates that T cell-mediated cell death (detected in a 4-hour assay) is 
dependent on granzyme B. As activation of caspases in the parasitized cells is tightly 
regulated by intracellular inhibitors induced by the NF-κB pathway, granzyme B is 
unlikely to break this regulation to fully activate caspases. The results strongly 
suggest that granzyme B bypasses the blockage and induces cell death by caspase-
independent mechanisms.  
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Further experiments were undertaken to test two inhibitors of Bax, which plays an 
important role in mitochondrial-dependent apoptosis. Unfortunately, these 
experiments did not provide informative data on the rol  for Bax in cell killing. One 
of the inhibitors (a Bax Channel Blocker) was found to be very toxic to T. parva-
infected cells, killing target cells in the absence of effector cells in a 4 hour 111In 
release cytotoxicity assay. The other inhibitor (BIP-V5) and its negative control 
(BIP-NC) did not affect the killing activity of two 641 CD8+ T cell clones used in 
the previous study in section 5.3.5 (data not shown). Although BIP had been shown 
to inhibit Bax-mediated apoptosis induced by anti-cancer drugs such as cisplatin in 
several types of human cells (Sawada et al., 2003), it had no effect on cisplatin-
induced cell death after incubation with parasitized c lls (641TAA) at concentrations 
of 100-200uM for 24 hour (data not shown). In addition to absence of lysis in a 4-
hour 111In release cytotoxicity assay, no evidence of apoptotic nuclear changes were 
detected by immunofluorescence staining with Hoechst dye (Sawada et al., 2003). 
There are several possible explanations for these findings. First, BIP which is 
described as an inhibitor for human, mouse, rat and porcine Bax, may be ineffective 
as an inhibitor in cattle. Secondly, Bax may not be essential for killing of Theileria-
infected cells by CD8+ T cells, other pro-apoptotic proteins possibly mediating 
mitochondrial-dependent apoptosis. A previous experiment has demonstrated that 
murine granzyme B induces mitochondrial depolarization and cell death in the 
absence of Bid, Bax and Bak in vitro (Thomas et al., 2001). As no inhibitors for 
other pro-apoptotic proteins are commercially available now, further work is required 
to determine whether the apparent resistance of T. parva-infected cells to apoptosis 
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induced by granzyme B is due to over-expression of anti-apoptotic proteins such as 
Bcl-2 (Davis et al., 2000).   
 
Recent studies have revealed that human and mouse granzyme B are functionally 
divergent with respect to their substrate preferences (Kaiserman et al., 2006; Cullen 
et al., 2007). GzmB inhibitor I (Z-AAD-CMK), an effective inhibitor for human and 
murine granzyme B in both cell lysates and live cells (Odake et al., 1991; Gorak-
Stolinska et al., 2001; Saito et al., 2008), has been shown to be ineffective at 
inhibiting bovine granzyme B. Sequence analyses described in section 3.3.6 revealed 
that key residues in granzyme B protein predicted to influence substrate recognition 
differed between the bovine, human and mouse proteins. Thus, although cattle 
granzyme B shares a high level of identity with human and mouse counterparts (72% 
and 69%, respectively) and is able to cleave a synthetic substrate AC-IEPD-pNA that 
has an optimal peptide recognition sequence (IEPD) for human granzyme B (section 











Chapter 7  General discussion 
 
It is well established that cytotoxic CD8+ T cells are important mediators of 
immunity against the bovine intracellular protozoan parasite T. parva. However, the 
mechanism by which the specific CD8+ T cells kill parasitized cells is not 
understood. Dissection of the mechanisms and host pr teins involved in killing by 
specific CD8+ T cells and how they may be regulated could be of value in designing 
vaccination protocols for inducing protective CD8+ T cell responses. In human and 
mouse, the predominant pathway used by CD8+ T cells to kill pathogen-infected 
cells is granule exocytosis, involving release of perforin and granzymes. Although 
bovine perforin has been described, there is to date a lack of published information 
on the identity and biological activities of bovine granzymes. The aim of this study 
was to determine the role of granule enzymes in mediating killing of T. parva-
infected cells, first by characterising the granzymes expressed by bovine 
lymphocytes and then by  investigating their involvement in killing of target cells, 
focusing particularly on the role of granzyme B. The work had three major outputs:  
 
1. Identification and genome annotation of granzyme genes expressed in cattle, 
including a novel granzyme not found in humans or mice.  
Six bovine granzyme genes (A, O, B, K, H and M) were identified by mining 
existing genomic and expression sequence tag databases. Specific PCR assays 
designed for amplification of the full length coding region of these granzyme genes 
were validated and used to demonstrate expression of transcripts for all of the genes 
in activated antigen-specific CD8+ T cells. Genome annotation revealed that the 
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genes were organised within 3 gene loci on separate chromosomes in a similar 
manner to the human and murine genes. Inter-species comparative analysis of their 
nucleotide and amino acid sequences was undertaken o infer the likely enzymatic 
specificities of the proteins. The 6 identified genes included one encoding a novel 
granzyme, termed granzyme O, found within the trypsin-like locus. This granzyme is 
most closely related to granzyme A. The detection of gene remnants in humans and 
mice showing similarity to the granzyme O gene indicates that this gene was present 
prior to species divergence but became non-functional in humans and mice. 
 
2. Successful development of molecular and biochemical methods to define the 
functional activities of bovine granzyme B. 
To investigate the role of granzyme B in killing byT. parva-specific CD8+ T cells it 
was necessary to establish methods to detect and quantify expression of bovine 
granzyme B protein. First, site-directed mutagenesis strategies, including PCR splice 
overlap extension and ‘megaprimer’ PCR, were used to produce DNA constructs 
encoding functional and non-functional forms of bovine granzyme B. Recombinant 
forms of these proteins were expressed in mammalian COS-7 cells and used with 
defined substrates to establish a biological assay to measure specific granzyme B 
activity. Initial experiments with known granzyme B inhibitors indentified one 
compound (AC-IEPD-CHO) that blocked the biological activity detected in this 
assay, confirming that it was attributable to granzyme B. Results obtained from these 
experiments confirmed that bovine granzyme B has the primary substrate specificity 
similar to that of its human and murine orthologues. This work is the first description 
of the biological activity of a member of the granzyme family in cattle and the 
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approach taken provides a system that could readily be applied to study other active 
bovine granzymes.  
 
3. Demonstration that granzyme B is an important mediator of the cytotoxic activity 
of CD8+ T cells specific for T. parva 
Initial experiments with the perforin inhibitor, concanamycin A, showed that 
cytotoxic activity of T. parva-specific CD8+ T cells is dependent on perforin, 
indicating that killing is mediated predominantly bthe granule exocytosis pathway. 
Moreover one of the granzyme B inhibitors tested, Z-IETD-FMK, which was shown 
to be an effective and specific inhibitor of bovine granzyme B in the substrate assay, 
dramatically inhibited killing by T. parva-specific CD8+ T cell clones, thus 
indicating a predominant role of granzyme B in cytotoxic activity of these T cells. 
Experiments in which granzyme B activity was measured in lysates and supernatants 
of T. parva-specific CD8+ T cell clones, using the specific substrate assay, revealed 
a significant correlation of granzyme B protein expression and its release upon 
incubation with target cells with the levels of killing of different T cell clones. 
However, this correlation was not absolute, suggesting that other factors that vary 
between T cells clones (possibly other granzymes) contribute to the cytotoxic activity 
of CD8+ T cells. Further studies showed that granzyme B-mediated death of T. 
parva-infected cells is independent of caspases. This is consistent with previous 
findings with some human and mouse CD8+ T cell models (Sarin et al., 1997; 
Trapani et al., 1998) and provides direct evidence for the important role of caspase-
independent pathway(s) in a non-human/non-murine species. These findings indicate 
that other pro-apoptotic proteins, most likely involved in mitochondrial-dependent 
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apoptosis, are required to be activated by bovine granzyme B for induction of cell 
death.  
 
This study represents the first dissection of the eff ctor mechanisms employed in 
killing of target cells by bovine CD8+ T cells and specifically provides the first 
evidence that granzyme B plays a key role in killing of T. parva-infected cells by 
specific CD8+ T cells. The findings are consistent wi h previous evidence that 
granzyme B is a potent inducer of apoptosis and an important mediator of 
cytotoxicity in human and mouse.  
 
Despite the evidence that granzyme B plays a central role in the killing of T. parva-
infected cells by CD8+ T cells, a number of questions remain concerning the precise 
mechanisms of killing and how the level of expression of granzyme B is regulated: 
 
(i) Which features of apoptosis are induced in T. parva-infected cells by bovine 
granzyme B? 
CD8+ T cell-induced cell death has classically been m asured as cytolysis using 51Cr 
release assays (Henkart et al., 1997), which have been considered to represent an 
apoptotic phenotype. The role of granzyme B in killing has been determined by 
testing specific inhibitors and/or by examining CD8+ T cells from gene knockout 
mice. The current study of CD8+ T cell-mediated killing of T. parva-infected T cells 
and the role of granzyme B relied on an 111In release assay, similar to the 51Cr release 
assay. By contrast, many of the experiments done to analyse the activities of 
granzyme B have studied the detailed cell biology of cells incubated with purified 
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granzyme protein along with sublytic concentrations of perforin. Using these 
systems, granzyme B has been shown to induce many cellular changes that can 
contribute to cell death, including rapid DNA fragmentation, chromatin 
condensation, membrane blebbing, phosphatidylserine (PS) exposure, mitochondrial 
membrane depolarisation and subsequent cytochrome c r lease, loss of inner 
mitochondrial membrane potential (∆Ψm), generation of reactive oxygen species 
(ROS) and membrane lysis (Shi et al., 1992a; Shi et al., 1992b; Nakajima et al., 
1995; Heibein et al., 1999; MacDonald et al., 1999). However, not all of these are 
required to result in cell death and different features may be induced in different 
target cells. Further more detailed studies are requi d to characterise which of these 
changes are induced in T. parva-infected cells by specific CD8+ T cells and the 
pathways activated by bovine granzyme B.  
 
(ii)  Does bovine granzyme B-mediated cytotoxicity require Bid?  
The pathways utilised by granzyme B to mediate killing are species-dependent.  
Mouse granzyme B directly activates caspases to promote apoptosis, whereas human 
granzyme B acts by a Bid-dependent pathway (Kaiserman et al., 2006; Cullen et al., 
2007). The evidence that granzyme B-mediated cell death of T. parva-infected cells 
is caspase-independent needs to be confirmed and, if so places the pro-apoptotic 
protein Bid as a candidate for future work to investigate mitochondrial-dependent 
pathways of apoptosis.  
 
(iii)  Do other granzymes cooperate with bovine granzyme B in achieving CD8+ T 
cell-mediating cell death?  
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Previous studies of human CD8+ T cells provided evid nce that other granzymes, 
such as granzyme A, H and M, cooperate with granzyme B in achieving CD8+ T 
cell-mediating cell death (Nakajima et al., 1995; Mahrus et al., 2004; Andrade et al., 
2007). Specific antibodies and/or biological assays for measuring other bovine 
granzyme proteins, as well as reagents to specifically inhibit their activities, would 
be required to investigate these interactions in cattle. The system used for eukaryotic 
expression of recombinant proteins in this study could be used for development of 
further biological assays or generation of specific antibodies. In the case of those 
granzymes where specific inhibitors are not commercially available, use of 
biochemical methods to synthesize the substrate specificity-based inhibitors would 
be desirable. Knock-down of gene expression could be considered as an alternative 
way, although the storage of granzyme proteins in pre-formed granules means that 
prolonged knockdown would be required. The function of Granzyme O, a novel 
functional granzyme in cattle, might be of interest in this regard, although further 
studies are required to determine the cell types in which this granzyme is expressed. 
 
(iv) Investigate cytokines involved in regulation of expression of granule enzymes 
in CD8+ T cells specific for T.parva  
The lack of cytotoxic activity of T. parva antigen-specific CD8+ T cells induced 
following prime-boost vaccination with defined antigens was reported by Graham et 
al (2006). One possible reason for this finding is that CD4+ T cells may be required 
for efficient induction and/or recall of the CD8 T cell response and that parasite-
specific CD4+ T cell responses were not induced by the vaccination protocol. A 
previous study involving co-culture of different combinations of purified CD4 T cells 
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and CD8 T cells from naïve and T. parva-immune calves suggested that CD4 T cells 
are required for efficient induction of CD8 T cell responses in vitro (Taracha et al., 
1997). Alternatively, the CD8+ T cell responses induced by vaccination may not 
have undergone appropriate functional differentiation and therefore were defective in 
expression of granule enzymes including granzyme B. Further work is required to 
investigate the functional properties of these respon es. Regulation of expression of 
granzymes and perforin in murine CD8+ T cells has been reported for IL-2, IL-4, IL-
12, IL-15 and IL-21 (Ye et al., 1996; Kienzle et al., 2002; Curtsinger et al., 2005; 
Zeng et al., 2005). Of these, provision of IL-12 as a third signal to the T cells (ie, in 
addition to TCR engagement and IL-2 co-stimulation), was found to promote 
development of full cytolytic function of CD8+ T cells and enhanced levels of 
granzyme B protein expression (Curtsinger et al., 2005). The current study has 
provided some of the tools to examine the levels of expression of granzyme B and 
other granzymes in different populations of CD8+ T cells and to investigate whether 
their expression is influenced by one or more cytokines.  
 
(v) Does T. parva enhance resistance to granzyme B-mediated cell death by 
upregulating of PI-9 in host cells? 
Previous studies have provided evidence thatT. parva protects infected cells from 
Fas/Fas ligand-induced apoptosis by upregulating a umber of anti-apoptotic proteins 
(Guergnon et al., 2003; Kuenzi et al., 2003). Recent studies have proposed that some 
tumour cells up-regulate PI-9 expression in order to evade the immune system 
(Medema et al., 2001; Bladergroen et al., 2002; ten B rge et al., 2002; van Houdt et 
al., 2005; Bossard et al., 2007). PI-9 acts as an endogenous inhibitor of human 
 221 
granzyme B and protects CTL itself against the actions of misdirected granzyme B 
(Sun et al., 1996; Bladergroen et al., 2001; Buzza et l., 2001; Hirst et al., 2001; Bird 
et al., 1998). The present study has demonstrated that T. parva-infected cells contain 
abundant transcripts for PI-9. Future work is required to examine the relative 
susceptibility of T. parva-infected and comparable uninfected target cells to CD8+ T 
cell-mediated killing (using defined peptide epitopes) and to determine whether 
expression of PI-9 in T. parva-infected cells enhances their resistance to granzyme 
B-mediated killing in comparison to uninfected target cells. 
 
In summary, the results presented in this study have established a system to further 
characterise the granzyme family in cattle and have demonstrated that cytotoxic 
activity of T. parva-specific CD8+ T cells is mediated by the granule exocytosis 














Chapter 8   Appendices 
 
8.1 Appendix A - Nucleotide sequences and intron-ex on structures of individual bovine granzyme 
genes  
 



















Granzyme A    Start Stop Length Splice sites Coding region UTR   
 Ori   Chromosome       Length Start Stop 
Exon 1 Rev 1 104 20 25672789 25672723 67   1 67 37 25672826 25672790 
Intron1        GTAAG AATAG      
Exon 2 Rev 105 243 20 25669217 25669079 139   68 206    
Intron 2        GTAAG TTCAG      
Exon 3 Rev 244 385 20 25667305 25667164 142   207 348    
Intron 3        GTACA AACAG      
Exon 4 Rev 386 655 20 25666965 25666696 270   349 618    
Intron 4        GTAAG CCAAG      
Exon 5 Rev 656 1501 20 25664708 25664547 162   619 780 684 25664546 25663863 
Gene A is reverse strand and locates in Chromosome 20: 25, 672,826-25,663,863. One transcript in this gene which consists of 5 exons has 
been identified and the length of cDNA and amino acid is 1501bp and 259residues, respectively.  
 














Granzyme O    Start Stop Length Splice sites Coding region UTR   
 Ori   Chromosome      Length Start Stop 
Exon 1 Rev 1 94 20 25689314 25689254 61   1 61 33 25689347 25689315 
Intron1        GTAAG TACAG      
Exon 2 Rev 95 242 20 25687153 25687006 148   62 209    
Intron 2        GTAAG TCAG      
Exon 3 Rev 243 384 20 25684037 25683896 142   210 351    
Intron 3        GTAAA TCTAG      
Exon 4 Rev 385 657 20 25680558 25680286 273   352 624    
Intron 4        GTAAG TTCAG      
Exon 5 Rev 658 951 20 25678856 25678704 153   625 777 141 25678703 25678563 
Gene J is reverse strand and locates in Chromosome 20: 25,689,347-25,678,563. One transcript in this gene which consists of 5 exons has 
been identified and the length of cDNA and amino acid is 951bp and 258residues, respectively 
 














Granzyme B    Start Stop Length Splice sites Coding region UTR   
 Ori   Chromosome      Length Start Stop 
Exon 1 Rev 1 147 21 34986649 34986595 55   1 55 92 34986741 34986650 
Intron1        GTGAG TTCAG      
Exon 2 Rev 148 295 21 34985351 34985204 148   56 203    
Intron 2        GTGAG CACAG      
Exon 3 Rev 296 431 21 34984717 34984582 136   204 339    
Intron 3        GTAAA CACAG      
Exon 4 Rev 432 689 21 34984384 34984127 258   340 597    
Intron 4        GTGAG CTCAG      
Exon 5 Rev 690 929 21 34983497 34983354 144   598 741 96 34983353 34983258 
Gene B is reverse strand and locates in Chromosome 21: 34,986,741-34,983,258. One transcript in this gene which consists of 5 exons has 
been identified and the length of cDNA and amino acid is 929bp and 246residues, respectively. 
 














Granzyme H    Start Stop Length Splice sites Coding region UTR   
 Ori   Chromosome      Length Start Stop 
Exon 1 For 1 104 21 34903703 34903756 54   1 54 50 34903653 34903703 
Intron1     1022   GTGAG TTCAG      
Exon 2 For 105 265 21 34904779 34904939 161   55 215    
Intron 2     529   GTGAG TGCAG      
Exon 3 For 266 401 21 34905469 34905604 136   216 351    
Intron 3     201   GCAAG ATCAG      
Exon 4 For 402 659 21 34905806 34906063 258   352 609    
Intron 4     379   GTCAG CACAG      
Exon 5 For 660 918 21 34906443 34906586 144   610 753 115 34906587 34906701 
Gene H is forward strand and locates in Chromosome 21: 34,903,653-34,906,701. One transcript in this gene which consists of 5 exons has 



















Granzyme K    Start Stop Length Splice sites Coding region UTR   
 Ori   Chromosome      Length Start Stop 
Exon 1 Rev 1 124 20 25737822 25737759 64   1 64 60 25737882 25737823 
Intron1        GTAAG GGCAG      
Exon 2 Rev 125 272 20 25737487 25737340 148   65 212    
Intron 2        GTGAG TTTAG      
Exon 3 Rev 273 423 20 25730684 25730534 151   213 363    
Intron 3        GTATG GTCAG      
 
 
 VII  
Exon 4 Rev 424 693 20 25729762 25729493 270   364 633    
Intron 4        GTAAG TCCAG      
Exon 5 Rev 694 1214 20 25727647 25727486 162   634 795 359 25727485 25727127 
Gene K is reverse strand and locates in Chromosome 20: 25,737,882 to 25,727,127. One transcript in this gene which consists of 5 exons 
has been identified and the length of cDNA and amino acid is 1214bp and 264residues, respectively.  
 
(f). Granzyme M: Full length nucleotide sequence: 
                                                                            -7 -6 -5 -4 -3 -2 -1 +1                                                                                               
                                                                            GlyAsnThrPheGluThrHisIleIleGlyGly                                 










Granzyme M    Start Stop Length Splice sites Coding region UTR   
 Ori   Chromosome      Length Start Stop 
Exon 1 For 1 68 7 42307080 42307119 68   1 40 28 42307052 42307079 
 
 
 VIII  
Intron1        GTGAG CCCAG      
Exon 2 For 69 231 7 42310514 42310676 163   41 203    
Intron 2        GTGAG CCCAG      
Exon 3 For 232 367 7 42311421 42311556 136   204 339    
Intron 3        GTGCT TATAG      
Exon 4 For 368 631 7 42311717 42311980 264   340 603    
Intron 4        GTGCG CACAG      
Exon 5 For 632 954 7 42312383 42312556 323   604 777 149 42312557 42312705 
Gene M is forward strand and locates in Chromosome 7: 42,307,052 to 42,312,705. One transcript in this gene which consists of 5 exons 
has been identified and the length of cDNA and amino acid is 954bp and 258residues, respectively.  
 
 




8.2 Appendix B- Comparison of bovine, human, murine and pig 
nucleotide sequences 
 
(a). Granzyme A 
 
            1          11         21         31         41         51                    
            .          .          .          .          .          .                    
BovineGZMA  ATGAGGAACT CCTCTACCTT TCTGGCAGCC ACTCTCTCAA TTGTCGTTTT TCTCCT---A 
HumanGZMA   .......... ...A..GA.. .......T.. T........G .........C ......GCT. 
MurineGZMA  .........G .....GGTCC C.G..GGC.A T....TG.T. C.C..C.... ...T..GCTT 
 
            61         71         81         91         101        111 
            .          .          .          .          .          .  
BovineGZMA  ATTCCTGAAG ATCTCTGTGA AAAAATTATT GGAGGAAATC AAGTGACTCC TCATTCAAGA 
HumanGZMA   .......... ..G....... .......... .........G ....A..... .......... 
MurineGZMA  .......... GAGG...... ..G...C... ......G.CA CG..TGT... ...C...... 
 
            121        131        141        151        161        171 
            .          .          .          .          .          .  
BovineGZMA  CCCTACATGG TGCTACTT-- ----GATGGG GGAAACATCT GTGCCGGAGC TTTGATTGCC 
HumanGZMA   .......... .C......AG TCTT..CA.A AA..C..... ....T..G.. .........A 
MurineGZMA  ..G..T.... CT......AA ACTTAG.TCA AAT.C..... ....T..C.. ........AA 
 
            181        191        201        211        221        231 
            .          .          .          .          .          .  
BovineGZMA  AAAGACTGGG TATTGACTGC AGCTCACTGT TCCCTGAACC AGAAATCCCA GATCATTCTT 
HumanGZMA   .......... .G........ .......... AA.T.....A .A.GG..... .G........ 
MurineGZMA  ..GA...... .G........ T..C...... AA.G..GGAA ...G...TA. .T........ 
 
           241        251        261        271        281        291 
            .          .          .          .          .          .  
BovineGZMA  GGGGCCCACT CAAGAAACAA GGAAGAGCCT GAAAAACAGA TTATGTTTGT TAAGAAAGAG 
HumanGZMA   .....T.... ...T..C..G .........A AC........ .A...C.... .......... 
MurineGZMA  .....T.... ...TC..T.. .---.....A ...C...... .AT..AC... ........CA 
 
            301        311        321        331        341        351                               
            .          .          .          .          .          .                                                                                          
BovineGZMA  TTTCCCTATC CATGCTATGA CCCGGACACA CATGAAGGCG ATCTTAAACT TCTAAAGCTG 
HumanGZMA   .......... .......... ...A.C.... .GC.....T. .C........ .T..C..... 
MurineGZMA  .......... .......... TGAAT.T... .G...G..G. ....AC.... .G..CG...A 
 
            361        371        381        391        401        411 
            .          .          .          .          .          .  
BovineGZMA  AACAAAAAAG CAACACTTAA TAAAAACGTG GCTATCCTTC AGCTCCCAAA AGAGGGCAAA 
HumanGZMA   .TGG...... ...A.A.... C...T.T... A......... .T..A..T.. .A....GG.C 
MurineGZMA  ..G....... .....G.... C.G...T... .......... .C..A..T.. .A....AG.T 
 
            421        431        441        451        461        471 
            .          .          .          .          .          .  
BovineGZMA  GATGTGGAAC CAGGAACTGC ATGTCGAGTT GCAGGGTGGG GACAGTTTTA CAATAATTCC 
HumanGZMA   ......A... .......CAT G..C.A.... .......... .CAG.AC.C. .....G.G.A 
MurineGZMA  ......A... .......CAG ...C.....A .....A.... .GAGA...GG ......G..A 
 
           481        491        501        511        521        531 
            .          .          .          .          .          .  
BovineGZMA  CCTGTGT CCAAGATTTT GAGAGAAGTC AATGTCACCA TCATAGACAG AAAAATCTGCAAT 
HumanGZMA   T..TG.. ..G.T.C.C. .......... ...A...... .......... ....G........ 
MurineGZMA  G..CCC. .TG.A.C.C. .......... ..CA....TG .......... ............. 
 
            541        551        561        571        581        591 
            .          .          .          .          .          .  
BovineGZMA  GATCAAT CACACTATAA TTATAATCCT GTGATTGGAC TGAATATGAT TTGTGCTGGAAGC 
HumanGZMA   ....G.A AT........ ..T...C... .........A ........G. ............. 
MurineGZMA  ...G..A A......... ..T.C..... ..A....... .A..C..... ......A..GGA. 
 
            601        611        621        631        641        651 
 
 
 II  
            .          .          .          .          .          .  
BovineGZMA  CTCCAAG GTGGAAAAGA CTCCTGCCAT GGAGATTCTG GAAGCCCTCT GATATGTAAAGAC 
HumanGZMA   ....G.. ......G... ...G...A.. .......... ........T. .T.G..CG.G.GT 
MurineGZMA  ....GT. .......G.. .......A.. ..G....... .C........ .C.....G.T.GT 
 
            661        671        681        691        701        711 
            .          .          .          .          .          .  
BovineGZMA  ACTTTCA GAGGCATCAC TGCCTTTGGC ATTCCGGGGA GATGTGGAGA CCCTCGAGGGCCC 
HumanGZMA   GT....C ....GG.... .T........ C..GAAAAT. A...C..... ......T.....T 
MurineGZMA  .T...GC .......... CT.T.....- --.GGA.A.. AG........ T.GC...T....T 
 
            721        731        741        751        761        771 
            .          .          .          .          .          .  
BovineGZMA  GGCGTCT ATACACTTCT CTCAAAGAAA CACCTCAACT GGATAGTTAA GACTATGAAGCAA 
HumanGZMA   ..T.... ...TT..... .......... .......... .....A...T ......C...GG. 
MurineGZMA  ..T.... ....TT.C.. ....G.T... ........T. .....AAG.. ..T.......GGT 
 
           781        791        
            .          .           
BovineGZMA  GCAGTTT AA 
HumanGZMA   ....... .. 
MurineGZMA  T.T..G. .. 
 
(b). Granzyme O  
 
                1          11         21         31         41         51                    
                .          .          .          .          .          .       
BovineGZMO ATGAATATTC CTTTTCCTTT CTCTTTTCCT CCTGCCATTT GTCTCCTTCT AATTCCTGGA 
PigGzmO    ...G.A.... .......... ..T....... G.......G. ........A. .......... 
 
61         71         81         91         101        111 
                .          .          .          .          .          .  
BovineGZMO GTTTTTCCAG TATCCTGCGA GGGAATTATA GGAGGAAATG AAGTGGCCCC TCACACAAGA 
PigGzmO    .......... .......T.. C......... .......... .....T.A.. C........G 
 
                121        131        141        151        161        171 
                .          .          .          .          .          . 
BovineGZMO CGCTACATGG CTCTAATCAA AGGGCTGAAA CTCTGTGCAG GGGCTTTAAT CAAAGAAAAC   
PigGzmO    .......... ..T....TG. .......... G......... .......G.. .......... 
 
                181        191        201        211        221        231 
                .          .          .          .          .          . 
BovineGZMO TGGGTGTTGA CAGCCGCTCA TTGTGACCTG AAGGGCAATC CTCAAGTTAT TCTTGGGGCC 
PigGzmO    .......... ....T..... C......... ..A.....C. .......... ......A... 
 
                       241        251        261        271        281        291 
                .          .          .          .          .          .  
BovineGZMO CACTCTACAT CCCATAAAGA GAAACTTGAC CAAGTATTTT CCATTAAAAA GGCAATTCCC 
PigGzmO    .......... .......... ....TA.... ..GAC..... .......... .........T 
 
                301        311        321        331        341        351                              
                .          .          .          .          .          .      
BovineGZMO TACCCATGCT TTGATCCACA GACATTTGAA GGGGATCTTC AACTACTTCA GCTGGAAGGT 
PigGzmO    ..T.....T. .......... .......... .......... .G..G..... .......... 
   
                361        371        381        391        401        411 
                .          .          .          .          .          .  
BovineGZMO AAAGCAACTA TGACCAAAGC TGTAGGAATA CTTCAGCTAC CAAGAACAGA AGACGATGTC 
PigGzmO    .......... .......... .......... ...A...... .C.AC....G .A.A...... 
 
                          481        491        501        511        521        531 
                .          .          .          .          .          .  
BovineGZMO AAACCCCACA CCAAGTGTCA TGTGGCAGGA TGGGGAAGCA CCAAAAAAGA CGCATGTCAA 
PigGzmO    G......... .......... .......... .......... ...G...... .T.G..CA.. 
 
541        551        561        571        581        591 
                .          .          .          .          .          .  
BovineGZMO ATGTCTAATG CCTTGAGAGA AGCCAACGTT ACAGTGATAG ATAGGAAAAT ATGCAATGAT 




 III  
                601        611        621        631        641        651 
                .          .          .          .          .          .  
BovineGZMO GCCCAGCACT ATAATTTTAA TCCAGTTATT GATCTCAGTA TGATCTGTGC TGGTGGTAGA 
PigGzmO    .......... .......... .......... ..C..TG... .......... A.T....... 
 
661        671        681        691        701        711 
                .          .          .          .          .          .  
BovineGZMO AAAGGTGAAG ATGATTCATG TGAAGGGGAT TCTGGAAGTC CTCTGATATG TGATAATGTT 
PigGzmO    .......... .......... ......A... .......... .......... ...C..CA.. 
 
721        731        741        751        761        771 
                .          .          .          .          .          .  
BovineGZMO TTCAGAGGTG TCACTTCCTT TGGCAAGTGT GGTAATCCCC AGAAGCCTGG CATCTACATC 
PigGzmO    ........G. .......... ...G...... .....C.... .......... .G.......T 
 
                     781        791        801        811        821        831 
                .          .          .          .          .          . 
BovineGZMO CTCCTTACCA AAAAACACCT CAACTGGATA AAGAAAACCA TTGCAGGAGC CATATAA 
PigGzmO    .....C.... .......... .......... .......... .......... ......G 
 
 
(c). Granzyme B  
 
           1          11         21         31         41         51 
           .          .          .          .          .          . 
BovineGZMB ATGAAGCCTC TCCTGCTCCT GGTGGCCTTT CTCCTGACCC CCAGGGCAAA GGCAGGGGAG 
HumanGZMB  ...C.A..AA .......T.. .C.......C ......CTG. ........G. T......... 
MurineGZMB ......ATC. .......A.. .C..A....G TCT...G..T .....A.... .......... 
 
           61         71         81         91         101        111 
           .          .          .          .          .          . 
BovineGZMB ATCATCGGGG GCCATGAAGC CAAGCCCCAC TCCCGCCCCT ACATGGCATA TCTTCAGTAC 
HumanGZMB  .......... .A.....G.. .......... .......... .......T.. ....AT.AT. 
MurineGZMB .......... .A.......T .......... ..T..A.... .......C.T A...TC.AT. 
 
           121        131        141        151        161        171 
           .          .          .          .          .          . 
BovineGZMB TGGAATCAGG ATGTCCAGAG TAGGTGCGGT GGGTTCCTGG TTCGACAGGA CTTCGTGCTG 
HumanGZMB  ...G.....A .GTCT.T..A G......... ..C......A .A...G.C.. .......... 
MurineGZMB AA.G.....C .GCCTG..GC G.TA..T..G ..C.....TA .....G.... ...T...... 
 
           181        191        201        211        221        231 
           .          .          .          .          .          . 
BovineGZMB ACAGCCGCTC ACTGCAACGG AAGCTCAATC AAAGTCACCC TGGGGGCCCA CAACATCAAA 
HumanGZMB  .....T.... ....TTGG.. ......C..A ..T......T .......... ...T...... 
MurineGZMB ..T..T.... ....TG.A.. ...TAT...A ..T.....TT .......... .......... 
 
           241        251        261        271        281        291 
           .          .          .          .          .          . 
BovineGZMB CAGCAGGAGA GGACCCAGCA GGTCATCAGG GTGAGAAGAG CCATCAGCCA CCCTGACTAT 
HumanGZMB  G.A......C C......... .T.T...CCT ....A....C .....CC... T..A.C.... 
MurineGZMB G.A....... A......... A......CCT A..GT..A.T G...TCC... ...A...... 
 
           301        311        321        331        341        351 
           .          .          .          .          .          . 
BovineGZMB AATCCTAAGA ACTTCTCCAA CGACATCATG TTATTAAAGC TGGAGAGAAA GGCCAAGCAG 
HumanGZMB  .......... .......... .......... C..C.GC... .......... ........G. 
MurineGZMB .......... CA........ T......... C.GC...... ..A....T.. .......AG. 
 
           361        371        381        391        401        411 
           .          .          .          .          .          . 
BovineGZMB ACATCAGCTG TGAAGCCCCT TAGTCTGCCC AGGGCCAAGG CCCGGGTGAA GCCAGGACAG 
HumanGZMB  ..CAG..... ..C....... C..G..A..T ..CAA..... ...A...... ......G... 
MurineGZMB ..TAG..... ...G...... C.AC...... ...CG...T. T.AAT..... .......G.T 
 
           421        431        441        451        461        471 
           .          .          .          .          .          . 
BovineGZMB ACGTGCAGCG TGGCCGGCTG GGGG---AGG GACTCCACGG ACACCTACGC TGACACACTA 
HumanGZMB  ..A.....T. .......... ....CAG.C. .C.C..CT.. GA.AAC..T. AC........ 





           481        491        501        511        521        531 
           .          .          .          .          .          . 
BovineGZMB CAGGAGGTAA AGCTGATCGT GCAGGAGGAT CAAAAGTGTG AGGCCTACTT ACGCAACTTT 
HumanGZMB  ..A.....G. ..A...CA.. ......A... .G......C. .AT.TG.... ....C.T.A. 
MurineGZMB ..A.....TG ......CA.. A...A..... .GGG...... ..T....... TAAA..TCG. 
 
           541        551        561        571        581        591 
           .          .          .          .          .          . 
BovineGZMB TATAACCGCG CCATCCAGCT GTGTGTGGGG GACCCAAAGA CAAAGAAAGC TTCCTTTCAG 
HumanGZMB  ..CG..A.TA ....TG..T. ...C...... ......G... TT..A..GA. .......A.. 
MurineGZMB ..C...AAAA ...AT...A. A....C.... .......... .C..ACGT.. ........G. 
 
           601        611        621        631        641        651 
           .          .          .          .          .          . 
BovineGZMB GGGGACTCGG GGGGCCCTCT CGTGTGTGAC AATGTGGCCC AGGGCATTGT CTCTTATGGA 
HumanGZMB  ........T. .A........ T......A.. ..G....... .......... ...C...... 
MurineGZMB .....T..T. .A.....G.. T......A.A ..A.....TG CA.....A.. T..C...... 
 
           661        671        681        691        701        711 
           .          .          .          .          .          . 
BovineGZMB AAAAGAGATG GATCAACTCC ACGGGCCTTC ACCAAAGTCT CAAGTTTCCT GCCCTGGATA 
HumanGZMB  CG..ACA... .CATGC.... ...A....G. .......... ....C..TG. A.A....... 
MurineGZMB T.T.AG.... .T...C.... ...T..T... .......... .G......T. AT........ 
 
           721        731        741 
           .          .          .         
BovineGZMB AAGAAAACCA TGAAAAGCCT CTGA 
HumanGZMB  .......... .....C..TA ..A. 
MurineGZMB ........A. ........AG ..A. 
 
(d). Granzyme H  
 
           1          11         21         31         41         51 
           .          .          .          .          .          . 
BovineGZMH ATGCAGCTAC TCCTGCTCCT GATGGCCTTT CTTCTGCCTC CTGGG-CTGG GAGAGCCTTT 
HumanGZMH  .......C.T ....C..... .T........ ......A.C. .....G.... ..C..----- 
 
           61         71         81         91         101        111 
           .          .          .          .          .          . 
BovineGZMH TCTTTCAGAG GAGATCATTG GGGGCCATGA GGCCAAGCCC CACTCCCGCC CCTACATGGC 
HumanGZMH  --------.. ........C. .......... .......... .......... .......... 
 
           121        131        141        151        161        171 
           .          .          .          .          .          . 
BovineGZMH TTTCGTTCAG TTTCTGGGTG AGAAGAGTTG GAAGAGGTGT GGCGGTGTTC TCATACAAAA 
HumanGZMH  C..T...... ......CAA. ........C. .......... .....CA.C. .AG.GAG... 
 
           181        191        201        211        221        231 
           .          .          .          .          .          . 
BovineGZMH AGACTTTGTT CTGACAGCTG CTCACTGCAG AGGAAGCTCA ATCAATGTCA CCCTGGGGGC 
HumanGZMH  G........G .......... ........CA G........C ..A....... ..T....... 
 
           241        251        261        271        281        291 
           .          .          .          .          .          . 
BovineGZMH CCACAACATC AAACAGCAGG AGAGGACCCA ACAGGTCATC CAGGTGAAAA GAGCCATCCA 
HumanGZMH  ......T... ..GG.A.... ..C....... G...T.T... .CT....... ..C......C 
 
           301        311        321        331        341        351 
           .          .          .          .          .          . 
BovineGZMH CCACCCAGAC TATAATCCTA AGACCTTCTC CAACGACATC ATGTTACTGC AGCTGGAGAG 
HumanGZMH  ...T....C. .......... ...A...... .......... ...C...... .......... 
 
           361        371        381        391        401        411 
           .          .          .          .          .          . 
BovineGZMH AAAGGCCAAG CAGACATCAG CTGTGAAGCC CCTTAGTCTG CCCAAGGCCA AGGCCCAGGT 
HumanGZMH  .......... TG...CA... .....CG... T..C..G..A ..T.GCAG.. .......... 
 
           421        431        441        451        461        471 
           .          .          .          .          .          . 
BovineGZMH GAAGCCAGGA GAAGTGTGCA GTCTGGCCGG CTGGGGGAAG GTGGCCCTGG GCACTCCAGC 





           481        491        501        511        521        531 
           .          .          .          .          .          . 
BovineGZMH CACCACCCTG CAGGAGGTAG AGCTGACGGT TCAGGAGGAT CGGGTGTGTG AATCACTCAA 
HumanGZMH  A.....A... .....A..GT T......A.. G...A....C T.CCA..... ..CGT...TT 
 
           541        551        561        571        581        591 
           .          .          .          .          .          . 
BovineGZMH CCCCAGGAAC TACAGTCGGG CCACCCAGAT TTGTGTCGGG GACCCAAGGA AGGTGAAAAC 
HumanGZMH  ..ATG.C..T .....CA.A. ....TG.... ......G... ..T....A.. ..ACAC.G.. 
 
           601        611        621        631        641        651 
           .          .          .          .          .          . 
BovineGZMH CGGCTTCAAG GGTGACTCCG GTGGACCCCT CGTGTGTAAA AAAGTGGTCC ATGGTATTTT 
HumanGZMH  ...T...... ..G....... .G..G..... .........G G.C..A.C.. .A......C. 
 
           661        671        681        691        701        711 
           .          .          .          .          .          . 
BovineGZMH CTCCTATGGA AAGACGAATG GGACACCTCC AGGAGTCTTC ACCCAGGTCT CACACTTCCT 
HumanGZMH  .......... ..C.AA..A. .......... ........A. .T.A...... .......... 
 
           721        731        741        751 
                            .          .          .          . 
BovineGZMH ACCCTGGATA AAGAGAACAA TGAAGCACCT CTAA 
HumanGZMH  G......... .......... ......G... .... 
 
(e). Granzyme K  
 
           1          11         21         31         41         51                               
           .          .          .          .          .          .                                                                                          
BovineGZMK ATGACTAAGT TTTCTTCTTT TTTTCTATGT TTCCTACTAG CCGGGACTTA CATGACTCCA 
HumanGZMK  .......... .......C.. ..C...G.T. ......A... TT...G.... T.......AT 
MurineGZMK ...---.G.. .......A.G GGC...GGT. .C...GG.G. .T..CGT... T...T..T.. 
 
           61         71         81         91         101        111 
           .              .          .          .          .          .  
BovineGZMK GAGTGTTTCA ACATGGAGAT TATTGGAGGG AGAGAAGTGT CCCCTCACTC CAGGCCGTTT 
HumanGZMK  .T........ .T.....A.. .......... .A........ .A.....T.. ......A... 
MurineGZMK .........C .T.CT..A.. .......... ..G.....CC AG..G..T.. ......A... 
 
           121        131        141        151        161        171 
           .          .          .          .          .          .  
BovineGZMK ATGGCGTCCC TGCAGTATGG CGGCGACCAC ATCTGCGGGG GAGTGCTGAT CCATCCTCAG 
HumanGZMK  .....C...A .C........ ...AC.T... G.T..T..A. .T..T..... TG....A... 
MurineGZMK .........A .C.....CC. .A..A.G..T ..T..T..A. ....C..... ...C..A... 
 
           181        191        201        211        221        231 
           .          .          .          .          .          .  
BovineGZMK TGGGTGCTCA CAGCAGCCCA CTGCCACTTG CGGTTTGCCA AAAGCCAGTC TTCCAAAGTG 
HumanGZMK  ........G. .......... ......A.AT ......A... ..G....... .C...CT... 
MurineGZMK ........A. ....C..... ....T...CT T.....C... G.G....C.. .C...CC... 
 
           241        251        261        271        281        291 
           .          .          .          .          .          .  
BovineGZMK GTTTTAGGAG CACACTCTCT CTCAAAGAAT GAGGCCTCCA AGCAAACATT TGAGATTAAA 
HumanGZMK  ........C. .......... .......... .......... .A......C. G.....C... 
MurineGZMK .......... ....T..... T..C...... ...C..ATG. ....G..... ...A...... 
 
           301        311        321        331        341        351                               
           .          .          .          .          .          .                                                                                          
BovineGZMK AAATTCATAC GATTCCCAGG ATTTGCATTA GCCCCTAAAT CAAACGATAT TATGCTGGTT 
HumanGZMK  .....T.... C....T..A. .G..A...C. .AT...C... ....T..... C......... 
MurineGZMK ..G.....C. C....T..C. .C..CAG.CC .GTT.CGC.. .GC.T..C.. C......A.A 
 
           361        371        381        391        401        411 
           .          .          .          .          .          .  
BovineGZMK AAGCTTCACA CGGCCGCAAT ACTCAACAGA CATGTCCAAC TGCTCCACCC AAGGGCTAAA 
HumanGZMK  ........A. .A.......A ......T.A. ......A.GA ........AT ...AT.C... 
MurineGZMK .......G.. .T..T...GA ...A....AG A......... ....T....T GG.AT.C... 
 




           .          .          .          .          .          .  
BovineGZMK AATGATATTA AAGCTGGAAC AAAATGCCAG GTTGTTGGCT GGGGAGCCAC TGACCCAGAA 
HumanGZMK  .CCTC.C... G.T....... C......A.. ...AC..... .......... C..T.....T 
MurineGZMK ..CT..C... G..A...G.. C......... ..GAC..... .....A.... CA.G.....T 
 
           481        491        501        511        521        531 
           .          .          .          .          .          .                                            
BovineGZMK GGCTTAAGCC TTTCTGATAC CCTGCGAGAA GTCACTGTCA CTGTTATAAG TCGAAAAACG 
HumanGZMK  TCA.....A. C......C.. .......... ........T. ....CC.... .......CTT 
MurineGZMK CTG....C.G CC........ ....A..... ........T. .CA.C..... .A.....CGC 
 
           541        551        561        571        581        591 
           .          .          .          .          .          .  
BovineGZMK TGCAACAGCC GAGATTATTA CAACCACAGC CCTGTTATAA CTAGAACCAT GCTATGTGCA 
HumanGZMK  .......... A.AG...C.. ....GG.GA. ...T....C. .C.A.GA... .G.C...... 
MurineGZMK ..T....... A.AGC..C.. ........AA .......... .C.AGGA... .A........ 
 
           601        611        621        631        641        651 
           .          .          .          .          .          .  
BovineGZMK GGAGACGCCA GAGGCCAGAA GGATTCCTGT CAGGGTGACT CAGGGGGCCC CTTGGTCTGC 
HumanGZMK  .....T.... A......... .......... A......... .......... ....A....T 
MurineGZMK .....T.... ....T..A.. .........C A......... .T..T..... T...A..... 
 
           661        671        681        691        701        711 
           .          .          .          .          .          .  
BovineGZMK AAAGGTGCCT TTCATGCCTT AGTTTCTGGA GGTCCCAAAT GTGGTGATGC CAAGAAACCT 
HumanGZMK  .......T.. .C..C..TA. ...C...... ....ATG... ......T... ..CA..G... 
MurineGZMK .....CAT.. .C......C. ...C...CAG ..CTAT.... ....CATC.. ...A..G... 
 
           721        731        741        751        761        771 
           .          .          .          .          .          .  
BovineGZMK GGAATCTACA TCCTACTAAC CCGGAAATTC CAAGCTTGGA TCAAAAGCAA CTTGGCCCCA 
HumanGZMK  .......... C...GT.... .AA.....A. ..GA...... .......... .C.T.T...G 
MurineGZMK ........T. CG...T.... TAA.....A. ..GA.C.... .......... GC.T...... 
 
           781        791         
           .          .           
BovineGZMK TCTCATGCAG ACTAA 
HumanGZMK  C.....A..A .T... 
MurineGZMK ..A.G....C .T.G. 
 
(f). Granzyme M  
 
           1          11         21         31         41         51 
           .          .          .          .          .          . 
BovineGZMM ATG-----CT G--------- -CTCCTGCTG GTGGTCCTGG AAGCTCTGTG GGCAGGAGGC 
HumanGZMM  ...GAGGC.. .CGTGTCTTC A..G...G.. C...C..... GG..C....- --...T.... 
MurineGZMM ...GAGGT.. .CTGGTCCCT G..G..A... C...C....A ..A.A..... .....C.... 
 
           61         71         81         91         101        111 
           .          .          .          .          .          . 
BovineGZMM AACACCTTCG AGACCCACAT CATCGGGGGT CGAGACGCTG TCCCCCACTC ACGCCCATAC 
HumanGZMM  .G.T....T. G......G.. .........C ..G..G.TGA .......... G.....G... 
MurineGZMM ....GA..T. .......G.. ...T...... .....G..A. ....G..... C......... 
 
           121        131        141        151        161        171 
           .          .          .          .          .          . 
BovineGZMM ATGGTCTCGC TGCAGAAGTC GTCTGGCTCA CACCAATGTG GTGGGGTGCT CCTGCACCAA 
HumanGZMM  ....C...A. ......GAA- --A......C ....TG..C. .G..T..C.. GG......C. 
MurineGZMM ....C...T. .A.....AG- --.CAAG..C ..TGTG.... .G..A..C.. TG....T.GG 
 
           181        191        201        211        221        231 
           .          .          .          .          .          . 
BovineGZMM AATTGGGTGT TGACAGCTGC CCACTGCCTG ACCCAGCCGA CGCAGCAGCT GAGGCTTGTG 
HumanGZMM  ..G......C ....G..... .......... G......G.. T.GCC..... ......G... 
MurineGZMM ..G.....A. .......... .......... T.TG.....C TA...A.C.. ..A...G... 
 
           241        251        261        271        281        291 
           .          .          .          .          .          . 
BovineGZMM CTGGGGCT-- -------TCA TGTGCTGGGA GAGATCAGCC CTATCTACCG CATCAGGAAG 
HumanGZMM  ........-- -------C.. CACC....AC AGCCC.G.T. TC.C..T..A .....A.GCA 
 
 
 VII  
MurineGZMM ..T..C..GC ACAACCTC.. ..AT..CCA. ..TCCTG... TC.C..T.TA ....C..G.A 
 
           301        311        321        331        341        351 
           .          .          .          .          .          . 
BovineGZMM GTGGTCCGGC ACCCCGAATA CAAGCCAGTC CCTCATCTGG AGAATGACCT CGCACTGCTA 
HumanGZMM  .CCA...A.. ....TCGC.. ......C... ...GCC.... ....C..... ...G.....T 
MurineGZMM .CCA.TAAA. ....T.GC.. ...------. .ACA.ATAT. ....C..... G........T 
 
           361        371        381        391        401        411 
           .          .          .          .          .          . 
BovineGZMM AAGCTGGACG GGAAGGTGAA GCCCAGCAGG ACCATCCAGC CCCTGGCGTT GCCCCGAGGG 
HumanGZMM  C......... ....A..... .......C.. .......G.. .GT....CC. ....A.TAA. 
MurineGZMM .....A..TA .ACGA...C. ........A. .ATG..A.A. .A..A..TC. ...AA..AA. 
 
           421        431        441        451        461        471 
           .          .          .          .          .          . 
BovineGZMM CGCCAG---A TGGTGGCCAC AGGCACCCGG TGCAGCCTGG CCGGCTGGGG CCTGACCCAC 
HumanGZMM  ......---G .......AG. ...G..T... ......A... .......... G......... 
MurineGZMM .C..GATCC. A.CC...AGA ...T...T.. ......ACA. .T........ AA........ 
 
           481        491        501        511        521        531 
           .          .          .          .          .          . 
BovineGZMM CAGCCTGGGA ACCTGGCCAG GGTGCTGCAG GAGCTGGACG TGCATGTGTT GGACACCAGG 
HumanGZMM  ...GGC...C G....T..C. ........G. .........C .C..A...C. .......C.C 
MurineGZMM ...GG....C C..G...... ..CC...... ...T....TC ...G....C. ...T...CAA 
 
           541        551        561        571        581        591 
           .          .          .          .          .          . 
BovineGZMM ATGTGCAACA ACAGTCGGTT CTGGCACGGC AACATCAGCT CCCACATGAT CTGCCTGGCA 
HumanGZMM  .....T.... ....C..C.. ....A..... .G.C..TC.C ..AG....G. .........G 
MurineGZMM .....T.... ....C..C.. ....A....T GT.C...TAG A.AG....C. A...T.AAAG 
 
           601        611        621        631        641        651 
           .          .          .          .          .          . 
BovineGZMM GCTGACTCCA AGAACCAGGC CCCCTGCAAG GGGGACTCAG GAGGGCCGGT GGTGTGCAAA 
HumanGZMM  ..C....... ..G....... T......... ..T.....G. .C.....CC. ......TGGC 
MurineGZMM ....GGAG.. ...G...A.. .......... ..T.....T. .......CC. ......TGGC 
 
           661        671        681        691        701        711 
           .          .          .          .          .          . 
BovineGZMM AGAGGCCAAG TG---GCTGG AATCCTGTCC TTCAGCTCTG AGAATTGCAC CGACATCTTC 
HumanGZMM  .A.....GG. ..TTG..CA. .G........ ........CA G.GTC..... T......... 
MurineGZMM .A......G. ..---.A... G........T ........CA .A.CC..... A......... 
 
           721        731        741        751        761        771 
           .          .          .          .          .          . 
BovineGZMM AAACCCCCCG TGGCTGTCGC TGTGGCCCCC TACATGCCCT GGATCAAGAA GGTCCTCCGC 
HumanGZMM  ..G..T.... ....CAC... ......G..T ...G..T... ......G... ....AC.G.. 
MurineGZMM ..G..A..T. ....CACT.. ...A...... ....GCT... ......G... ....A.TG.T 
 
           781        791        801 
           .          .          . 
BovineGZMM CAC-AATGGC TCACCTCCCT CACCTTGA 
HumanGZMM  .G--.TC... C--------- -----... 
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8.3 Appendix C – Solutions and media 
 
All reagents were obtained from Sigma (Poole, Doreset, UK) unless otherwise stated. 
Double-distilled water (DDW) was sourced from a Millipore-RO 60 Plus unit 
(Millipore, Billerica, MA, USA) 
 
C.1 Alsever’s Solution 10x stock  
• D-glucose                                       205.0 g                (113.8mM) 
• Citric acid                                        5.5 g                 (2.9mM) 
• Sodium chloride                                 42.0                   (71.9mM) 
• Tris-sodium citrate Di-hydrate           80.0                   (27.2mM)   
 
Made up to a volume of 1 L with DDW 
Made up to 1x solution by filter sterilizing 0.1 L stock solution using 0.45 µm 
Minisart single-use filter (Sartorius, Goettingen, Germany) and adding to 0.9 L of 
sterile DDW 
 
C.2 Standard Culture Medium (SCM)  
• RPMI 1640 medium + 20mM HEPES + L-Glutamine (Gibco, Paisley, UK) 
• 10% Foetal bovine serum (Gibco, Paisley, UK) 
• 100U/ml Penicillin, 100µg/ml streptomycin, 292µg/ml L-glutamine 
• 5 x 10-5M 2-Mercaptoethanol (2-ME) 
 
C.3 FACS Medium 
• RPMI 1640 medium + 20mM HEPES + L-Glutamine (Gibco, Paisley, UK) 
• 2% Foetal bovine serum (Gibco, Paisley, UK) 
• 0.2% Sodium Azide  
 
C.4 Cytotoxic Medium  
• RPMI 1640 medium + 20mM HEPES + L-Glutamine (Gibco, Paisley, UK) 





C.5 SM-0005 PCR Buffer  
• 45mM Tris-HCL (pH 8.8 at 25°C) 
• 11mM Ammonium sulphate  
• 4.5mM Magnesium chloride  
• 0.113mg/ml Bovine serum albumin  
• 4.4uM EDTA  
• 1.0mM each of dATP, dCTP, dGTP and dTTP 
 
Purchased from ABgene (Epsom, Surrey, UK) 
 
C.6 Tris-acetate/EDTA electrophoresis buffer (TAE) 50x stock  
• Trizma base                                     242g                             (2M) 
• Glacial acetic acid                           57.1ml                           (2M) 
• EDTA                                    100ml of 0.5M solution          (50mM) 
 
pH adjusted to 7.7-8.0 with glacial acetic acid if required, make up to a volume of 1L 
with distilled water 
 
C.7 Loading Buffer for Agarose Gel Electrophoresis  
• 15% w/v Ficoll (Type 400) in DDW with bromophenol blue (0.25% v/v) and 
xylene cyanol (0.25%) dyes  
 
C.8 SOC medium 
• Tryptone                                          20g 
• Yeast Extract                                   5g 
• Sodium chloride                              0.5g  
• Potassium chloride                          0.19g 
• Magnesium chloride                        0.95g 





pH adjusted to 7.0 with 5M sodium hydroxide, made up to a volume of 1 L with 
DDW and autoclaved  
  
C.9 Luria-Bertani (LB) Agar plates with ampicillin  
• Tryptone                                      10g  
• Yeast extract                                5g 
• Sodium chloride                          10g  
• Agar                                             15g  
 
pH adjusted to 7.0 with 5M sodium hydroxide, make up to a volume of 1L with 
DDW and autoclaved  
Upon use, LB agar was melted and ampicillin added to give a final concentration of 
100ug/ml. The required amount of medium was poured into sterile Petri dished and 
allowed to set and dry. If LB/ampicillin/IPTG/X-Gal plates were required for 
blue/white colony selection, 100ul of 24mg/ml IPTG (Isopropyl β-D-1-
thiogalactopyranoside) and 50ul of 50mg/ml XGal (5-bromo-4-chloro-3-indolyl-β-D-
galactoside) in 50ul of SOC medium (Appendix C.8) was applied to the surface of 
the medium and allowed to dry before application of any culture. 
 
C.10 LB Medium  
• Tryptone                                      10g  
• Yeast extract                                5g 
• Sodium chloride                          10g  
pH adjusted to 7.0 with 5M sodium hydroxide, make up to a volume of 1L with 
DDW and autoclaved  
 
C.11 PBS/EDTA 10x stock  
• Sodium chloride                             40.0g  
• Potassium chloride                         1.0g 
• Sodium phosphate, dibasic             5.75g  
• Potassium phosphate, monobasic   1.0g  





pH adjusted to 7.2 -7.4, made up to a volume of 500 ml with DDW.  
Made up to 1x solution by filter sterilizing 100ml stock solution using 0.45 µm 
Minisart single-use filter (Sartorius, Goettingen, Germany), adding to 900ml of 
DDW and autoclaved  
 
C. 12 Phosphate Buffered Saline (PBS) 
• Sodium chloride                             170.0mM 
• Potassium chloride                         3.4mM 
• Sodium phosphate, dibasic             9.2mM 
• Potassium phosphate, monobasic   1.8mM 
 
pH adjusted to 6.8.  
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